



National Comprehensive
Cancer Network®

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Hodgkin Lymphoma

Version 2.2023 — November 8, 2022

NCCN.org

NCCN Guidelines for Patients® available at www.nccn.org/patients

Continue



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

[NCCN Guidelines Index](#)
[Table of Contents](#)
[Discussion](#)

***Richard T. Hoppe, MD/Chair §**
Stanford Cancer Institute

***Ranjana H. Advani, MD/Vice Chair †**
Stanford Cancer Institute

Richard F. Ambinder, MD, PhD †
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins

Philippe Armand, MD, PhD ‡
Dana-Farber/Brigham and Women's
Cancer Center

Celeste M. Bello, MD, MSPH †
Moffitt Cancer Center

Cecil M. Benitez, MD, PhD ¥ §
UCLA Jonsson
Comprehensive Cancer Center

Weina Chen, MD, PhD ≠
UT Southwestern Simmons
Comprehensive Cancer Center

Sheen Cherian, MD §
Case Comprehensive Cancer Center/
University Hospitals Seidman Cancer
Center and Cleveland Clinic Taussig
Cancer Institute

Bouthaina Dabaja, MD §
The University of Texas
MD Anderson Cancer Center

Megan E. Daly, MD §
UC Davis Comprehensive Cancer Center

Jamie Flerlage, MD, MS €
St. Jude Children's Research Hospital/
The University of Tennessee Health
Science Center

Leo I. Gordon, MD ‡
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University

Neil Hansen, MD ☐
Fred & Pamela Buffett Cancer Center

Alex F. Herrera, MD ‡ §
City of Hope
National Medical Center

Ephraim P. Hochberg, MD †
Massachusetts General Hospital
Cancer Center

Patrick B. Johnston, MD, PhD ‡ † ☐
Mayo Clinic Cancer Center

Mark S. Kaminski, MD †
University of Michigan
Rogel Cancer Center

Christopher R. Kelsey, MD §
Duke Cancer Institute

Vaishalee P. Kenkre, MD ‡
University of Wisconsin
Carbone Cancer Center

Ryan C. Lynch, MD † ‡
Fred Hutchinson Cancer Center

Kami Maddocks, MD ‡
The Ohio State University Comprehensive
Cancer Center- James Cancer Hospital
and Solove Research Institute

Jonathan McConathy, MD, PhD ☐
O'Neal Comprehensive
Cancer Center at UAB

David Morgan, MD † ‡ §
Vanderbilt-Ingram Cancer Center

Carolyn Mulrone, MD † ‡ §
UC San Diego Moores Cancer Center

Sheeja T. Pullarkat, MD ≠
UCLA Jonsson
Comprehensive Cancer Center

Rachel Rabinovitch, MD §
University of Colorado Cancer Center

Karen C. Rosenspire, MD, PhD ☐
Abramson Cancer Center
at the University of Pennsylvania

Stuart Seropian, MD ‡ † ☐
Yale Cancer Center/
Smilow Cancer Hospital

Michael Spinner, MD ‡
UCSF Helen Diller Family
Comprehensive Cancer Center

Randa Tao, MD §
Huntsman Cancer Institute
at the University of Utah

Pallawi Torka, MD ‡
Roswell Park
Comprehensive Cancer Center

Jane N. Winter, MD ‡ †
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University

Joachim Yahalom, MD §
Memorial Sloan Kettering Cancer Center

Joanna C. Yang, MD, MPH §
Siteman Cancer Center at Barnes-
Jewish Hospital and Washington
University School of Medicine

NCCN

Megan Lyons, MS
Katie Stehman, PA-C, MMS
Hema Sundar, PhD

§ Bone marrow transplantation	☐ Nuclear medicine
☐ Diagnostic radiology	≠ Pathology
‡ Hematology/ Hematology oncology	¥ Patient advocacy
☐ Internal medicine	€ Pediatric oncology
† Medical oncology	§ Radiation oncology
	* Discussion writing committee member

Continue

[NCCN Guidelines Panel Disclosures](#)



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

[NCCN Guidelines Index](#)
[Table of Contents](#)
[Discussion](#)

[NCCN Hodgkin Lymphoma Panel Members](#)
[Summary of Guidelines Updates](#)

[Diagnosis and Workup \(HODG-1\)](#)

[Staging /Risk Classification of Classic Hodgkin Lymphoma \(CHL\) \(HODG-2\)](#)

Primary Treatment of Classic Hodgkin Lymphoma (CHL):

- [Stage I–II Favorable \(IA/IIA, non-bulky\) \(HODG-3\)](#)
- [Stage I–II Unfavorable \(B symptoms or bulky mediastinal disease or >10 cm adenopathy\) \(HODG-4\)](#)
- [Stage III–IV \(HODG-5\)](#)

Primary Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL):

- [Stage IA–IV \(HODG-8\)](#)

[Follow-up After Completion of Treatment and Monitoring for Late Effects \(HODG-9\)](#)

[Refractory CHL \(HODG-11\)](#)

[Suspected Relapse of CHL \(HODG-12\)](#)

[Refractory or Suspected Relapse of NLPHL \(HODG-13\)](#)

[Principles of FDG-PET/CT \(HODG-A\)](#)

[Unfavorable Risk Factors \(HODG-B\)](#)

[Principles of Systemic Therapy \(HODG-C\)](#)

[Principles of Radiation Therapy \(HODG-D\)](#)

- [General Principles \(HODG-D 1 of 12\)](#)
- [RT Dose Constraint Guidelines for Lymphoma \(HODG-D, 3 of 12\)](#)

[Management of CHL in Adults Age >60 Years \(HODG-E\)](#)

[Staging \(ST-1\)](#)

[Abbreviations \(ABBR-1\)](#)

See the [NCCN Guidelines for Pediatric Hodgkin Lymphoma](#) for additional recommendations for pediatric patients (including adolescents and young adults [AYAs]).

Clinical Trials: NCCN believes that the best management for any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

Find an NCCN Member Institution:
<https://www.nccn.org/home/member-institutions>.

NCCN Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise indicated.

See [NCCN Categories of Evidence and Consensus](#).

NCCN Categories of Preference: All recommendations are considered appropriate.

See [NCCN Categories of Preference](#).

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2022.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

Updates in Version 2.2023 of the NCCN Guidelines for Hodgkin Lymphoma from Version 1.2023 include:

MS-1

- The discussion section has been updated to reflect the changes in the algorithm.

Updates in Version 1.2023 of the NCCN Guidelines for Hodgkin Lymphoma from Version 2.2022 include:

Global Changes

- References updated throughout the guidelines
- "FDG" added to all instances of PET or PET/CT
- Terminologies modified to be more inclusive of all sexual and gender identities

HODG-2

- Bullet added: See HODG-E for the Management of CHL in Adults Age >60 Years

HODG-3

- Additional Therapy
 - ▶ Deauville 1-2
 - ◊ Chemotherapy alone modified: ABVD x 1 cycles (*adapted per from H10F, CALGB (preferred)*)
 - ◊ Combined modality therapy options clarified as follows: ABVD x 2 cycles + ISRT (per GHSG HD16; if ESR <50, no e-lesions, <3 nodal sites per GHSG favorable criteria) or ABVD x 1 cycle (total 3) + ISRT 30 Gy (adapted from RAPID, H10F)
 - ▶ Deauville 3, Combined modality therapy options revised to include ABVD x 2 cycles (total 4) + ISRT 30 Gy (*adapted per from RAPID, H10F*)
- Footnote n modified: The degree of abnormality of a Deauville 4 score is quite variable and may influence further therapy. (eg, If only focally positive on interim FDG-PET it may be *feasible appropriate* to continue with 2 more cycles of ABVD and then repeat the FDG-PET scan.) For a Scans that remain positive *warrant a biopsy and/or treatment escalation. If a post-chemotherapy PET is only focally positive, consolidation RT utilizing a higher dose may be considered, especially if a biopsy is not feasible. See Principles of Radiation Therapy (HODG-D 2 of 12) throughout the area(s) of initial disease, the consensus is to escalate therapy. (with consideration of biopsy, especially if an easily accessible site).* (also in Special considerations box on HODG-4 and HODG-5)
- Footnote o modified: A Deauville 5 score ~~should prompt re-~~ *would warrant a biopsy, especially if a readily accessible site, which would then to inform subsequent therapy. If a biopsy is not performed feasible, treatment should be escalated.* (also on HODG-6 and HODG-7 and in the Special

considerations box on HODG-4 and HODG-5)

HODG-5

- Primary Treatment
 - ▶ Both ABVD x 2 cycles and Brentuximab vedotin + AVD are now listed as "Preferred Regimens" with a category 1 recommendation

HODG-6

- Restaging recommendations clarified as follows: Restage with FDG-PET/CT *after 6 cycles of AVD*
- Footnote y modified: *An interim FDG-PET/CT after 2 cycles may be helpful in further defining therapy.* If performing an interim FDG-PET/CT before completion of 6 cycles, and FDG-PET is positive...

HODG-8

- Footnote ff modified: An FDA-approved biosimilar is an acceptable substitute for rituximab. *Rituximab and hyaluronidase human injection for subcutaneous use may be substituted for rituximab after patients have received the first full dose of rituximab by intravenous infusion.* (Also on HODG-13, footnote b on HODG-C 2 of 5, HODG-C 3 of 5)

HODG-10

- Interim H&P: Annually
 - ▶ 2nd sub-bullet modified: ...with splenic RT or previous splenectomy (*according to See CDC recommendations*).
 - ▶ 4th sub-bullet added: For guidance on COVID-19 vaccination, see NCCN COVID-19 Vaccination Guide for People with Cancer
 - ▶ 5th sub-bullet added: For guidance on general recommendations for vaccination in patients with cancer, see NCCN Guidelines for the

[Continued](#)**UPDATES**



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

Updates in Version 1.2023 of the NCCN Guidelines for Hodgkin Lymphoma from Version 2.2022 include:

Prevention and Treatment of Cancer-Related Infections

- ▶ 6th bullet added: For guidance on the adolescent and young adult population, see NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology
- Annual breast screening modified: Initiate ~~8–10 y post-therapy~~, or at age 40 y or 8 y post-therapy, whichever comes first, if chest or axillary radiation.

HODG-11

- Maintenance Therapy, Recommendations modified as follows:
 - ▶ Deauville 1–3: Observe or *Consider* brentuximab vedotin maintenance for 1 y for patients with high risk of relapse
 - ▶ Deauville 4: *Consider* brentuximab vedotin maintenance for 1 y for patients with high risk of relapse

HODG-13

- Footnote tt modified: At relapse, *rebiopsy* should be considered because of risk for transformation, especially if intra-abdominal or splenic disease...

HODG-C (3 of 5)

- Second-Line and Subsequent Therapy
 - ▶ CHL
 - ◊ ESHAP (etoposide, methylprednisolone, high-dose cytarabine, cisplatin) removed as treatment option
 - ◊ Pembrolizumab: Qualifier removed: for patients not candidates for transplant
 - ◊ The following regimens were added as options:
 - ICE + nivolumab
 - ICE + brentuximab vedotin
 - ▶ NLPHL
 - ◊ R + ESHAP removed as a treatment option
- Heading revised: ~~Third-Line and Subsequent Therapy for Disease Refractory to at Least 3 Prior Lines of Therapy~~
- ▶ CHL
 - ◊ Pembrolizumab removed as a treatment option
 - ◊ Vinblastine added as a treatment option
- General Guidelines for Checkpoint Inhibitors (CPI) for Relapsed/Refractory CHL
 - ▶ 3rd bullet modified: Post-allogeneic transplant, patients can receive

either nivolumab or pembrolizumab. There are limited data regarding the use of CPI following allogeneic transplantation; ~~CPI should be used with caution before allogeneic transplantation due to increased risk of GVHD (graft-versus-host disease) and other immunologic complications. If a CPI is used, the transplant regimen will need to be carefully considered.~~

HODG-D (1 of 12)

- General Principles, 4th bullet modified: ...have been shown to decrease incidental dose to the heart and lungs in many disease presentations. *In certain circumstances, the use of protons for mediastinal lymphoma provides dosimetric advantages that may reduce long-term toxicity. The potential advantage of protons is related to the localization of disease within the mediastinum as well as patient gender and age.*

HODG-D (2 of 12)

- Involved-Site Radiation Therapy (ISRT): Dose
 - ▶ 1st bullet, 4th sub-bullet modified: Sites of *Deauville 4–5* and partial response to chemotherapy: 36–45 Gy or greater
- Heading revised: *ISRT: Volumes*
 - ▶ 3rd bullet modified: *For CHL, the pre-chemotherapy or pre-biopsy gross tumor volume (GTV) provides the basis for determining the clinical target volume (CTV).*
 - ▶ 4th bullet modified: ~~For NLPHL, often treated with RT alone, treatment should extend beyond the PET-positive or CT-enlarged nodes. the CTV will depend on whether treatment consists of RT alone or CMT.~~
 - ▶ 4th bullet
 - ◊ Sub-bullet removed: The CTV definition for treating NLPHL with RT alone will be greater than that used for CHL with similar disease distribution being treated with combined modality therapy.
 - ◊ Sub-bullet added: ISRT alone: The CTV should be expanded to include potential microscopic disease in the immediate region of the FDG-PET-positive disease
 - ◊ Sub-bullet added: CMT: Similar to CHL after chemotherapy [treating originally involved lymph node(s) only]

HODG-D (4 of 12)

- Organ at Risk
 - ▶ Thorax modified: Coronary vessels *including the left main, left anterior descending (LAD), left circumflex (LCx), and right coronary artery (RCA)*



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

Updates in Version 1.2023 of the NCCN Guidelines for Hodgkin Lymphoma from Version 2.2022 include:

- Dose Recommendation (1.5–2 Gy/fraction)
 - ▶ Thorax modified: ~~Avoid hotspots~~ LAD V15 Gy <10%, Left circumflex V15 Gy <14%, Coronary vessels (total)- Mean <7 Gy, Minimize the maximum dose to individual coronary arteries
- Toxicity
 - ▶ Thorax, bullet added: Major adverse cardiac events
- Footnote d modified: As cardiac toxicity is likely related to dose to specific substructures, it is recommended that these are contoured, constraints are applied, and doses are recorded. Contouring atlases are available. *It is recognized that contouring the coronary arteries is challenging given anatomical variations and lung/heart motion. This may warrant designing a planning organ-at-risk OAR volume in some patients. Further, it is important to preferentially spare high-dose overlap with the proximal coronary arteries (left main, proximal LAD). For example, a plan may achieve an LAD V15 Gy <10% but it is not ideal if most of the 15 Gy or higher dose overlap is surrounding the proximal LAD while the distal LAD is spared to meet the volumetric dose goal. Reviewing both dose to the entire coronary tree and the individual components, particularly the proximal vessels, is important.*

[HODG-D \(5 of 12\)](#)

- Secondary Malignancies
 - ▶ Breast, Dose Recommendation modified: Minimize volume >4 Gy (ideally <10%)

[HODG-D \(9 of 12\)](#)

- Lungs, 4th bullet added: Radiation therapy RT, and possibly some chemotherapy drugs such as alkylating agents, increase the risk of developing lung cancer. The risk increases linearly with dose to the lung. The increased risk is most apparent in smokers, particularly those who continue to use tobacco after diagnosis. In fact, continuing to smoke after thoracic RT multiplies the risk of developing lung cancer. Therefore, a concerted effort should be made to help current smokers requiring thoracic RT to stop smoking. Lung cancer screening with low-dose CT may also be appropriate depending upon clinical circumstances including age, pack-year tobacco exposure history, and interval since quitting. See NCCN Guidelines for Lung Cancer Screening
- Breast: New section added.

[HODG-E \(1 of 2\)](#)

- Relapsed or Refractory Diseases, 3rd bullet
 - ▶ Sub-bullet removed: Second-line, third-line and subsequent therapy options (only for CHL) as listed on Principles of Systemic Therapy for Relapsed or Refractory Disease HODG-C (3 of 5)

[ABBR-1](#)

- New section added: Abbreviations



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

DIAGNOSIS/WORKUP

Excisional biopsy
(recommended)
Core needle biopsy
may be adequate if
diagnostic^a
Immunohistochemistry
evaluation^b

Essential:

- History & Physical (H&P) including: B symptoms (unexplained fever >38°C; drenching night sweats; or weight loss >10% of body weight within 6 mo of diagnosis), alcohol intolerance, pruritus, fatigue, performance status, and examination of lymphoid regions, spleen, and liver
- Complete blood count (CBC), differential
- Erythrocyte sedimentation rate (ESR)
- Comprehensive metabolic panel, lactate dehydrogenase (LDH), and liver function test (LFT)
- Pregnancy test for those of childbearing potential prior to cytotoxic chemotherapy or radiation therapy (RT)
- FDG-PET/CT scan (skull base to mid-thigh or vertex to feet in selected cases)^c
- Counseling: Fertility/psychosocial^d and smoking cessation ([See NCCN Guidelines for Smoking Cessation](#))

Useful in selected cases:

- Fertility preservation^{d,e}
- Pulmonary function tests ([PFTs] including diffusing capacity of the lung for carbon monoxide [DLCO])^f if ABVD or escalated BEACOPP are being used
- Pneumococcal, Haemophilus influenzae (H-flu), meningococcal vaccines, if splenic RT contemplated
- Human immunodeficiency virus (HIV) and hepatitis B/C testing (encouraged)
- Diagnostic CT^g (contrast-enhanced)
- Chest x-ray (encouraged, especially if large mediastinal mass)
- Adequate bone marrow biopsy if there are unexplained cytopenias other than anemia (eg, thrombocytopenia or neutropenia) and negative FDG-PET^h
- Evaluation of ejection fraction if anthracycline-based chemotherapy is indicated
- MRI of select sites, with contrast unless contraindicated
- PET/MRI (skull base to mid-thigh) without contrast

CLINICAL PRESENTATION

Classic Hodgkin lymphoma (CHL)ⁱ → [See HODG-2](#)

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) → [See HODG-8](#)

See Footnotes on [HODG-1A](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

FOOTNOTES

- ^a Fine-needle aspiration (FNA) alone, in distinction from a core biopsy, is generally insufficient for diagnosis.
- ^b Typical immunophenotype for CHL: CD15+, CD30+, PAX-5+ (weak); CD3-, CD20- (majority), CD45-, CD79a-. Typical immunophenotype for NLPHL: CD20+, CD45+, CD79a+, BCL6+, PAX-5+; CD3-, CD15-, CD30- (Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2017). Epstein-Barr encoding region in situ hybridization (EBER-ISH) is recommended at initial diagnosis (CHL: EBER+/-; NLPHL: EBER-). An expanded panel of markers (eg, MUM-1, BOB-1, OCT-2) may be required, especially if equivocal diagnosis. [See NCCN Guidelines for B-Cell Lymphomas](#). For NLPHL, immunoarchitectural pattern should be specified as A or B (typical) vs. C–F (variant).
- ^c [See Principles of FDG-PET/CT \(HODG-A\)](#).
- ^d [See NCCN Guidelines for Adolescent and Young Adult \(AYA\) Oncology](#) for more details on fertility/fertility preservation and psychosocial assessments in AYA patients.
- ^e Fertility preservation options include: semen cryopreservation, in vitro fertilization (IVF), or ovarian tissue or oocyte cryopreservation.
- ^f In general, a DLCO threshold of ≥60% is acceptable for use of bleomycin.
- ^g Imaging should be obtained in accordance with the American College of Radiology (ACR) practice guidelines. CT is considered diagnostic if it is enhanced with oral and/or IV contrast. CT component of a conventional PET/CT is often not IV contrast-enhanced. Although the diagnostic CT will often be of the neck/chest/abdomen/pelvis, at minimum include the areas identified as abnormal on PET/CT.
- ^h In most instances, if the PET/CT displays a homogeneous pattern of marrow uptake (thought to be secondary to cytokine release) bone marrow involvement is not assumed. If there are multifocal (three or more) skeletal PET/CT lesions, marrow may be assumed to be involved. In general, bone marrow biopsies are no longer indicated.
- ⁱ CHL includes nodular sclerosis (NSHL), mixed cellularity (MCHL), lymphocyte-depleted (LDHL), and lymphocyte-rich (LRHL) subtypes. If grey-zone, [see NCCN Guidelines for B-Cell Lymphomas](#).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

STAGING/RISK CLASSIFICATION OF CHL^j

Stage	Bulky Mediastinal Disease ^j or >10 cm Adenopathy	ESR >50 or # Sites >3	Type	Guidelines Page
IA/IIA	No	No	Favorable Disease	HODG-3
	No	Yes	Favorable/Unfavorable Disease	HODG-3 or HODG-4
	Yes	Yes/No	Unfavorable Disease	HODG-4
IB/IIB	Yes/No	Yes/No	Unfavorable Disease	HODG-4
III–IV	Yes/No	N/A	Advanced Disease	HODG-5

- Selection of treatment (combined modality therapy or chemotherapy alone) should be based on patient age, sex, family history of cancer or cardiac disease, comorbid conditions, and sites of involvement (especially within mediastinum or axilla).
- Most patients will benefit from multidisciplinary input prior to final treatment decisions
- See [HODG-E](#) for the Management of CHL in Adults Age >60 Years

^j For definitions of bulky disease and lymph node regions, [see HODG-B](#).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)


CLINICAL PRESENTATION: Stage IA/IIA Favorable (Non-Bulky) CHL^k

Important Considerations:

- Selection of treatment (combined modality therapy or chemotherapy alone) should be based on patient age, sex, family history of cancer or cardiac disease, comorbid conditions, and sites of involvement (especially within mediastinum or axilla).
- In general, treatment with combined modality therapy provides for a better progression free survival (PFS)/freedom from progression (FFP), but no difference in overall survival.
- Most patients will benefit from multidisciplinary team input prior to final treatment decisions.

PRIMARY TREATMENT

ADDITIONAL THERAPY

For footnotes, see [HODG-3A](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

For references 1–5,
[see HODG-7A](#)



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

Footnotes

^c [See Principles of FDG-PET/CT \(HODG-A\).](#)

^k Individualized treatment may be necessary for patients >60 years and patients with concomitant disease. [See Management of CHL in Adults Age >60 Years \(HODG-E\).](#)

^l [See Principles of Systemic Therapy \(HODG-C\).](#)

^m [See FDG-PET 5-Point Scale \(Deauville Criteria\) \(HODG-A, 2 of 2\).](#)

ⁿ The degree of abnormality of a Deauville 4 score is quite variable and may influence further therapy. If only focally positive on interim FDG-PET, it may be appropriate to continue with ABVD and then repeat the FDG-PET scan. Scans that remain positive warrant a biopsy and/or treatment escalation. If a post-chemotherapy FDG-PET is only focally positive, consolidation RT may be considered, especially if a biopsy is not feasible. See [Principles of Radiation Therapy \(HODG-D 2 of 12\)](#)

^o A Deauville 5 score would warrant a biopsy to inform subsequent therapy. If a biopsy is not feasible, treatment should be escalated.

^p Consider PFTs after 4 cycles of ABVD.

^q [See Principles of Radiation Therapy \(HODG-D\).](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

CLINICAL PRESENTATION:

Stage I/II Unfavorable

CHL^k


(B symptoms or bulky mediastinal disease or >10 cm adenopathy)

Important Considerations:

- Selection of treatment (combined modality therapy or chemotherapy alone) should be based on patient age, sex, family history of cancer or cardiac disease, comorbid conditions, and sites of involvement (especially within mediastinum or axilla).
- In general, treatment with combined modality therapy provides for a better PFS/FFP, but no difference in overall survival.
- Most patients will benefit from multidisciplinary team input prior to final treatment decisions.

PRIMARY TREATMENT^k

ADDITIONAL THERAPY



Special considerations for Deauville 4–5 after ABVD x 2 cycles:

- The degree of abnormality of a Deauville 4 score is quite variable and may influence further therapy. If only focally positive on interim FDG-PET, it may be appropriate to continue with ABVD and then repeat the FDG-PET scan. Scans that remain positive warrant a biopsy and/or treatment escalation. If a post-chemotherapy FDG-PET is only focally positive, consolidation RT may be considered, especially if a biopsy is not feasible. [See Principles of Radiation Therapy \(HODG-D 2 of 12\)](#).
- A Deauville 5 score would warrant a biopsy to inform subsequent therapy. If a biopsy is not feasible, treatment should be escalated.

^c [See Principles of FDG-PET/CT \(HODG-A\)](#).

^k Individualized treatment may be necessary for patients >60 years and patients with concomitant disease. [See Management of CHL in Adults >60 Years \(HODG-E\)](#).

^l [See Principles of Systemic Therapy \(HODG-C\)](#).

^m [See FDG-PET 5-Point Scale \(Deauville Criteria\) \(HODG-A, 2 of 2\)](#).

^p Consider PFTs after 4 cycles of ABVD.

^q [See Principles of Radiation Therapy \(HODG-D\)](#).

^r NCCN Unfavorable Factors include bulky mediastinal or >10 cm disease, B symptoms, ESR ≥50, and >3 sites of disease ([see HODG-B](#)).

^s Escalated BEACOPP is an option only for those aged <60 y.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

For references 2 and 5
[see HODG-7A](#)




NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

CLINICAL PRESENTATION: Stage III–IV CHL^k

PRIMARY TREATMENT^k



Special considerations for Deauville 4–5 after ABVD x 2 cycles:

- The degree of abnormality of a Deauville 4 score is quite variable and may influence further therapy. If only focally positive on interim FDG-PET, it may be appropriate to continue with ABVD and then repeat the FDG-PET scan. Scans that remain positive warrant a biopsy and/or treatment escalation. If a post-chemotherapy FDG-PET is only focally positive, consolidation RT may be considered if a biopsy is not feasible. [See Principles of Radiation Therapy \(HODG-D 2 of 12\)](#).
- A Deauville 5 score would warrant a biopsy to inform subsequent therapy. If a biopsy is not feasible, treatment should be escalated.

^c See Principles of FDG-PET/CT (HODG-A).

^k Individualized treatment may be necessary for patients >60 years and patients with concomitant disease. [See Management of CHL in Adults Age >60 Years \(HODG-E\)](#).

^l See Principles of Systemic Therapy (HODG-C).

^m See FDG-PET 5-Point Scale (Deauville Criteria) (HODG-A, 2 of 2).

^s Escalated BEACOPP is an option only for those aged <60 y.

^u See International Prognostic Score (IPS) (HODG-B).

^v All cycles include growth factor support. [See NCCN Guidelines for Hematopoietic Growth Factors](#).

^w The value of interim FDG-PET imaging is unclear for many clinical scenarios. All measures of response should be considered in the context of management decisions.

^x Consider ISRT to initially bulky or FDG-PET–positive sites. [See Principles of Radiation Therapy \(HODG-D\)](#).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**For reference 5,
see HODG-7A**




NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

CLINICAL PRESENTATION: Stage III–IV CHL

PRIMARY TREATMENT^k (continued from [HODG-5](#))

^c See [Principles of FDG-PET/CT \(HODG-A\)](#).^k Individualized treatment may be necessary for patients >60 years and patients with concomitant disease. See [Management of CHL in Adults Age >60 Years \(HODG-E\)](#).^l See [Principles of Systemic Therapy \(HODG-C\)](#).^m See [FDG-PET 5-Point Scale \(Deauville Criteria\) \(HODG-A, 2 of 2\)](#).^o A Deauville 5 score would warrant a biopsy to inform subsequent therapy. If a biopsy is not feasible, treatment should be escalated.^v All cycles include growth factor support. See [NCCN Guidelines for Hematopoietic Growth Factors](#).^x Consider ISRT to initially bulky or FDG-PET–positive sites. See [Principles of Radiation Therapy \(HODG-D\)](#).^y An interim FDG-PET/CT after 2 cycles may be helpful in further defining therapy. If performing an interim FDG-PET/CT before completion of 6 cycles, and FDG-PET is positive (Deauville 5), conduct a biopsy; if biopsy positive, change therapy.**Note:** All recommendations are category 2A unless otherwise indicated.**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**For reference 6,
see [HODG-7A](#)**




NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

CLINICAL PRESENTATION: Stage III–IV CHL

PRIMARY TREATMENT^k (continued from [HODG-5](#))



^c See [Principles of FDG-PET/CT \(HODG-A\)](#).

^k Individualized treatment may be necessary for patients >60 years and patients with concomitant disease. See [Management of CHL in Adults Age >60 Years \(HODG-E\)](#).

^l See [Principles of Systemic Therapy \(HODG-C\)](#).

^m See [FDG-PET 5-Point Scale \(Deauville Criteria\) \(HODG-A, 2 of 2\)](#).

^o A Deauville 5 score would warrant a biopsy to inform subsequent therapy. If a biopsy is not feasible, treatment should be escalated.

^s Escalated BEACOPP is an option only for those aged <60 y.

^u See [International Prognostic Score \(IPS\) \(HODG-B\)](#).

^x Consider ISRT to initially bulky or FDG-PET–positive sites. See [Principles of Radiation Therapy \(HODG-D\)](#).

^z Bleomycin is optional.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

For references 5, 7, and 8, see [HODG-7A](#)



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

CLASSIC HODGKIN LYMPHOMA PRIMARY TREATMENT REFERENCES

- ¹ CALGB 50604: Straus DJ, Jung SH, Pitcher B, et al. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. *Blood* 2018;132:1013-1021.
- ² EORTC/LYSA/FIL H10: André MPE, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: Final results of the randomized EORTC/LYSA/FIL H10 trial. *J Clin Oncol* 2017;35:1786-1794.
- ³ RAPID study: Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. *N Engl J Med* 2015;372:1598-1607.
- ⁴ GHSG H16: Fuchs M, Goergen H, Kobe C, et al. Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: Final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group. *J Clin Oncol* 2019;37:2835-2845.
- ⁵ RATHL study: Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. *N Engl J Med* 2016;374:2419-2429.
- ⁶ ECHELON-1: Ansell SM, Radford J, Connors JM, et al. Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma. *N Engl J Med* 2022;387:310-320.
- ⁷ GHSG HD18: Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. *Lancet* 2018;390:2790-2802.
- ⁸ AHL2011: Casasnovas RO, Bouabdallah R, Brice P, et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. *Lancet Oncol* 2019;20:202-215.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.




NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

CLINICAL PRESENTATION: NLPHL^{aa}

PRIMARY TREATMENT



^c See Principles of FDG-PET/CT (HODG-A).

^q See Principles of Radiation Therapy (HODG-D).

^{aa} NLPHL has a different natural history and response to therapy than CHL, especially stages I–II. For that reason, separate guidelines are presented for NLPHL. Patients who present with bulky disease, subdiaphragmatic disease, or splenic involvement have a high risk for initial or later transformation to large cell lymphoma. Data suggest outcomes differ for typical immunoarchitectural patterns (A/B) versus variant patterns (C/D/E/F). (Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2017).

^{bb} For select patients with Stage IB, or Stage IIA non-contiguous disease, ISRT alone may be an option.

^{cc} Observation may be an option for stage IA patients with a completely excised solitary lymph node. See Follow-up (HODG-9).

^{dd} See Principles of Systemic Therapy (HODG-C, 2 of 5).

^{ee} Generally, a brief course of chemotherapy (2–4 mo) would be given with RT.

^{ff} An FDA-approved biosimilar is an acceptable substitute for rituximab. Rituximab and hyaluronidase human injection for subcutaneous use may be substituted for rituximab after patients have received the first full dose of rituximab by intravenous infusion.

^{gg} Biopsy is recommended for sites of progressive disease, especially subdiaphragmatic sites, to rule out transformation.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

FOLLOW-UP AFTER COMPLETION OF TREATMENT AND MONITORING FOR LATE EFFECTS

- Complete response should be documented including reversion of FDG-PET to "negative" within 3 mo following completion of therapy.
- It is recommended that the patient be provided with a treatment summary at the completion of therapy, including details of RT, organs at risk (OAR), and cumulative anthracycline dosage given.
- Follow-up with an oncologist is recommended and should be coordinated with the primary care physician (PCP), especially during the first 5 y after treatment to detect recurrence, and then annually due to the risk of late complications including second cancers and cardiovascular disease ([see NCCN Guidelines for Survivorship](#)).^{hh,ii} Late relapse or transformation to large cell lymphoma may occur in NLPHL.
- The frequency and types of tests may vary depending on clinical circumstances: age and stage at diagnosis, social habits, treatment modality, etc. There are few data to support specific recommendations; these represent the range of practice at NCCN Member Institutions.

Follow-up After Completion of Treatment Up to 5 Years

- Interim H&P: Every 3–6 mo for 1–2 y, then every 6–12 mo until year 3, then annually.
- Annual influenza vaccine and other vaccines as clinically indicated ([see NCCN Guidelines for Survivorship](#)).
- Laboratory studies^{jj}:
 - CBC, platelets, ESR (if elevated at time of initial diagnosis), chemistry profile as clinically indicated.
 - Thyroid-stimulating hormone (TSH) at least annually if RT to neck.
- Consider neck/chest/abdomen/pelvis CT scan with contrast no more often than every 6 mo for the first 2 y following completion of therapy, or as clinically indicated after 2 y, especially in NLPHL where late relapse may occur. FDG-PET/CT only if last FDG-PET was Deauville 4–5, to confirm complete response.
- Counseling: Reproduction, health habits, psychosocial, cardiovascular, breast self-examination, skin cancer risk, end-of-treatment discussion.
- Surveillance FDG-PET should not be done routinely due to risk for false positives. Management decisions should not be based on FDG-PET scan alone; clinical or pathologic correlation is needed.

Suspected Relapse CHL ([HODG-12](#)) or NLPHL ([HODG-13](#))

[Follow-Up and Monitoring After 5 Years \(HODG-10\)](#)

^{hh} Mauch P, Ng A, Aleman B, et al. Report from the Rockefeller Foundation Sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9-16, 2003, Bellagio, Italy. Eur J Haematol Suppl 2005;(66):68-76.

ⁱⁱ Appropriate medical management should be instituted for any abnormalities.

^{jj} Lynch RC, Sundaram V, Desai M, et al. Utility of routine surveillance laboratory testing in detecting relapse in patients with classic Hodgkin lymphoma in first remission: Results from a large single-institution study. JCO Oncol Pract 2020;16:e902-e911.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

FOLLOW-UP AFTER COMPLETION OF TREATMENT AND MONITORING FOR LATE EFFECTS

Follow-up and Monitoring After 5 Years^{hh,ii}

- **Interim H&P: Annually**
 - Annual blood pressure, aggressive management of cardiovascular risk factors.
 - Pneumococcal, meningococcal, and Haemophilus influenzae type b revaccination after 5–7 y, if patient treated with splenic RT or previous splenectomy (See [CDC recommendations](#)).
 - Annual influenza vaccine and other vaccines as clinically indicated ([see NCCN Guidelines for Survivorship](#)).
 - For guidance on COVID-19 vaccination, see [NCCN COVID-19 Vaccination Guide for People with Cancer](#).
 - For guidance on general recommendations for vaccination in patients with cancer, see [NCCN Guidelines for the Prevention and Treatment of Cancer-Related Infections](#).
 - For guidance on the adolescent and young adult population, see [NCCN Guidelines for Adolescent and Young Adult \(AYA\) Oncology](#).
- Cardiovascular symptoms may emerge at a young age.
 - Consider stress test/ECHO at 10-y intervals after treatment is completed.
 - Consider carotid ultrasound at 10-y intervals if neck irradiation.
- Laboratory studies:
 - CBC, platelets, chemistry profile annually
 - TSH at least annually if RT to neck
 - Biannual lipids
 - Annual fasting glucose
- Annual breast screening: Initiate at age 40 y or 8 y post-therapy, whichever comes first, if chest or axillary radiation. The NCCN Hodgkin Lymphoma Guidelines Panel recommends breast MRI in addition to mammography for patients assigned female at birth who received irradiation to the chest between ages 10–30 y, which is consistent with the American Cancer Society (ACS) Guidelines. Consider referral to a breast specialist.
- Perform other routine surveillance tests for cervical, colorectal, endometrial, lung, and prostate cancer as per the [NCCN Guidelines for Detection, Prevention, and Risk Reduction](#) and the [ACS Cancer Screening Guidelines](#).
- Counseling: Reproduction, health habits, psychosocial, cardiovascular, breast self-examination, and skin cancer risk.
- Treatment summary and consideration of transfer to PCP.
- Consider a referral to a survivorship clinic.

^{hh} Mauch P, Ng A, Aleman B, et al. Report from the Rockefeller Foundation-Sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9-16, 2003, Bellagio, Italy. Eur J Haematol Suppl 2005;(66):68-76.

ⁱⁱ Appropriate medical management should be instituted for any abnormalities.


Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)


^c See Principles of FDG-PET/CT (HODG-A).^m See FDG-PET 5-Point Scale (Deauville Criteria) (HODG-A, 2 of 2).^q See Principles of Radiation Therapy (HODG-D).^{kk} See Principles of Systemic Therapy for Relapsed or Refractory Disease (HODG-C, 3 of 5).^{ll} Strongly consider RT for selected sites that have not been previously irradiated. In a radiation-naïve patient, total lymphoid irradiation (TLI) may be an appropriate component of HDT.^{mm} Conventional-dose chemotherapy may precede HDT. Timing of RT may vary.ⁿⁿ Subsequent systemic therapy options include second-line therapy options that were not previously used (See HODG-C, 3 of 5).^{oo} Patients with 2 or more of the following risk factors are considered high risk: Remission duration <1 year, extranodal involvement, FDG-PET-positive response at time of transplant, B symptoms, and/or >1 second-line/subsequent therapy regimen. AETHERA Trial: Moskowitz CH, et al. Blood 2018;132:2639-2642^{pp} The role of maintenance brentuximab vedotin has not been well-defined in patients who received brentuximab vedotin prior to maintenance therapy.**Note:** All recommendations are category 2A unless otherwise indicated.**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

CHL SUSPECTED RELAPSE



^c See Principles of FDG-PET/CT (HODG-A).

^q See Principles of Radiation Therapy (HODG-D).

^{kk} See Principles of Systemic Therapy for Relapsed or Refractory Disease (HODG-C, 3 of 5).

^{ll} Strongly consider RT for selected sites that have not been previously irradiated. In a radiation-naïve patient, TLI may be an appropriate component of HDT.

^{mm} Conventional-dose chemotherapy may precede HDT. Timing of RT may vary.

ⁿⁿ Subsequent therapy options include second-line therapy options that were not previously used. ([See HODG-C, 3 of 5](#)).

^{qq} Allotransplant is an option in select patients as a category 3 recommendation.

^{rr} There are no data to support a superior outcome with any of the treatment modalities. Individualized treatment is recommended.

^{ss} For select patients with long disease-free interval and other favorable features, selection of chemotherapy should be individualized.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.




NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

NLPHL REFRACTORY OR SUSPECTED RELAPSE

SECOND-LINE THERAPY^{rr}



^c See Principles of FDG-PET/CT (HODG-A).

^q See Principles of Radiation Therapy (HODG-D).

^{ff} An FDA-approved biosimilar is an acceptable substitute for rituximab. Rituximab and hyaluronidase human injection for subcutaneous use may be substituted for rituximab after patients have received the first full dose of rituximab by intravenous infusion.

^{kk} See Principles of Systemic Therapy for Relapsed or Refractory Disease (HODG-C, 3 of 5).

ⁿⁿ Subsequent therapy options include second-line therapy options that were not previously used. (See HODG-C, 3 of 5).

^{rr} There are no data to support a superior outcome with any of the treatment modalities. Individualized treatment is recommended.

^{tt} At relapse, rebiopsy should be considered because of risk for transformation, especially if intra-abdominal or splenic disease. Some patients with NLPHL have a chronic indolent course that may not require aggressive re-treatment. These asymptomatic patients may be observed.

^{uu} In some patients treated with rituximab alone, maintenance rituximab may be considered for 2 years (Schulz H, et al. Blood 2008;111:109-111; Advani RH, et al. J Clin Oncol 2014;32:912-918).

^{vv} Consider rebiopsy to rule out transformation.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

PRINCIPLES OF FDG-PET/CT

Technique

- An integrated FDG-PET/CT or an FDG-PET with a diagnostic CT is recommended for initial diagnosis and restaging.
- For FDG-PET/CT performed in the staging or response assessment in Hodgkin lymphoma (HL), image acquisition should be obtained in accordance with the American College of Radiology (ACR) practice parameter guidelines¹ or the Society of Nuclear Medicine and Molecular Imaging (SNMMI), which adopted the European Association of Nuclear Medicine (EANM) procedure guidelines for tumor imaging: version 2.0 (with the exception that the "standardized uptake value (SUV) max" is used in the United States as the quantitative measurement).²
 - ▶ FDG-PET/CT should be performed with the patient on a flat table with arms up, if possible. In cases of FDG-PET positivity where disease sites are inconsistent with usual presentation of HL or if an unusual disease presentation (ie, HIV), additional clinical evaluation may be required to stage the patient. [See \(ST-1\)](#).
- FDG-PET/CT scans obtained outside of these parameters (eg, in outdated mobile tomographs) can result in both false-negative and false-positive tests, and lead to inappropriate disease management. In these cases, consideration should be made for repeating the study on an acceptable FDG-PET/CT tomograph.

Timing

- Initial staging of FDG-PET/CT for patients with lymphoma should be obtained no longer than 1 month prior to the initiation of therapy.
- The initial study should include a contrast-enhanced diagnostic CT if it is expected that RT may be a component of initial treatment.

Interpretation

- The panel supports the ACR¹ and SNMMI² recommendation for FDG-PET/CT interpretation, including the requirement that FDG-PET/CT examinations should be performed under the supervision of and interpreted by a physician with the following qualifications:
 - ▶ Board certification in radiology or diagnostic radiology, nuclear radiology, or nuclear medicine
 - OR
 - ▶ Completion of a formal Accreditation Council for Graduate Medical Education (ACGME)-approved general nuclear medicine program in addition to 1000 hours of clinical training in general nuclear medicine, 20 hours of continuing medical education (CME) in FDG-PET, and at least 150 oncologic FDG-PET/CT examinations interpreted or multi-read during the previous 3 years.¹
- Continuing experience/education should include interpretation of a minimum of 150 FDG-PET/CT examinations in 3 years (multi-read is acceptable) and completion of 150 hours (including 75 hours of Category 1 CME) during the preceding 3 years pertinent to the physician's practice patterns, including FDG-PET imaging.¹
- The interpreting radiology or nuclear medicine physician should have adequate training and CME/experience in interpreting FDG-PET/CT for patients with lymphoma, including use of the Deauville 5-point scoring system.
- The final report for any FDG-PET/CT examination to define response should include the Deauville 5-point scale score, which is a visual score.
- A second opinion/overread is encouraged of scans that are not initially interpreted by qualified individuals, when there is a discrepancy between the clinical presentation and radiology report, and/or when no appropriate Deauville score has been provided.

¹ American College of Radiology. ACR-SPR Practice Parameters for Performing FDG-PET/CT in Oncology. 2016. Available at: <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/FDG-PET-CT.pdf?la=en>. Accessed November 19, 2021.

² Boellaard R, Delgado-Bolton R, Oyen WJG, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 2015;42:328-354.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

PET 5-POINT SCALE (DEAUVILLE CRITERIA)

Score		PET/CT Scan Result
Negative	1	No uptake
	2	Uptake ≤ mediastinum
	3	Uptake > mediastinum but ≤ liver
Positive	4	Uptake moderately higher than liver and visually above adjacent background activity
	5	Uptake markedly higher than liver and/or new lesions
	X ^a	New areas of uptake unlikely to be related to lymphoma

Adapted with kind permission from Springer International Publishing: Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014;32:3048-3058.

^a Watchful waiting, biopsy, or additional imaging tests may be appropriate depending on clinical circumstances. Obtaining a second opinion/overread of the imaging may be beneficial.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

UNFAVORABLE RISK FACTORS

Unfavorable Risk Factors for Stage I–II Hodgkin Lymphoma

Risk Factor	GHSG	EORTC	NCCN
Age		≥50	
Histology			
ESR and B symptoms	>50 if A; >30 if B	>50 if A; >30 if B	≥50 or any B symptoms
Mediastinal mass	MMR >0.33	MTR >0.35	MMR >0.33
# Nodal sites	>2*	>3*	>3
E lesion	any		
Bulky			>10 cm

GHSG = German Hodgkin Study Group
 EORTC = European Organization for
 Research and Treatment of Cancer

MMR = Mediastinal mass ratio, maximum width of mass/maximum intrathoracic diameter
 MTR = Mediastinal thoracic ratio, maximum width of mediastinal mass/intrathoracic
 diameter at T5–6

International Prognostic Score (IPS) 1 point per factor (advanced disease)[†]

- Albumin <4 g/dL
- Hemoglobin <10.5 g/dL
- Male
- Age ≥45 years
- Stage IV disease
- Leukocytosis (white blood cell count ≥15,000/mm³)
- Lymphocytopenia (lymphocyte count <8% of white blood cell count, and/or lymphocyte count <600/mm³)

[†]From: Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506-1514. Copyright © 1998 Massachusetts Medical Society. Adapted with permission.

*Note that the EORTC includes the infraclavicular/subpectoral area with the axilla while the GHSG includes it with the cervical. Both EORTC and GHSG combine the mediastinum and bilateral hila as a single region.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

UNFAVORABLE RISK FACTORS

Definitions of Lymph Node Regions*

		Ann Arbor	EORTC	GHSG
Supradiaphragmatic Nodal Regions	R Cervical/Supraclavicular			
	R ICL/Subpectoral			
	R Axilla			
	L Cervical/Supraclavicular			
	L Infraclavicular/Subpectoral			
	L Axilla			
	Mediastinum			
	R Hilum			
	L Hilum			
Infradiaphragmatic Nodal Regions	Celiac/Spleen hilar			
	Paraortic			
	Mesenteric			
	R Iliac			
	L Iliac			
	R Inguinal/Femoral			
	L Inguinal/Femoral			

*Note that the EORTC includes the infraclavicular/subpectoral area with the axilla while the GHSG includes it with the cervical. Both EORTC and GHSG combine the mediastinum and bilateral hila as a single region.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

PRINCIPLES OF SYSTEMIC THERAPY

Primary Systemic Therapy Regimens

Classic Hodgkin Lymphoma

- The most common variant of chemotherapy used at NCCN Member Institutions is ABVD.
- Routine use of growth factors is not recommended with ABVD.
- Leukopenia is not a factor for delay of treatment or reduction of dose intensity (except for escalated BEACOPP).

Regimens and References (listed in alphabetical order)

ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) ± ISRT

Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. *N Engl J Med* 2010;363:640-652.

Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. *N Engl J Med* 2015;372:1598-1607.

André MPE, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: Final results of the randomized EORTC/LYSA/FIL H10 trial. *J Clin Oncol* 2017;35:1786-1794.

Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. *J Clin Oncol* 2010;28:4199-4206.

Straus DJ, Jung SH, Pitcher B, et al. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. *Blood* 2018;132:1013-1021.

ABVD followed by escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) ± ISRT

Straus DJ, Jung SH, Pitcher B, et al. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. *Blood* 2018;132:1013-1021.

Escalated BEACOPP

Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. *Lancet* 2012;379:1791-1799.

Casasnovas RO, Bouabdallah R, Brice P, et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. *Lancet Oncol* 2019;20:202-215.

Escalated BEACOPP followed by ABVD with ISRT

von Tresckow B, Plütschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. *J Clin Oncol* 2012;30:907-913.

Brentuximab vedotin + AVD (doxorubicin, vinblastine, and dacarbazine)

Ansell SM, Radford J, Connors JM, et al. Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma. *N Engl J Med* 2022;387:310-320.

[See Principles of Systemic Therapy for NLP HL \(HODG-C, 2 of 5\)](#)

[See Principles of Systemic Therapy for Relapsed or Refractory Disease \(HODG-C, 3 of 5\)](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

PRINCIPLES OF SYSTEMIC THERAPY

Primary Systemic Therapy Regimens

Nodular Lymphocyte-Predominant Hodgkin Lymphoma

• The most common chemotherapy regimens used at NCCN Member Institutions for NLPHL are listed below.^a

Regimens and References (listed in alphabetical order)

ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) + rituximab^b

Savage KJ, Skinnider B, Al-Mansour M, et al. Treating limited stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. *Blood* 2011;118:4585-4590.

Canellos GP, Mauch P. What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin's lymphoma? *J Clin Oncol* 2010;28:e8.

CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) + rituximab^b

Fanale MA, Cheah CY, Rich A, et al. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. *Blood* 2017;130:472-477.

CVbP (cyclophosphamide, vinblastine, prednisolone) + rituximab^b

Shankar A, Hall GW, Gorde-Grosjean S, et al. Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin's lymphoma - an Anglo-French collaborative report. *Eur J Cancer* 2012;48:1700-1706.

Rituximab^b

Advani RH, Hoppe RT. How I treat nodular lymphocyte predominant Hodgkin lymphoma. *Blood* 2013;122:4182-4188.

Advani RH, Horning SJ, Hoppe RT, et al. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. *J Clin Oncol* 2014;32:912-918.

Eichenauer DA, Fuchs M, Pluetschow A, et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. *Blood* 2011;118:4363-4365.

Eichenauer DA, Plütschow A, Fuchs M, et al. Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group. *J Clin Oncol* 2015;33:2857-2862.

Davies A, Merli F, Mihaljević B, et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. *Lancet Haematol* 2017;4:e272-e282.

Lugtenburg P, Avivi I, Berenschot H, et al. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. *Haematologica* 2017;102:1913-1922.

^a Ongoing clinical trials will help to clarify the role of a watch-and-wait strategy or systemic therapy, including anthracycline (epirubicin or doxorubicin), bleomycin, and vinblastine-based chemotherapy or antibody-based approaches, in the treatment of these patients.

^b An FDA-approved biosimilar is an acceptable substitute for rituximab. Rituximab and hyaluronidase human injection for subcutaneous use may be substituted for rituximab after patients have received the first full dose of rituximab by intravenous infusion.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

PRINCIPLES OF SYSTEMIC THERAPY RELAPSED OR REFRACTORY DISEASE

Relapsed or Refractory Disease

	Second-Line and Subsequent Therapy ^{c,d} (in alphabetical order)	Therapy for Disease Refractory to at Least 3 Prior Lines of Therapy (in alphabetical order)
CHL	<ul style="list-style-type: none"> • Brentuximab vedotin¹ • Brentuximab vedotin + bendamustine² • Brentuximab vedotin + nivolumab³ • DHAP (dexamethasone, cisplatin, high-dose cytarabine)^{4,5} • Gemcitabine/bendamustine/vinorelbine⁶ • GVD (gemcitabine, vinorelbine, liposomal doxorubicin)⁷ • GVD + pembrolizumab⁸ • ICE (ifosfamide, carboplatin, etoposide)^{5,9,10} • ICE + brentuximab vedotin¹¹ • ICE + nivolumab¹² • IGEV (ifosfamide, gemcitabine, vinorelbine)¹³ • Pembrolizumab^{14,15} 	<ul style="list-style-type: none"> • Bendamustine¹⁶ • Bendamustine + carboplatin + etoposide¹⁷ • C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone)^{18,19} • Everolimus²⁰ • GCD (gemcitabine, cisplatin, dexamethasone)²¹ • GEMOX (gemcitabine, oxaliplatin)²² • Lenalidomide²³ • MINE (etoposide, ifosfamide, mesna, mitoxantrone)²⁴ • Mini-BEAM (carmustine, cytarabine, etoposide, melphalan)^{25,26} • Nivolumab^{27,28} (see indications below) • Vinblastine²⁹
NLPHL^d	<ul style="list-style-type: none"> • R (rituximab)^b + bendamustine³⁰ • R^b + DHAP^{4,5} • R^b + ICE^{5,10} • R^b + IGEV¹³ • If not previously used³¹: <ul style="list-style-type: none"> ▶ R^b + ABVD ▶ R^b + CHOP ▶ R^b + CVbP 	

General Guidelines for Checkpoint Inhibitors (CPI) for Relapsed or Refractory CHL^{e,f}

- CPI are recommended for any patients with CHL that has relapsed or progressed after HDT/ASCR ± brentuximab vedotin.
- CPI are also an option for patients with relapsed or refractory CHL who are transplant-ineligible based on comorbidity or failure of second-line chemotherapy.
- Post-allogeneic transplant, patients can receive either nivolumab or pembrolizumab. There are limited data regarding the use of CPI following allogeneic transplantation. If a CPI is used, the transplant regimen will need to be carefully considered.

^b An FDA-approved biosimilar is an acceptable substitute for rituximab. Rituximab and hyaluronidase human injection for subcutaneous use may be substituted for rituximab after patients have received the first full dose of rituximab by intravenous infusion.

^c Choice depends on prior therapies and prior toxicities. There are no preferred second-line or subsequent therapy options.

^d Subsequent systemic therapy options include second-line therapy options that were not previously used.

^e National Institutes of Health. Nivolumab package insert. Available at: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f570b9c4-6846-4de2-abfa-4d0a4ae4e394>. Accessed November 19, 2021.

^f National Institutes of Health. Pembrolizumab package insert. Available at: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9333c79b-d487-4538-a9f0-71b91a02b287>. Accessed November 19, 2021.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

References

HODG-C
3 OF 5



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

PRINCIPLES OF SYSTEMIC THERAPY FOR RELAPSED OR REFRACTORY DISEASE

REFERENCES

- ¹ Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. *J Clin Oncol* 2012;30:2183-2189.
- ² O'Connor OA, Lue JK, Sawas A, et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial. *Lancet Oncol* 2018;19:257-266.
- ³ Herrera AF, Moskowitz AJ, Bartlett NL, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. *Blood* 2018;131:1183-1194.
- ⁴ Josting A, Rudolph C, Reiser M, et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. *Ann Oncol* 2002;13:1628-1635.
- ⁵ Abali H, Urün Y, Oksüzöğlü B, Budakoğlu B, et al. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. *Cancer Invest* 2008;26:401-406.
- ⁶ Santoro A, Mazza R, Pulsoni A, et al. Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: final results of a multicenter phase II study. *J Clin Oncol* 2016;34:3293-3299.
- ⁷ Bartlett N, Niedzwiecki D, Johnson J, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. *Ann Oncol* 2007;18:1071-1079.
- ⁸ Moskowitz AJ, Shah G, Schöder H, et al. Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. *J Clin Oncol* 2021;39:3109-3117.
- ⁹ Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. *Blood* 2001;97:616-623.
- ¹⁰ Hertzberg MS, Crombie C, Benson W, et al. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma. *Ann Oncol* 2006;17 Suppl 4:iv25-30.
- ¹¹ Lynch RC, Cassaday RD, Smith SD, et al. Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. *Lancet Haematol* 2021;8:e562-e571.
- ¹² Mei MG, Lee HJ, Palmer J, et al. Response-adapted anti-PD1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. *Blood* 2022;139:3605-3616.
- ¹³ Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. *Haematologica* 2007;92:35-41.
- ¹⁴ Kuruvilla J, Ramchandren R, Santoro A, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. *Lancet Oncol* 2021;22:512-524.
- ¹⁵ Chen R, Zinzani PL, Fanale MA, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. *J Clin Oncol* 2017;35:2125-2132.
- ¹⁶ Moskowitz AJ, Hamlin PA, Perales M-A, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. *J Clin Oncol* 2013;31:456-460.
- ¹⁷ Budde LE, Wu D, Martin DB, et al. Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. *Br J Haematol* 2018;183:601-607.
- ¹⁸ Anderson T, Bender RA, Fisher RI, et al. Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup. *Cancer Treat Rep* 1977;61:1057-1066.
- ¹⁹ Longo DL, Young RC, Hubbard SM, et al. Prolonged initial remission in patients with nodular mixed lymphoma. *Ann Intern Med* 1984;100:651-656.
- ²⁰ Johnston PB, Inwards DJ, Colgan JP, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. *Am J Hematol* 2010;85:320-324.
- ²¹ Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. *J Clin Oncol* 2014;32:3490-3496.
- ²² Gutierrez A, Rodriguez J, Martinez-Serra J, et al. Gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma. *Onco Targets Ther* 2014;7:2093-2100.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

PRINCIPLES OF SYSTEMIC THERAPY FOR RELAPSED OR REFRACTORY DISEASE

REFERENCES

- ²³ Fehniger TA, Larson S, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. *Blood* 2011;118:5119-25.
- ²⁴ Rodriguez MA, Cabanillas FC, Hagemester FB, et al. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. *Ann Oncol* 1995;6:609-611.
- ²⁵ Colwill R, Crump M, Couture F, et al. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. *J Clin Oncol* 1995;13:396-402.
- ²⁶ Martín A, Fernández-Jiménez MC, Caballero MD, et al. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. *Br J Haematol* 2001;113:161-171.
- ²⁷ Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. *Lancet Oncol* 2016;17:1283-1294.
- ²⁸ Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: Extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. *J Clin Oncol* 2018;36:1428-1439.
- ²⁹ Neoplastic disease. Treatment with vinblastine. A cooperative study. *Arch Intern Med* 1965;116:856-852.
- ³⁰ Prusila REI, Haapasaari KM, Marin K, et al. R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma. *Acta Oncol* 2018;57:1265-1267.
- ³¹ Advani RH, Hoppe RT. How I treat nodular lymphocyte predominant Hodgkin lymphoma. *Blood* 2013;122:4182-4188.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

PRINCIPLES OF RADIATION THERAPY

General Principles

- Treatment with photons, electrons, or protons may all be appropriate, depending on clinical circumstances.
- Advanced RT technologies such as intensity-modulated RT (IMRT)/volumetric modulated arc therapy (VMAT),¹⁻³ breath hold or respiratory gating,⁴⁻⁵ and/or image-guided RT (IGRT),⁵ or proton therapy⁶⁻⁸ may offer significant and clinically relevant advantages in specific instances to spare important OAR such as the heart (including coronary arteries, valves, and left ventricle), lungs, kidneys, spinal cord, esophagus, carotid artery, bone marrow, breasts, stomach, muscle/soft tissue, and salivary glands and decrease the risk for late, normal tissue damage while still achieving the primary goal of local tumor control. For optimal mediastinal treatment planning, organs/tissues to be contoured should include the lungs, heart, coronary arteries, and left ventricle.
- The demonstration of significant dose-sparing for these OAR reflects best clinical practice, as it reduces the risk of late complications from normal tissue damage. Achieving highly conformal dose distributions is especially important for patients who are being treated with curative intent or who have long life expectancies following therapy.
- In mediastinal HL, the use of four dimensional (4D)-CT for simulation and the adoption of strategies to deal with respiratory motion and minimize dose to OAR are essential, especially deep inspiration breath-hold techniques, respiratory gating, and image-guided RT during treatment delivery. breath-hold techniques have been shown to decrease incidental dose to the heart and lungs in many disease presentations.⁵ In certain circumstances, the use of protons for mediastinal lymphoma provides dosimetric advantages that may reduce long-term toxicity. The potential advantage of protons is related to the localization of disease within the mediastinum as well as patient gender assigned at birth and age.⁹⁻¹¹
- Although the advantages of these techniques include tightly conformal doses and steep gradients next to normal tissues, the "low-dose bath" to normal structures such as the breasts must be considered in choosing the final RT technique. In any case, target definition and delineation and treatment delivery verification require careful monitoring to avoid the risk of tumor geographic miss and subsequent decrease in tumor control. Initial diagnostic imaging with contrast-enhanced CT, MRI, FDG-PET, ultrasound, and other imaging modalities facilitate target definition. Image guidance may be required to provide assurance of accurate daily delivery.
- Randomized studies to test these concepts are unlikely to be done since these techniques are designed to decrease late effects, which take 10+ years to develop. In light of that, the modalities and techniques that are found to best reduce the doses to the OAR in a clinically meaningful way without compromising target coverage should be considered.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

References



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

PRINCIPLES OF RADIATION THERAPY

Involved-Site Radiation Therapy (ISRT): Dose

- Combined Modality Therapy (CMT)
 - ▶ Non-bulky disease (stage I–II): 20^a–30 Gy (if treated with ABVD); 1.5–2.0 Gy per fraction
 - ▶ Non-bulky disease (stage IB–IIB): 30 Gy; 1.5–2.0 Gy per fraction
 - ▶ Bulky disease sites (all stages): 30–36 Gy; 1.5–2.0 Gy per fraction
 - ▶ Sites of Deauville 4–5 and partial response (PR) to chemotherapy: 36–45 Gy
- ISRT Alone (uncommon, except)
 - ▶ Involved regions: 30–36 Gy (the dose of 30 Gy is mainly used for NLPHL); 1.5–2.0 Gy per fraction
 - ▶ Uninvolved regions: 25–30 Gy; 1.5–2.0 Gy per fraction. ISRT for NLPHL includes extension to clinically relevant initially uninvolved nodes.
- Palliative RT: 4–30 Gy

ISRT: Volumes

- ISRT is recommended as the appropriate field for HL.¹²
 - ▶ Planning for ISRT requires modern CT-based simulation and treatment planning capabilities.
 - ▶ Incorporating other modern imaging such as FDG-PET and MRI often enhances treatment volume determination.¹³
- ISRT targets the site of the originally involved lymph node(s).
 - ▶ The volume encompasses the original or suspected extent of disease prior to chemotherapy or surgery. However, it spares adjacent uninvolved organs (eg, lungs, bone, muscle, kidney) when lymphadenopathy regresses following chemotherapy.
- For CHL, the pre-chemotherapy or pre-biopsy gross tumor volume (GTV) provides the basis for determining the clinical target volume (CTV).
 - ▶ Concerns for questionable subclinical disease and uncertainties in original imaging accuracy or localization may lead to expansion of the CTV and are determined individually using clinical judgment.

- For NLPHL, the CTV will depend on whether treatment consists of ISRT alone or CMT.
 - ▶ ISRT alone: The CTV should be expanded to include potential microscopic disease in the immediate region of the FDG-PET–positive disease.
 - ▶ CMT: Similar to CHL after chemotherapy [treating originally involved lymph node(s) only]
- Possible movement of the target by respiration as determined by 4D-CT or fluoroscopy (internal target volume; [ITV]) should also influence the final CTV.
- The planning target volume (PTV) is an additional expansion of the CTV that accounts only for setup variations and may differ by site and immobilization technique.
 - ▶ See ICRU definitions¹⁴
- OAR should be outlined for optimizing treatment plan decisions.
- The treatment plan can be designed using conventional, 3-D conformal, proton therapy, or IMRT techniques using clinical treatment planning considerations of coverage and normal tissue avoidance.
- The treatment of extranodal disease is individualized, but similar principles of GTV/CTV/PTV definition should be applied as for nodal disease.
 - ▶ Chest wall extension – Effort should be made to include regions of initial chest wall extension to definitive doses.
 - ▶ Lung involvement – Areas of extension into the lung from mediastinal or hilar disease may be treated with lower doses (~15 Gy) unless the relative volume is small, in which case higher doses may be utilized. Careful consideration of partial lung tolerance is essential. Pulmonary nodular disease is usually not treated following chemotherapy unless residual disease is present.
 - ▶ Pleural or pericardial effusions are not included in the GTV. Nodular pericardial involvement may be included with consideration of cardiac tolerance.
 - ▶ Bone – Areas of osseous disease may be treated with a CTV expansion beyond the GTV defined by imaging. In vertebral body disease, the entire vertebra is generally treated.

^a A dose of 20 Gy following ABVD x 2 is sufficient if the patient has non-bulky stage I–IIA disease with an ESR <50, no extralymphatic lesions, and only 1 or 2 lymph node regions involved. See [HODG-B](#) for definition of nodal sites according to GHSG.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[References](#)



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

PRINCIPLES OF RADIATION THERAPY

RT DOSE CONSTRAINT GUIDELINES FOR LYMPHOMA^b

OAR		Dose Recommendation (1.5–2 Gy/fraction)	Toxicity
Head and Neck	Parotid glands	Ipsilateral: Mean <11 Gy (recommended); <24 Gy (acceptable) Contralateral: ALARA ^c	Xerostomia ^{15,16}
	Submandibular glands	Ipsilateral: Mean <11 Gy (recommended); <24 Gy (acceptable) Contralateral: ALARA ^c	Xerostomia ¹⁷
	Oral cavity (surrogate for minor salivary glands)	Mean <11 Gy	Xerostomia, dysgeusia, oral mucositis ¹⁷
	Thyroid	V25 Gy <63.5% Minimize V30 Gy	Hypothyroidism ¹⁸
	Lacrimal glands	V20 Gy <80%	Dry eye syndrome ¹⁹
	Larynx/Pharyngeal constrictors	Mean <25 Gy	Laryngeal edema, dysphagia ²⁰
	Carotids	Ipsilateral: Avoid hotspots Contralateral: ALARA ^c	Carotid artery atherosclerosis

^b General Principles of RT Dose Constraints, [see HODG-D \(6 of 12\)](#).

^c ALARA - as low as reasonably achievable.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

References

**NCCN Guidelines Version 2.2023**
Hodgkin Lymphoma (Age ≥18 years)**PRINCIPLES OF RADIATION THERAPY**
RT DOSE CONSTRAINT GUIDELINES FOR LYMPHOMA^b

OAR		Dose Recommendation (1.5–2 Gy/fraction)	Toxicity
Thorax	Heart ^d	Mean <8 Gy (recommended) Mean <15 Gy (acceptable)	Major adverse cardiac events ²¹⁻²⁴
	Aortic and mitral valves	Dmax <25 Gy	Valvular heart disease ^{22,25,26}
	Tricuspid and pulmonic valves	Dmax <30 Gy	
	Left ventricle	Mean <8 Gy (recommended) Mean <15 Gy (acceptable)	Heart failure ^{22,27}
	Pericardium	D100 (heart) <5 Gy	Pericarditis ²⁸
	Coronary vessels including the left main, left anterior descending (LAD), left circumflex (LCx), and right coronary artery (RCA) ^d	LAD V15 Gy <10% ^d LCx V15 Gy <14% Coronary vessels (total)- Mean <7 Gy Minimize the maximum dose to individual coronary arteries	Major adverse cardiac events ²⁹
	Lungs	Mean dose <13.5 Gy V20 <30% V5 <55%	Pneumonitis ^{30,31}

^b General Principles of RT Dose Constraints, [see HODG-D \(6 of 12\)](#).^d As cardiac toxicity is likely related to dose to specific substructures, it is recommended that these are contoured, constraints are applied, and doses are recorded. Contouring atlases are available.^{32, 33} It is recognized that contouring the coronary arteries is challenging given anatomical variations and lung/heart motion. This may warrant designing a planning OAR volume in some patients. Further, it is important to preferentially spare high-dose overlap with the proximal coronary arteries (left main, proximal LAD). For example, a plan may achieve an LAD V15 Gy <10%, but it is not ideal if most of the 15 Gy or higher dose overlap is surrounding the proximal LAD while the distal LAD is spared to meet the volumetric dose goal. Reviewing both dose to the entire coronary tree and the individual components, particularly the proximal vessels, is important.**Note: All recommendations are category 2A unless otherwise indicated.****Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.****References**



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

PRINCIPLES OF RADIATION THERAPY

RT DOSE CONSTRAINT GUIDELINES FOR LYMPHOMA^b

OAR		Dose Recommendation (1.5–2 Gy/fraction)	Toxicity
Abdomen	Liver	Mean <15 Gy V20 <30% V30 <20%	Hepatic toxicity ^{34, 35}
	Stomach	Dmax <45 Gy	Ulceration ³⁶
	Spleen	Mean <10 Gy V5 ≤30% V15 ≤20%	Late infections ³⁷ Lymphopenia ³⁸
	Pancreas	Minimize volume >36 Gy (especially to pancreatic tail)	Diabetes ³⁹
	Small bowel	V15 <120 cc Dmax <45 Gy	Diarrhea ³⁶ Obstruction, ulceration, fistula ³⁶
	Kidneys	Mean <8 Gy V10 <30% V20 <15% (recommended); <25% (acceptable)	Renal insufficiency ^{40, 41}
Other	Bone marrow ^e	V5: ALARA ^c V10 <50% V25 <25%	Acute cytopenias ^{42,43} Chronic cytopenias ⁴⁴
	Long bone	V40 <64%	Fracture ⁴⁵

SECONDARY MALIGNANCIES^f

OAR	Dose Recommendation (1.8–2 Gy/fraction)	Secondary Malignancy
Breast	Minimize volume >4 Gy (ideally <10%)	Breast cancer (adenocarcinoma) ⁴⁶
Esophagus	Minimize volume >30 Gy	Esophageal cancer ⁴⁷
Stomach	Minimize volume >25 Gy	Gastric cancer ⁴⁸
Pancreas	Minimize volume >5–10 Gy	Pancreatic cancer ⁴⁹

^b General Principles of RT Dose Constraints, [see HODG-D \(6 of 12\)](#).

^c ALARA - as low as reasonably achievable.

^e Active bone marrow can be delineated using various imaging modalities and is most abundant in the pelvic bones, thoracic-lumbar spine, and sacrum.^{50, 51, 52}

^f The linear no-threshold model supports limiting RT dose to susceptible organs as low as reasonably achievable. The following dose guidelines, based on published data, may further guide treatment decisions.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[References](#)



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

PRINCIPLES OF RADIATION THERAPY

RT DOSE CONSTRAINT GUIDELINES FOR LYMPHOMA

General Principles of RT Dose Constraints

- Patients with hematologic malignancies typically receive far lower doses than patients with epithelial or mesenchymal malignancies and generally have more favorable long-term outcomes. Therefore, more stringent dose constraints, often proportionally reduced from acceptable thresholds in other malignancies, are recommended. Doses to OAR should follow principles of ALARA (as low as reasonably achievable). In some scenarios, target coverage may require dose constraints to be exceeded if the OAR is within the PTV.
- A relatively rare but serious complication of RT is induction of secondary malignancies. Most studies have shown that increasing dose is associated with increasing risk without a safe threshold dose (linear no-threshold model).⁵³ Therefore, limiting radiation dose to susceptible organs as much as possible is vital. Disease- and patient-related factors are also contributory (eg, age, tobacco exposure).
- In addition to secondary malignancies, cardiac and pulmonary complications after RT are most concerning and are reviewed further in the following sections.

Heart

- Multiple cardiac complications can develop from mediastinal RT, including pericarditis, arrhythmias, coronary artery disease (CAD), valvular heart disease (VHD), and cardiomyopathy/congestive heart failure.^{24,54} In addition to RT factors, the risk of cardiac events is also influenced by chemotherapy administration (eg, doxorubicin), pre-existing cardiovascular disease, age, and other cardiac risk factors (eg, diabetes, hypertension, hyperlipidemia).^{24,55-57} While global heart metrics such as mean heart dose are most commonly used to assess risk, there is an increasing recognition that radiation dose-fractionation to cardiac substructures must be accounted for. Atlases for radiation oncologists to assist with contouring cardiac substructures are available.⁵⁸⁻⁶⁰
- Because of the long-term survival of thousands of patients with breast cancer and HL, many large cohort studies have been able to explore the relationship of heart RT dose with cardiac toxicity and death. Mediastinal RT for lymphomas, relative to breast cancer and other thoracic malignancies, is characterized by radiation exposures to larger volumes of the heart and substructures, albeit to lower doses (20–40 Gy). Common for both breast and lymphoma RT, there is typically a latency of >20 years for secondary cardiac disease.^{24,61-63}
- As mentioned previously, most studies have associated cardiac events with either prescribed mediastinal radiation dose or mean heart dose. In both the breast cancer and lymphoma radiotherapy literature, mean heart dose has been related to the risk of cardiac events despite the variable volume of whole heart exposed in these two diseases. The risk appears to be linear, without a clear safe threshold dose, with the risk of heart disease increasing by 4.1%–7.4% per 1 Gy of cardiac radiation dose administered.^{24,61-63} One of the best data sets relating radiation dose to cardiac disease risk in adult patients is an HL case-control study from the Netherlands.²⁴ Patients were treated prior to 1996 mainly using anteroposterior/posteroanterior (AP/PA) fields. Using the metric of mean heart dose as a measure of cardiac toxicity risk, Van Nimwegen et al demonstrated an excess relative risk of 7.4% per Gy mean heart dose. A statistically significant increased risk of coronary heart disease was demonstrated among patients getting a mean heart dose as low as 5–14 Gy (RR, 2.31) compared with a mean heart dose of 0 Gy. This risk was even higher for a mean heart dose of 15 Gy or higher (RR, 2.83 for 15–19 Gy; RR, 2.9 for 20–24 Gy; and RR, 3.35 for 25–34 Gy). This study also explored different age-of-diagnosis cohorts and generally showed the same radiation dose-response relationships.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

References



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

PRINCIPLES OF RADIATION THERAPY

RT DOSE CONSTRAINT GUIDELINES FOR LYMPHOMA

Heart (continued)

- The number of studies evaluating specific dose constraints for cardiac substructures is rather limited. Dutch investigators demonstrated a relationship between heart failure and mean dose to the left ventricle.²⁷ Chemotherapy was a clear confounder in regards to the risk of heart failure. Among patients treated with anthracyclines, the 25-year cumulative risk of heart failure was 11.2% for mean left ventricle dose <15 Gy, 15.9% for 16–20 Gy, and 32.9% for ≥21 Gy.
- In regards to VHD, increasing mediastinal radiation dose, especially >30 Gy, has been associated with an elevated risk of valvular dysfunction.^{24,62} Using a large Dutch cohort of adult patients treated with radiation to the mediastinum, Cutter et al demonstrated 30-year cumulative risks of VHD of 3%, 6.4%, 9.3%, and 12.4% for mean valvular doses of <30, 31–35, 36–40, and >40 Gy.²⁵ VHD was related to aortic valve abnormalities in 71% of patients. Mitral valvular abnormalities, which can also be related to ischemic heart disease due to papillary muscle dysfunction after myocardial infarction, occurred in 50% of patients (some patients had multiple dysfunctional valves). Tricuspid valvular disease was uncommon and pulmonic valve dysfunction was not reported—perhaps due to right heart dysfunction tending to be less clinically problematic. There was no confounding effect of anthracycline chemotherapy on VHD risk in this study. In agreement with this Dutch study, the previously mentioned German-Austrian pediatric cohort showed that prescribed mediastinal radiation dose was the only independent risk factor for VHD.²⁶ No cases of VHD were observed for individuals with doses of 20 Gy, while the 25-year cumulative risks among individuals with prescribed doses of 25 Gy, 30 Gy, and 36 Gy were 2%, 1%, and 16%, respectively.
- Radiation dose constraints for coronary arteries is a work in progress. Standard CT-simulation imaging, even with contrast, does not identify the entire coronary tree very well. There are resolution issues, acquisition time issues, and cardiac motion issues. Coronary anatomy is variable along with some individual variation with collateral blood flow. Proximal coronary arteries and the mid-trunk of the LAD are often visible, since the latter is located in the epicardial fat of the left anterolateral aspect of the global heart structure, apparently with minimal motion artifact. Even with research techniques to merge coronary CT angiograms,^{64,65} the important branch vessels (diagonals off the LAD; obtuse marginals off the LCx, posterior descending branch of the RCA) are not well demonstrated. Nevertheless, there have been studies in breast and lymphoma radiotherapeutic management to contour the major coronary arteries and try to relate coronary dosimetry to risk of CAD. Moignier et al analyzed 33 irradiated patients with HL—21 without coronary stenosis (controls) and 12 patients with critical coronary stenosis (cases) seen on CT angiography.⁶⁵ Radiation dose to stenotic coronary segments and normal coronary segments was compared using a logistic regression. In this manner, the risk of stenosis was found to be increased by 4.9% per Gy over the median dose to the control segments. This data set is too small to be a basis of radiation dose constraints, but does support the general notion of a dose-response effect in the clinical range of lymphoma radiation prescriptions. Another study by Hahn et al used a sample of 125 patients with HL treated with mediastinal RT and analyzed various dosimetry parameters of whole heart and coronary segments, looking for a relationship to cardiac events.⁶⁶ Multivariable competing risk regression models found that when any adverse cardiac event was the outcome, models using coronary artery variables did not perform better than models using whole heart variables. However, in a subanalysis of ischemic cardiac events only, the model using coronary artery variables was superior to the whole heart. Major findings for this study were that the V5 Gy for the LAD and the V20 Gy for the LCx had predictive value when looking at ischemic endpoints such as need for coronary revascularization, myocardial infarction, or cardiac death. The modeling analysis was not robust enough to yield specific guidance on dose constraints to specific coronary arteries.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[References](#)



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

PRINCIPLES OF RADIATION THERAPY

RT DOSE CONSTRAINT GUIDELINES FOR LYMPHOMA

Heart (continued)

- From the historical use of extended-field radiotherapy for HL, whole heart irradiation increases the risk of constrictive pericarditis, especially with doses >15 Gy. Modern radiotherapy for lymphomas rarely requires whole heart irradiation.
- Patients who survived childhood cancers represent a unique high-risk group. In a French cohort study of pediatric survivors with HL, the relative risk of severe cardiac disease at age 40 y is 1.9 at a cardiac radiation dose of 1–5 Gy and increases to 19.5–75.2 at a dose >15 Gy for survivors of childhood cancer.²¹ There are at least two other notable pediatric survivorship study cohorts that provide insights to radiation dose relationship with subsequent cardiovascular disease. Schellong et al reported on 1132 survivors of HL treated on the German-Austrian pediatric cooperative group studies from 1978–1995.²⁶ Patients could be binned into mediastinal radiation dose exposures of 36 Gy, 30 Gy, 25 Gy, 20 Gy, and 0 Gy. Cardiac valvular defects were the most frequent late cardiac disease, followed by CAD, cardiomyopathy, conduction disorders, and pericardial abnormalities. The cumulative incidence of cardiac disease after 25 years correlated with radiation dose with incidence of 21% for 36 Gy, decreasing to 10%, 6%, 5%, and 3% for the lower dose groups, respectively ($P < .001$). Multivariate analysis of several putative risk factors showed that mediastinal radiation dose was the only significant variable predicting for cardiac disease-free survival ($P = .0025$). Mulrooney et al published the Childhood Cancer Survivor Study (CCSS) analysis of cardiovascular disease risk in pediatric cancer survivors (not just HL) and analyzed the confounding and independent effects of anthracycline and mediastinal radiation prescribed dose showing a dose-response effect for both chemotherapy and radiotherapy.²² In this study of 14,358 patients, doses between 15 Gy and 35 Gy were not well distinguished, but there was a suggestion that 15 Gy might be a threshold dose associated with not only future VHD but also congestive heart failure and myocardial infarction. Bates et al recently updated the CCSS experience in a 2019 publication of 24,214 5-year survivors, providing further insights into the relationships between radiation and risk of long-term cardiac disease.²³ Mean heart doses >10 Gy were associated with increasing cardiac disease risk in a dose-response manner. Volumes of the heart receiving radiation also were correlated with cardiac risk. Children receiving a heart V5 of >50% had a 1.6-fold increased risk of late cardiac disease. Those receiving at least 20 Gy to any part of the heart also were at increased risk.
- While the data regarding cardiac constraints for modern RT of lymphomas are imperfect, we recommend that the mean heart dose be kept as low as possible, ideally <8 Gy, although in some patients a higher dose will be necessary given lymphoma extent. This also recognizes that patients with lymphoma tend to also receive anthracycline chemotherapy, although cumulative chemotherapy doses in modern practice tend to be lower than historical cohorts. Rarely should mean heart dose exceed 15 Gy, unless patients are being treated in the second-line setting with curative intent where larger RT doses are necessary.²³ Ideally, mean left ventricular dose should be kept lower than 8 Gy, although up to 15 Gy may be necessary in some circumstances. Aortic and mitral valve doses should be kept below 25 Gy, and ideally even lower. Tricuspid and pulmonic valves may be less critical OAR and it is recommended that doses be kept below 30 Gy. Constraints to coronary arteries are less well defined but should be as low as possible in terms of dose and volume/length.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[References](#)



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

PRINCIPLES OF RADIATION THERAPY

RT DOSE CONSTRAINT GUIDELINES FOR LYMPHOMA

Lungs

- The primary pulmonary toxicity related to mediastinal RT is radiation pneumonitis. Other complications, such as symptomatic fibrosis or bronchopleural fistula, are rarely encountered given the lower doses used for lymphoma management. Radiation pneumonitis is a clinical diagnosis consisting of dry cough, dyspnea, and occasionally low-grade fevers. Radiation pneumonitis must be distinguished from other entities including infectious pneumonia, acute bronchitis, pulmonary embolism, etc. Pulmonary complications, including pneumonitis, can arise from systemic modalities also, including bleomycin and immunotherapy.
- The most important risk factor for radiation pneumonitis is lung dose–volume metrics including mean lung dose (MLD), V20, and V5. Such metrics have been associated with pneumonitis risk in both epithelial⁶⁷ and hematologic malignancies.^{30,68} For epithelial malignancies, such as non-small cell lung cancer, guidelines generally recommend MLD <20 Gy and V20 <35%. In most circumstances, given the lower doses used in lymphoma management, much lower doses are generally achievable with careful planning.
- We recommend limiting MLD <13.5 Gy and V20 <30%, although dose to the lungs in most patients with lymphoma can be kept below these thresholds. More pertinent to IMRT or volumetric arc techniques, we recommend limiting the V5 <55%.
- RT, and possibly some chemotherapy drugs such as alkylating agents,⁶⁹ increase the risk of developing lung cancer.^{69,70} The risk increases linearly with dose to the lung.⁶⁹ The increased risk is most apparent in people who smoke, particularly those who continue to use tobacco after diagnosis.⁷¹ In fact, continuing to smoke after thoracic RT multiplies the risk of developing lung cancer. Therefore, a concerted effort should be made to help patients who currently smoke and require thoracic RT to stop smoking. Lung cancer screening with low-dose CT may also be appropriate depending upon clinical circumstances including age, pack-year tobacco exposure history, and interval since quitting. See [NCCN Guidelines for Lung Cancer Screening](#)

Breast

- Doses for epithelial breast cancer are significantly greater than doses utilized for lymphomas involving the mediastinum and axilla. As such, dose to the breast would fall well within acceptable dose constraints for breast tissue with regard to toxicity and cosmesis.
- Whole breast RT increases the risk of subsequent malignancies within the irradiated tissue. A latency period of >8 years is considered necessary before observation of this phenomenon and routine breast exams 1–2 times per year are indicated after this time frame. Patients should also undergo annual mammography beginning at age 40 or 8 years after RT to the breast, whichever comes first. Patients who received breast radiation between ages 10–30 should undergo screening with both MRI and mammography, often alternated every 6 months. While MRI can begin earlier, mammography should not be pursued until the patient is at least 30 years of age. See [NCCN Guidelines for Breast Cancer Screening and Diagnosis \(BSCR-2\)](#).
- Chemoprevention with selective estrogen receptor modulators and aromatase inhibitors have been demonstrated to reduce the risk of breast cancer by 50%–60% in high-risk populations. These trials, however, did not include individuals who received prior breast radiation for non-epithelial breast cancers. Patients should consider discussion of chemoprevention with their oncologist or breast specialist. See [NCCN Guidelines for Breast Cancer Risk Reduction](#).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

References



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

PRINCIPLES OF RADIATION THERAPY REFERENCES

- ¹ Filippi AR, Ragona R, Piva C, et al. Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: a comparison of second cancers and heart disease risk. *Int J Radiat Oncol Biol Phys* 2015;92:161-168.
- ² Girinsky T, Pichenot C, Beaudre A, et al. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? *Int J Radiat Oncol Biol Phys* 2006;64:218-226.
- ³ Voong KR, McSpadden K, Pinnix CC, et al. Dosimetric advantages of a "butterfly" technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin's lymphoma. *Radiat Oncol* 2014;9:94.
- ⁴ Paumier A, Ghalibafian M, Gilmore J, et al. Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin's lymphoma. *Int J Radiat Oncol Biol Phys* 2012;82:1522-1527.
- ⁵ Petersen PM, Aznar MC, Berthelsen AK, et al. Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma: benefit of deep inspiration breath-hold. *Acta Oncol* 2015;54:60-66.
- ⁶ Hoppe BS, Flampouri S, Su Z, et al. Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. *Int J Radiat Oncol Biol Phys* 2012;84:449-455.
- ⁷ Hoppe BS, Hill-Kayser CE, Tseng YD, et al. Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma. *Ann Oncol* 2017;28:2179-2184.
- ⁸ Tseng YD, Cutter DJ, Plastaras JP, et al. Evidence-based review on the use of proton therapy in lymphoma from the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee. *Int J Radiat Oncol Biol Phys* 2017;99:825-842.
- ⁹ Ntentas G, Dedeckova K, Andriik M, et al. Proton therapy in supradiaphragmatic lymphoma: Predicting treatment-related mortality to help optimize patient selection. *Int J Radiat Oncol Biol Phys* 2022;112:913-925.
- ¹⁰ Dabaja BS, Hoppe BS, Plastaras JP, et al. Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. *Blood* 2018;132:1635-1646.
- ¹¹ Rechner LA, Maraldo MV, Vogelius IR, et al. Life years lost attributable to late effects after radiotherapy for early stage Hodgkin lymphoma: The impact of proton therapy and/or deep inspiration breath hold. *Radiother Oncol* 2017;125:41-47.
- ¹² Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). *Int J Radiat Oncol Biol Phys* 2014;89:854-862.
- ¹³ Figura N, Flampouri S, Mendenhall NP, et al. Importance of baseline PET/CT imaging on radiation field design and relapse rates in patients with Hodgkin lymphoma. *Adv Radiat Oncol* 2017;2:197-203.
- ¹⁴ Gregoire V, Mackie TR. State of the art on dose prescription, reporting and recording in intensity-modulated radiation therapy (ICRU report No. 83). *Cancer Radiother* 2011;15:555-559.
- ¹⁵ Li Y, Taylor JM, Ten Haken RK, et al. The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy. *Int J Radiat Oncol Biol Phys* 2007;67:660-669.
- ¹⁶ Xu YG, Qi SN, Wang SL, et al. Dosimetric and clinical outcomes with intensity modulated radiation therapy after chemotherapy for patients with early-stage diffuse large B-cell lymphoma of Waldeyer ring. *Int J Radiat Oncol Biol Phys* 2016;96:379-386.
- ¹⁷ Rodrigues NA, Killian L, Hickey G, et al. A prospective study of salivary gland function in lymphoma patients receiving head and neck irradiation. *Int J Radiat Oncol Biol Phys* 2009;75:1079-1083.
- ¹⁸ Pinnix CC, Cella L, Andraos TY, et al. Predictors of hypothyroidism in Hodgkin lymphoma survivors after intensity modulated versus 3-dimensional radiation therapy. *Int J Radiat Oncol Biol Phys* 2018;101:530-540.
- ¹⁹ Wang K, Tobillo R, Mavroidis P, et al. Prospective assessment of patient-reported dry eye syndrome after whole brain radiation. *Int J Radiat Oncol Biol Phys* 2019;105:765-772.
- ²⁰ Sanguineti G, Adapala P, Endres EJ, et al. Dosimetric predictors of laryngeal edema. *Int J Radiat Oncol Biol Phys* 2007;68:741-749.
- ²¹ Haddy N, Diallo S, El-Fayech C, et al. Cardiac diseases following childhood cancer treatment: Cohort study. *Circulation* 2016;133:31-38.
- ²² Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. *BMJ* 2009;339:b4606.
- ²³ Bates JE, Howell RM, Liu Q, et al. Therapy-related cardiac risk in childhood cancer survivors: An analysis of the childhood cancer survivor study. *Journal of Clinical Oncology* 2019;37:1090-1101.
- ²⁴ Van Nimwegen FA, Schaapveld M, Cutter DJ, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. *J Clin Oncol* 2016;34:235-243.
- ²⁵ Cutter DJ, Schaapveld M, Darby SC, et al. Risk for valvular heart disease after treatment for Hodgkin lymphoma. *J Natl Cancer Inst* 2015;107:djv008.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

PRINCIPLES OF RADIATION THERAPY REFERENCES

- ²⁶ Schellong G, Riepenhausen M, Bruch C, et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: Report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. *Pediatric Blood and Cancer* 2010;55:1145-1152.
- ²⁷ Van Nimwegen FA, Ntents G, Darby SC, et al. Risk of heart failure in survivors of Hodgkin lymphoma: Effects of cardiac exposure to radiation and anthracyclines. *Blood* 2017;129:2257-2265.
- ²⁸ Carmel RJ, Kaplan HS. Mantle irradiation in Hodgkin's disease. An analysis of technique, tumor eradication, and complications. *Cancer* 1976;37:2813-2825.
- ²⁹ Atkins KM, Chaunzwa TL, Lamba N, et al. Association of left anterior descending coronary artery radiation dose with major adverse cardiac events and mortality in patients with non-small cell lung cancer. *JAMA Oncol* 2021;7:206-219.
- ³⁰ Pinnix CC, Smith GL, Milgrom S, et al. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. *Int J Radiat Oncol Biol Phys* 2015;92:175-182.
- ³¹ Fox AM, Dosoretz AP, Mauch PM, et al. Predictive factors for radiation pneumonitis in Hodgkin lymphoma patients receiving combined-modality therapy. *Int J Radiat Oncol Biol Phys* 2012;83:277-283.
- ³² Milo MLH, Offersen BV, Bechmann T, et al. Delineation of whole heart and substructures in thoracic radiation therapy: National guidelines and contouring atlas by the Danish Multidisciplinary Cancer Groups. *Radiother Oncol* 2020;150:121-127.
- ³³ Duane F, Aznar MC, Bartlett F, et al. A cardiac contouring atlas for radiotherapy. *Radiother Oncol* 2017;122:416-422.
- ³⁴ Kim TH, Kim DY, Park JW, et al. Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy. *Int J Radiat Oncol Biol Phys* 2007;67:225-231.
- ³⁵ Cheng JC, Wu JK, Lee PC, et al. Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. *Int J Radiat Oncol Biol Phys* 2004;60:1502-1509.
- ³⁶ Kavanagh BD, Pan CC, Dawson LA, et al. Radiation dose-volume effects in the stomach and small bowel. *Int J Radiat Oncol Biol Phys* 2010;76:S101-107.
- ³⁷ Weil BR, Madenci AL, Liu Q, et al. Late infection-related mortality in asplenic survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. *J Clin Oncol* 2018;36:1571-1578.
- ³⁸ Chadha AS, Liu G, Chen HC, et al. Does unintentional splenic radiation predict outcomes after pancreatic cancer radiation therapy? *Int J Radiat Oncol Biol Phys* 2017;97:323-332.
- ³⁹ van Nimwegen FA, Schaapveld M, Janus CP, et al. Risk of diabetes mellitus in long-term survivors of Hodgkin lymphoma. *J Clin Oncol* 2014;32:3257-3263.
- ⁴⁰ May KS, Khushalani NI, Chandrasekhar R, et al. Analysis of clinical and dosimetric factors associated with change in renal function in patients with gastrointestinal malignancies after chemoradiation to the abdomen. *Int J Radiat Oncol Biol Phys* 2010;76:1193-1198.
- ⁴¹ Inaba K, Okamoto H, Wakita A, et al. Long-term observations of radiation-induced creatinine clearance reduction and renal parenchymal volume atrophy. *Radiother Oncol* 2016;120:145-149.
- ⁴² Mell LK, Kochanski JD, Roeske JC, et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. *Int J Radiat Oncol Biol Phys* 2006;66:1356-1365.
- ⁴³ Mell LK, Schomas DA, Salama JK, et al. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. *Int J Radiat Oncol Biol Phys* 2008;70:1431-1437.
- ⁴⁴ McGuire SM, Bhatia SK, Sun W, et al. Using [(18)F]fluorothymidine imaged with positron emission tomography to quantify and reduce hematologic toxicity due to chemoradiation therapy for pelvic cancer patients. *Int J Radiat Oncol Biol Phys* 2016;96:228-239.
- ⁴⁵ Dickie CI, Parent AL, Griffin AM, et al. Bone fractures following external beam radiotherapy and limb-preservation surgery for lower extremity soft tissue sarcoma: relationship to irradiated bone length, volume, tumor location and dose. *Int J Radiat Oncol Biol Phys* 2009;75:1119-1124.
- ⁴⁶ Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. *JAMA* 2003;290:465-475.
- ⁴⁷ Morton LM, Gilbert ES, Stovall M, et al. Risk of esophageal cancer following radiotherapy for Hodgkin lymphoma. *Haematologica* 2014;99:e193-e196.
- ⁴⁸ Morton LM, Dores GM, Curtis RE, et al. Stomach cancer risk after treatment for Hodgkin lymphoma. *J Clin Oncol* 2013;31:3369-3377.
- ⁴⁹ Dores GM, Curtis RE, van Leeuwen FE, et al. Pancreatic cancer risk after treatment of Hodgkin lymphoma. *Ann Oncol* 2014;25:2073-2079.
- ⁵⁰ Hayman JA, Callahan JW, Herschtal A, et al. Distribution of proliferating bone marrow in adult cancer patients determined using FLT-PET imaging. *Int J Radiat Oncol Biol Phys* 2011;79:847-852.
- ⁵¹ Liang Y, Bydder M, Yashar CM, et al. Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies. *Int J Radiat Oncol Biol Phys* 2013;85:406-414.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

PRINCIPLES OF RADIATION THERAPY REFERENCES

- ⁵² Basu S, Houseni M, Bural G, et al. Magnetic resonance imaging based bone marrow segmentation for quantitative calculation of pure red marrow metabolism using 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography: A novel application with significant implications for combined structure-function approach. *Mol Imaging Biol* 2007;9:361-365.
- ⁵³ Berrington de Gonzalez A, Gilbert E, Curtis R, et al. Second solid cancers after radiation therapy: a systematic review of the epidemiologic studies of the radiation dose-response relationship. *Int J Radiat Oncol Biol Phys* 2013;86:224-233.
- ⁵⁴ Wright JL, Yom SS, Awan MJ, et al. Standardizing normal tissue contouring for radiation therapy treatment planning: An ASTRO consensus paper. *Pract Radiat Oncol* 2019;9:65-72.
- ⁵⁵ Hoppe BS, Bates JE, Mendenhall NP, et al. The meaningless meaning of mean heart dose in mediastinal lymphoma in the modern radiotherapy era. *Pract Radiat Oncol* 2020;10:e147-e154.
- ⁵⁶ Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). *Eur J Heart Fail* 2017;19:9-42.
- ⁵⁷ Totzeck M, Schuler M, Stuschke M, et al. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. *Int J Cardiol* 2019;280:163-175.
- ⁵⁸ Duane F, Aznar MC, Bartlett F, et al. A cardiac contouring atlas for radiotherapy. *Radiother Oncol* 2017;122:416-422.
- ⁵⁹ Milo MLH, Offersen BV, Bechmann T, et al. Delineation of whole heart and substructures in thoracic radiation therapy: National guidelines and contouring atlas by the Danish Multidisciplinary Cancer Groups. *Radiother Oncol* 2020;150:121-127.
- ⁶⁰ Kırılı M, Akçay D, Barış MM, et al. A heart atlas for breast radiation therapy and the influence of delineation education on both intra and interobserver variability. *Jpn J Radiol* 2019;37:420-430.
- ⁶¹ Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. *N Engl J Med* 2013;368:987-998.
- ⁶² Taylor C, Duane FK, Dodwell D, et al. Estimating the risks of breast cancer radiotherapy: Evidence from modern radiation doses to the lungs and heart and from previous randomized trials. *J Clin Oncol* 2017;35:1641-1649.
- ⁶³ Maraldo MV, Giusti F, Vogelius IR, et al. Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials. *Lancet Haematol* 2015;2:e492-e502.
- ⁶⁴ Milgrom SA, Varghese B, Gladish GW, et al. Coronary artery dose-volume parameters predict risk of calcification after radiation therapy. *J Cardiovasc Imaging* 2019;27:268-279.
- ⁶⁵ Moignier A, Broggio D, Derreumaux S, et al. Coronary stenosis risk analysis following Hodgkin lymphoma radiotherapy: A study based on patient specific artery segments dose calculation. *Radiother Oncol* 2015;117:467-472.
- ⁶⁶ Hahn E, Jiang H, Ng A, et al. Late cardiac toxicity after mediastinal radiation therapy for Hodgkin lymphoma: Contributions of coronary artery and whole heart dose-volume variables to risk prediction. *Int J Radiat Oncol Biol Phys* 2017;98:1116-1123.
- ⁶⁷ Marks LB, Bentzen SM, Deasy JO, et al. Radiation dose-volume effects in the lung. *Int J Radiat Oncol Biol Phys* 2010;76:S70-S76.
- ⁶⁸ Tseng YD, Hoppe BS, Dedeckova K, et al. Risk of pneumonitis and outcomes after mediastinal proton therapy for relapsed/refractory lymphoma: A PTCOG and PCG collaboration. *Int J Radiat Oncol Biol Phys* 2021;109:220-230.
- ⁶⁹ Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. *J Natl Cancer Inst* 2002;94:182-192.
- ⁷⁰ Schaapveld M, Aleman BM, van Eggermond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma. *N Engl J Med* 2015;373:2499-2511.
- ⁷¹ van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. *J Natl Cancer Inst* 1995;87:1530-1537.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age >60 Years)

MANAGEMENT OF CHL IN ADULTS AGE >60 YEARS

- CHL in older adult patients is associated with poorer disease outcomes.¹ B symptoms, poor performance status, mixed cellularity, histologic subtype, EBV+ disease, and medical comorbidities are more frequent in this population.²
- Standard chemotherapy regimens are associated with dose reductions, treatment toxicity, and treatment-related mortality in older patients.³⁻⁶
- There are limited prospective data evaluating alternatives to standard therapies for patients >60 years. Selection of standard versus alternate first-line therapy for a patient >60 years should be based on clinical judgment, with the goal of minimizing toxicity while maximizing efficacy.
- The regimens listed below should be considered in patients >60 years to lessen/minimize toxicity. These regimens have not been proven to overcome the poorer disease outcomes observed in patients >60 years.
- Clinical trial is recommended when available.
- ISRT alone is an option when systemic therapy is not considered feasible or safe.

SUGGESTED TREATMENT REGIMENS

(Listed in alphabetical order)

Stage I–II Favorable Disease

- A(B)VD^a (2 cycles) ± AVD (2 cycles) + ISRT^b (preferred)^{7,8,9}
- CHOP (4 cycles) + ISRT^{b,10}

Stage I–II Unfavorable or Stage III–IV Disease

- A(B)VD^a (2 cycles) followed by AVD (4 cycles),^c if FDG-PET scan is negative after 2 cycles of ABVD.¹¹
 - ▶ Patients with a positive FDG-PET scan after 2 cycles of ABVD need individualized treatment.
- Brentuximab vedotin followed by AVD, conditionally followed by brentuximab vedotin in responding patients with CR or PR¹²
- Brentuximab vedotin + DTIC (dacarbazine)^{13,14}
- CHOP (6 cycles) ± ISRT^{b,10}

Relapsed or Refractory Disease

- Outcomes are uniformly poor for patients with relapsed or refractory disease.¹⁵
- No uniform recommendation can be made, although clinical trials or possibly single-agent therapy with a palliative approach is recommended.
- Individualized treatment is necessary. Palliative therapy options include:
 - ▶ Bendamustine
 - ▶ Brentuximab vedotin
 - ▶ ISRT
 - ▶ Nivolumab and pembrolizumab [See Checkpoint Inhibitors \(CPI\) HODG-C \(3 of 5\)](#)

^a Bleomycin should be used with caution as it may not be tolerated in patients >60 years, and it should not be used beyond 2 cycles.

^b [See Principles of Radiation Therapy \(HODG-D\)](#).

^c If stage I–II is unfavorable, consider a total of 4 cycles.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

References



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age >60 Years)

MANAGEMENT OF CHL IN ADULTS AGE >60 YEARS

REFERENCES

- ¹ Jagadeesh D, Diefenbach C, Evens AM. XII. Hodgkin lymphoma in older patients: challenges and opportunities to improve outcomes. *Hematol Oncol* 2013;31 Suppl 1:69-75.
- ² Evens AM, Sweetenham JW, Horning SJ. Hodgkin lymphoma in older patients: an uncommon disease in need of study. *Oncology (Williston Park)* 2008;22:1369-1379.
- ³ Ballova V, Rüffer JU, Haverkamp H, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). *Ann Oncol* 2005;16:124-131.
- ⁴ Halbsguth TV, Nogová L, Mueller H, et al. Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). *Blood* 2010;116:2026-2032.
- ⁵ Böll B, Görgen H, Fuchs M, et al. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. *J Clin Oncol* 2013;31:1522-1529.
- ⁶ Evens AM, Hong F, Gordon LI, et al. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. *Br J Haematol* 2013;161:76-86.
- ⁷ Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. *N Engl J Med* 2010;363:640-652.
- ⁸ Stamatoullas A, Brice P, Bouabdallah R, et al. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. *Br J Haematol* 2015;170:179-184.
- ⁹ Behringer K, Goergen H, Hitz F, et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. *Lancet* 2015;385:1418-1427.
- ¹⁰ Kolstad A, Nome O, Delabie J, et al. Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma. *Leuk Lymphoma* 2007;48:570-576.
- ¹¹ Johnson P, Federico M, Fossa A, et al. Response-adapted therapy based on interim FDG-PET scans in advanced Hodgkin lymphoma: first analysis of the safety of de-escalation and efficacy of escalation in the international RATHL study (CRUK/07/033) [abstract]. *Hematol Oncol* 2015;33 (Suppl S1):Abstract 008.
- ¹² Evens AM, Advani RH, Helenowski IB, et al. Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. *J Clin Oncol* 2018;36:3015-3022.
- ¹³ Friedberg JW, Forero-Torres A, Bordon RE, et al. Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL. *Blood* 2017;130:2829-2837.
- ¹⁴ Friedberg JW, Forero-Torres A, Holkova B, et al. Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma [abstract]. *J Clin Oncol* 2018;36 (Suppl 15): Abstract 7542.
- ¹⁵ Böll B, Goergen H, Arndt N, et al. Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group. *J Clin Oncol* 2013;31:4431-4437.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



HODGKIN LYMPHOMA STAGING¹

Table 1

Definitions of Stages in Hodgkin Lymphoma²

Stage I Involvement of a single lymph node region (I) or localized involvement of a single extralymphatic organ or site (I_E).

Stage II Involvement of two or more lymph node regions on the same side of the diaphragm (II) or localized involvement of a single associated extralymphatic organ or site and its regional lymph node(s), with or without involvement of other lymph node regions on the same side of the diaphragm (II_E).

Note: The number of lymph node regions involved may be indicated by a subscript (eg, II₃).

Stage III Involvement of lymph node regions on both sides of the diaphragm (III), which may also be accompanied by localized involvement of an associated extralymphatic organ or site (III_E), by involvement of the spleen (III_S), or by both (III_{E+S}).

Stage IV Disseminated (multifocal) involvement of one or more extralymphatic organs, with or without associated lymph node involvement, or isolated extralymphatic organ involvement with distant (nonregional) nodal involvement.

A No systemic symptoms present

B Unexplained fevers >38°C; drenching night sweats; or weight loss >10% of body weight (within 6 months prior to diagnosis)

Adapted with permission from the American Association for Cancer Research: Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1861.

¹ For additional information regarding the staging of Hodgkin lymphoma, refer to: Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano Classification. J Clin Oncol 2014;32:3059-3068.

² FDG-PET scans are useful for upstaging in stage I–II disease. If there is FDG-PET positivity outside of disease already identified, further clinical investigation is recommended to confirm or refute the observation. FDG-PET scans are usually positive in patients with HIV infection, even in the absence of Hodgkin lymphoma.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

ABBREVIATIONS

4D-CT	four-dimensional computed tomography	GHSG	German Hodgkin Study Group	RCA	right coronary artery
ALARA	as low as reasonably achievable	GTV	gross tumor volume	RT	radiation therapy
ASCR	autologous stem cell rescue	H&P	history and physical	SNMMI	Society of Nuclear Medicine and Molecular Imaging
AYA	adolescent and young adult	HDT	high-dose therapy	TLI	total lymphoid irradiation
CAD	coronary artery disease	HIV	human immunodeficiency virus	TSH	thyroid-stimulating hormone
CBC	complete blood count	HL	Hodgkin lymphoma	VHD	valvular heart disease
CCSS	Childhood Cancer Survivor Study	ICRU	International Commission on Radiation Units and Measurements		
CHL	classic Hodgkin lymphoma	IMRT	intensity-modulated radiation therapy		
CME	continuing medical education	IPS	International Prognostic Score		
CMT	combined modality therapy	ISRT	involved-site radiation therapy		
CPI	checkpoint inhibitors	LAD	left anterior descending		
CT	computed tomography	LCx	left circumflex		
CTV	clinical target volume	MLD	mean lung dose		
DLCO	diffusing capacity of the lung for carbon monoxide	MRI	magnetic resonance imaging		
EANM	European Association of Nuclear Medicine	NLPHL	nodular lymphocyte-predominant Hodgkin lymphoma		
ECHO	echocardiogram	OAR	organs at risk		
EORTC	European Organisation for Research and Treatment of Cancer	PCP	primary care physician		
ESR	erythrocyte sedimentation rate	PET	positron emission tomography		
FDG	fluorodeoxyglucose	PFS	progression-free survival		
FFP	freedom from progression	PFT	pulmonary function test		
		PTV	planning target volume		



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma (Age ≥18 years)

NCCN Categories of Evidence and Consensus

Category 1	Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Category 2A	Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Category 2B	Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.
Category 3	Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise indicated.

NCCN Categories of Preference

Preferred intervention	Interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability.
Other recommended intervention	Other interventions that may be somewhat less efficacious, more toxic, or based on less mature data; or significantly less affordable for similar outcomes.
Useful in certain circumstances	Other interventions that may be used for selected patient populations (defined with recommendation).

All recommendations are considered appropriate.



Discussion

This discussion corresponds to the NCCN Guidelines for Hodgkin Lymphoma. Last updated: November 8, 2022

Table of Contents

Overview	MS-2
Literature Search Criteria and Guidelines Update Methodology.....	MS-2
Staging and Prognosis	MS-3
The Role of FDG-PET Imaging in Management of CHL.....	MS-4
Interim FDG-PET Imaging.....	MS-4
Principles of Radiation Therapy	MS-4
Principles of RT Dose Constraints	MS-6
Heart.....	MS-6
Lungs.....	MS-7
Breast.....	MS-8
Treatment Guidelines	MS-8
Diagnosis and Workup.....	MS-8
Classic Hodgkin Lymphoma.....	MS-9
Management of Classic Hodgkin Lymphoma in Adults Age >60 years	MS-16
Nodular Lymphocyte-Predominant Hodgkin Lymphoma	MS-17
Follow-up After Completion of Treatment.....	MS-20
Monitoring for Late Effects	MS-21
Relapsed or Refractory Disease	MS-23
Summary.....	MS-28
References.....	MS-30



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

Overview

Hodgkin lymphoma (HL) is an uncommon malignancy of B-cell origin. Most patients are diagnosed between ages 15 and 30 years, followed by another peak in adults ≥ 55 years. In 2022, an estimated 8540 people will be diagnosed with HL in the United States and 920 people will die from the disease.¹ The World Health Organization (WHO) classification divides HL into two main types: classic Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL).² In Western countries, CHL accounts for 95% and NLPHL accounts for 5% of all HL.

CHL is divided into four subtypes: nodular sclerosis CHL; mixed cellularity CHL; lymphocyte-depleted CHL; and lymphocyte-rich CHL. CHL is characterized by the presence of Reed-Sternberg cells in an inflammatory background, whereas NLPHL lacks Reed-Sternberg cells but is characterized by the presence of lymphocyte-predominant cells, sometimes termed *popcorn cells*.

The past few decades have seen significant progress in the management of HL. The advent of more effective treatment options has improved the 5-year survival rates, which have been unmatched in any other cancer over the past 4 decades. HL is among the most curable of malignancies with modern treatments, and newly diagnosed HL has a very high likelihood of being cured with appropriate management. In fact, cure rates for HL have increased so markedly that overriding treatment considerations often relate to long-term toxicity. Clinical trials still emphasize improvement in cure rates for patients with advanced disease, but the potential long-term effects of treatment remain an important consideration.

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hodgkin Lymphoma discuss the clinical management of CHL and NLPHL, focusing on adult patients ≥ 18 years who do not have serious

intercurrent disease. The Guidelines do not address HL in pediatric patients or those with unusual situations, such as human immunodeficiency virus (HIV) positivity or pregnancy. Individualized treatment may be necessary for older patients and those with concomitant disease. Consistent with NCCN philosophy, participation in clinical trials is always encouraged.

Literature Search Criteria and Guidelines Update Methodology

Prior to the update of this version of the NCCN Guidelines® for Hodgkin Lymphoma, an electronic search of the PubMed database was performed to obtain key literature in Hodgkin lymphoma since the previous Guidelines update, using the following search terms: Hodgkin Lymphoma, Classic Hodgkin Lymphoma, and Nodular Lymphocyte Predominant. The PubMed database was chosen as it remains the most widely used resource for medical literature and indexes peer-reviewed biomedical literature.³

The search results were narrowed by selecting studies in humans published in English. Results were confined to the following article types: Clinical Trial, Phase II; Clinical Trial, Phase III; Clinical Trial, Phase IV; Guideline; Practice Guideline; Randomized Controlled Trial; Meta-Analysis; Systematic Reviews; and Validation Studies.

The data from key PubMed articles as well as articles from additional sources deemed as relevant to these Guidelines as discussed by the panel during the Guidelines update have been included in this version of the Discussion section. Recommendations for which high-level evidence is lacking are based on the panel's review of lower-level evidence and expert opinion.

NCCN recommendations have been developed to be inclusive of individuals of all sexual and gender identities to the greatest extent



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

possible. When citing published studies and recommendations from other organizations, the terms used (eg, *male*, *female*) reflect the cited sources.

The complete details of the Development and Update of the NCCN Guidelines are available at www.NCCN.org.

Staging and Prognosis

Staging for HL is based on the Ann Arbor staging system.^{4,5} The system divides each stage into subcategories A and B, the latter for presence of B symptoms. “A” indicates that no systemic symptoms are present and “B” is assigned to patients with unexplained fevers greater than 38°C, drenching night sweats, or unexplained weight loss of greater than 10% of their body weight within 6 months of diagnosis.

Patients with HL are usually classified into three groups: early-stage favorable (stage I–II with no unfavorable factors); early-stage unfavorable (stage I–II with any of the unfavorable factors such as large mediastinal adenopathy, multiple involved nodal regions, B symptoms, extranodal involvement, or significantly elevated erythrocyte sedimentation rate [ESR] ≥ 50); and advanced-stage disease (stage III–IV).

Mediastinal bulk, an unfavorable prognostic factor in patients with early-stage HL, is measured most commonly using the mediastinal mass ratio (MMR).⁶ The MMR is the ratio of the maximum width of the mass and the maximum intrathoracic diameter. Any mass with MMR greater than 0.33 is defined as bulky disease. This is the definition used most commonly in North America and also by the German Hodgkin Study Group (GHSG). Another definition of bulk is any single node or nodal mass that is 10 cm or greater in diameter. According to the Cotswolds modification of the Ann Arbor staging system, bulky disease is defined as the mediastinal thoracic ratio (MTR), which is the ratio of the maximum width of the mediastinal mass and the internal transverse diameter of the thorax at the T5–T6 interspace on a posteroanterior chest radiograph.⁷ In

this context, any mass with MTR greater than 0.35 is defined as bulky disease. This is the definition used by the European Organization for Research and Treatment of Cancer (EORTC).

The early-stage unfavorable factors are based largely on a composite of factors derived from the definition of unfavorable prognostic groups from the clinical trials conducted by the EORTC, GHSG, and the National Cancer Institute of Canada (NCIC).^{8,9} Of note, the nodal *regions* as defined by the GHSG and EORTC are not the same as the Ann Arbor *sites*. Both research groups bundle the mediastinum and bilateral hila as a single region. In addition, the GHSG combines subpectoral with supraclavicular or cervical, while the EORTC combines subpectoral with axilla as one region. The NCCN and EORTC unfavorable factors for stage I–II disease include bulky mediastinal disease (MMR > 0.33 and MTR > 0.35 , respectively) or bulky disease greater than 10 cm, B symptoms, ESR 50 or greater, and greater than three involved nodal regions. In contrast, the GHSG considers patients with greater than two nodal regions as having unfavorable disease.

An international collaborative effort evaluating more than 5000 patients with advanced CHL (stage III–IV) identified seven adverse prognostic factors, each of which reduced survival rates by 7% to 8% per year,¹⁰ including: age ≥ 45 years; male gender; stage IV disease; albumin level below 4 g/dL; hemoglobin level below 10.5 g/dL; leukocytosis (white blood cell [WBC] count $> 15,000/\text{mm}^3$); and lymphocytopenia (lymphocyte count $< 8\%$ of the WBC and/or lymphocyte count $< 600/\text{mm}^3$). The International Prognostic Score (IPS) is defined by the number of adverse prognostic factors present at diagnosis.^{10,11} The IPS helps to determine the clinical management and predict prognosis for patients with stage III–IV disease.^{10,11}



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

The Role of FDG-PET Imaging in Management of CHL

Clinical management of CHL involves initial treatment with chemotherapy or combined modality therapy (CMT; chemotherapy and radiation therapy [RT]), followed by restaging at the completion of chemotherapy to assess treatment response. Assessment of response to initial treatment is essential because the need for additional treatment is based on the treatment response. ¹⁸F-fluorodeoxyglucose (FDG)-PET should not be used for routine surveillance following the completion of therapy.

FDG-PET imaging including integrated FDG-PET and CT (FDG-PET/CT) has become an important tool for initial staging and response assessment at the completion of treatment in patients with HL.^{12,13} In a meta-analysis, FDG-PET scans showed high positivity and specificity when used to stage and restage patients with lymphoma.¹⁴ FDG-PET positivity at the end of treatment has been shown to be a significant adverse risk factor in patients with early-stage as well as advanced-stage disease.¹⁵⁻¹⁷ In 2009, the Deauville criteria were defined for the interpretation of interim and end-of-treatment FDG-PET scans based on the visual assessment of FDG uptake in the involved sites. These criteria use a 5-point scale (5-PS) to determine the FDG uptake in the involved sites relative to that of the mediastinum and the liver.^{13,18,19} In the 5-PS (Deauville criteria), scores of 1 to 4 refer to initially involved sites and a score of 5 refers to an initially involved site and/or new lesions related to lymphoma.^{18,19} Interim or end-of-treatment FDG-PET scans with a score of 1, 2, or 3 are considered “negative” and FDG-PET scans with a score of 4 and 5 are considered “positive.”²⁰ A score of 4 can be difficult to assess when FDG uptake in mediastinal masses cannot clearly be differentiated from thymic uptake or inflammatory reactions,^{13,21,22} and treatment decisions in these cases will require clinical judgment. In addition, Deauville 4 may represent just a single area of persistent disease or failure to respond in any site. The 5-PS (Deauville criteria) has been validated in international multicenter trials for FDG-PET–guided interim response assessment and risk-adapted

therapy in patients with HL.²³⁻²⁷ The NCCN Hodgkin Lymphoma Panel encourages a second opinion of scans when there is a discrepancy between the clinical presentation and radiology report of a scan that was not originally interpreted by a qualified individual, and/or when no Deauville score is provided.

Interim FDG-PET Imaging

Interim FDG-PET scans can be prognostic and are increasingly being used to assess treatment response during therapy,^{28,29} as they can inform treatment adaptation, including treatment escalation and de-escalation.^{30,31} Early interim FDG-PET imaging after chemotherapy has been shown to be a sensitive prognostic indicator of treatment outcome in patients with advanced-stage disease (stage II disease with unfavorable risk factors [with or without bulky disease] or stage III–IV disease).^{32,33} Interim FDG-PET scans may also be useful to identify a subgroup of patients with early- and advanced-stage disease that can be treated with chemotherapy alone.^{27,34} The NCCN Guidelines emphasize that the value of interim FDG-PET scans remains unclear for some clinical scenarios, and all measures of response should be considered in the context of management decisions. It is important that the Deauville score be incorporated into the nuclear medicine FDG-PET scan report, since subsequent management is often dependent on that score. Individual prospective trials that use interim FDG-PET imaging are discussed below in the treatment management section.

Principles of Radiation Therapy

RT can be delivered with photons, electrons, or protons, depending on clinical circumstances.³⁵ Preliminary results from single-institution studies have shown that significant dose reduction to organs at risk (OAR; eg, lungs, heart, breasts, kidneys, spinal cord, esophagus, carotid artery, bone marrow, stomach, muscle, soft tissue, salivary glands) can be achieved with advanced RT planning and delivery techniques such as



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

four-dimensional CT (4D-CT) simulation, intensity-modulated RT (IMRT)/volumetric modulated arc therapy (VMAT), image-guided RT (IGRT), respiratory gating, or deep inspiration breath hold.^{36,37} These techniques offer significant and clinically relevant advantages in specific instances to spare OAR and decrease the risk for normal tissue damage and late effects without compromising the primary goal of local tumor control.^{35,38-44} Although advanced RT techniques emphasize tightly conformal doses and steep gradients adjacent to normal tissues, the “low-dose bath” to normal structures such as the breasts must be considered in choosing the final RT technique. Therefore, target definition, delineation, and treatment delivery verification require careful monitoring to avoid the risk of tumor geographic miss and subsequent decrease in tumor control. Initial diagnostic imaging with contrast-enhanced CT, MRI, FDG-PET, ultrasound (US), and other imaging modalities facilitate target definition.

For optimal mediastinal treatment planning, organs or tissues to be contoured should include the lungs, heart, and the cardiac subunits, including the coronary arteries (the left main, circumflex, left anterior descending [LAD], and right coronary arteries, with priority placed on sparing the proximal over distal portions of the arteries), valves, and left ventricle. In certain circumstances, the use of protons for mediastinal lymphoma provides dosimetric advantages that may reduce long-term toxicity. The potential advantage of protons is related to the localization of disease within the mediastinum as well as patient gender assigned at birth and age.^{35,45,46}

Randomized prospective studies to test these concepts are unlikely to be done since these techniques are primarily designed to decrease late effects, which usually develop greater than or equal to 10 years after completion of treatment. Therefore, the Guidelines recommend that RT delivery techniques that are found to best reduce the doses to the OAR in

a clinically meaningful manner without compromising target coverage should be considered in these patients, who are likely to enjoy long life expectancies following treatment.

Involved-site RT (ISRT) and involved-node RT (INRT) are being used as alternatives to involved-field RT (IFRT) in an effort to further restrict the size of the RT fields and to further minimize the radiation exposure to adjacent uninvolved organs and the potential long-term toxicities associated with radiation exposure.⁴⁷⁻⁴⁹ ISRT targets the originally involved nodal sites and possible extranodal extensions, which generally defines a smaller field than the classical IFRT that encompassed entire lymph node regions, without a demonstrable attendant decrease in efficacy.⁵⁰

ISRT targets the initially involved nodal and extranodal sites as defined by the pre-treatment evaluation (physical examination, CT, and FDG-PET imaging). However, it is intended to spare the adjacent uninvolved organs (such as lungs, bone, muscle, or kidney) when lymphadenopathy regresses following chemotherapy. Treatment planning for ISRT requires the use of CT-based simulation. The incorporation of additional imaging techniques such as FDG-PET and MRI often enhances the treatment planning. The optimized treatment plan for ISRT is designed using conventional 3-D conformal RT, proton therapy,³⁵ or IMRT techniques using clinical treatment planning considerations of coverage and dose reductions for OAR. For CHL, the gross tumor volume (GTV) defined by FDG-PET/CT imaging prior to chemotherapy or surgery provides the basis for determining the clinical target volume (CTV). For NLPHL treated with ISRT alone, the CTV should be expanded to include potential microscopic disease in the immediate region of the FDG-PET–positive disease. The planning target volume (PTV) is an additional expansion of the CTV to account for any setup variations and internal organ motion.⁵¹ PTV margins should be defined individually for each disease site.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

In the setting of CMT, the panel recommends an RT dose of 30 to 36 Gy when combined with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for most patients.⁵² In patients with stage I–II non-bulky disease, the recommended RT dose is 20 to 30 Gy following ABVD.^{53,54} For patients treated with RT alone (uncommon, except for NLPHL) the recommended dose is 30 to 36 Gy for the involved regions and 25 to 30 Gy for uninvolved regions. The panel recommends that high cervical regions in all patients and axillae in patients assigned female at birth always be excluded from RT fields, if those regions are uninvolved.

Principles of RT Dose Constraints

Patients with hematologic malignancies typically receive far lower doses of RT than patients with epithelial or mesenchymal malignancies, while generally achieving more favorable long-term outcomes. More stringent dose constraints, often proportionally reduced from acceptable thresholds in other malignancies, are recommended. Doses to OAR should follow principles of ALARA (as low as reasonably achievable). In some scenarios, target coverage may require dose constraints to be exceeded if the OAR is within the PTV.

A late side effect of RT is the development of radiation-induced secondary cancers. Studies have reported that increasing RT dose without a safe threshold dose (linear no-threshold model) is associated with an increased risk for secondary cancers, although the pattern of risk is less well understood than those after low-dose exposure.⁵⁵ Other contributing factors include age, environmental exposure, genetic risk factors, and radiation technique, among others.⁵⁶

RT dose constraints recommended for OAR, especially heart, lung, and breast, are described below.

Heart

Multiple cardiac complications can develop from mediastinal RT including pericarditis, arrhythmias, coronary artery disease (CAD), valvular heart disease (VHD), and cardiomyopathy/congestive heart failure.^{57,58} In addition to factors related to RT, the risk of cardiac events is also influenced by chemotherapy administration (eg, doxorubicin), pre-existing cardiovascular disease, age, and other cardiac risk factors (eg, diabetes, hypertension, hyperlipidemia).^{57,59–61} While global heart metrics such as mean heart dose (MHD) are most commonly used to assess risk, there is an increasing recognition that radiation dose-fractionation to cardiac substructures must be accounted for.

Mediastinal RT for lymphomas, relative to breast cancer and other thoracic malignancies, is characterized by radiation exposures to larger volumes of the heart and substructures, albeit to lower doses (20–40 Gy). The MHD has been related to the risk of cardiac events, although the volume of the whole heart exposed to RT is variable.^{62,63} In a case-control study of survivors of HL who were treated mainly with anteroposterior/posteroanterior (AP/PA) fields, using MHD as a measure of cardiac toxicity risk, van Nimwegen et al demonstrated an excess relative risk (RR) of 7.4% per Gy MHD.⁶³ A significantly increased risk of coronary heart disease was reported among patients who received an MHD as low as 5 to 14 Gy (RR, 2.31) compared to a MHD of 0 Gy.⁶³ This risk was increased for an MHD of greater than or equal to 15 Gy (RR, 2.83 for 15–19 Gy, 2.9 for 20–24 Gy, and 3.35 for 25–34 Gy).⁶³

The number of studies evaluating specific dose constraints for cardiac substructures is limited.^{57,64,65} The prescribed mediastinal RT dose was the only independent risk factor for VHD in a pediatric cohort study, and increasing mediastinal RT dose (especially >30 Gy) has been associated with an elevated risk of valvular dysfunction.^{64,65} In a large Dutch cohort of adult patients treated with mediastinal RT, the 30-year cumulative risks of



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

VHD increased with increasing mean valvular RT doses (3% for <30 Gy, 6.4% for 31–35 Gy, 9.3% for 36–40 Gy, and 12.4% for >40 Gy) and there was no confounding effect of anthracycline chemotherapy on the risk of VHD.⁶⁵ van Nimwegen et al demonstrated a relationship between heart failure and mean left ventricular (LV) dose.⁵⁷ Chemotherapy was a clear confounder in regards to the risk of heart failure. Among patients treated with anthracyclines, the 25-year cumulative risk of heart failure was 11.2% for mean LV dose less than 15 Gy, 15.9% for 16 to 20 Gy, and 32.9% for greater than or equal to 21 Gy.

RT dose constraints for coronary arteries is a work in progress and only a few studies have evaluated the effect of coronary RT dose on the risk of CAD.⁶⁶⁻⁶⁹ In a large retrospective study of patients with non-small cell lung cancer (NSCLC) treated with thoracic RT, major adverse cardiac events were found to be associated with the volume of the LAD receiving 15 Gy (V15 Gy ≥10%).⁶⁹ Although there is no robust evidence to recommend specific guidance on dose constraints to specific coronary arteries in patients with lymphomas, limited available evidence supports the general notion of a dose-response effect in the clinical range of lymphoma RT prescriptions.

NCCN Recommendations

While the data regarding cardiac constraints for modern RT for lymphomas are imperfect, the panel recommends that the MHD be kept as low as possible, ideally less than 8 Gy, although in some patients a higher dose will be necessary given lymphoma extent. The panel recognizes that nearly all patients with lymphoma receive anthracycline-based chemotherapy, although cumulative chemotherapy doses in modern practice tend to be lower than historical cohorts. Whole heart irradiation increases the risk of constrictive pericarditis, especially with whole heart RT doses greater than 15 Gy⁷⁰; therefore, it is recommended that MHD should rarely exceed 15 Gy. This may be reconsidered if patients are

being treated in the second-line setting with curative intent where larger RT doses are necessary. Mean LV dose should not exceed 8 Gy, although in some circumstances up to 15 Gy may be necessary. Aortic and mitral valve doses should be less than 25 Gy, although lower doses would be optimal. Given that tricuspid and pulmonic valves may be less affected OAR, it is recommended that doses less than 30 Gy be administered. Constraints to coronary arteries are less well defined,⁷¹ but should be as low as possible in terms of dose, volume, and length. It is recognized that contouring the coronary arteries is challenging given anatomical variations and lung/heart motion. This may warrant designing a planning OAR volume in some patients. Furthermore, it is also important to preferentially spare high-dose overlap with the proximal coronary arteries. For dose recommendations for OAR, see *Principles of RT - RT Dose Constraint Guidelines for Lymphoma* in the algorithm.

Lungs

Mediastinal RT-related pulmonary toxicity is primarily radiation pneumonitis, although complications including symptomatic fibrosis or bronchopleural fistula have been encountered rarely. Radiation pneumonitis is a clinical diagnosis consisting of dry cough, dyspnea, and occasional low-grade fevers, and must be distinguished from other entities including drug-induced (especially bleomycin) pneumonitis, infectious pneumonia, acute bronchitis, and pulmonary embolism. Pulmonary complications can also arise from systemic therapies such as brentuximab vedotin (BV) and immunotherapy.

The most important risk factors for radiation pneumonitis are lung dose-volume metrics, including mean lung dose (MLD), V20 Gy, and V5 Gy. Such metrics have been associated with pneumonitis risk in both epithelial⁷² and hematologic malignancies.⁷³ For epithelial malignancies such as NSCLC, it is generally recommended that MLD be less than 20 Gy and V20 Gy be less than 35%. In most circumstances, given the lower



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

doses used in lymphoma management, much lower doses are generally achievable with careful planning.

NCCN Recommendations

The panel recommends limiting MLD less than 13.5 Gy and V20 Gy less than 30%, although RT to the lungs in most patients with lymphoma can be maintained below these thresholds. In cases where IMRT or volumetric arc techniques are appropriate, limiting the V5 to less than 55% is recommended.

Breast

Whole breast RT increases the risk of subsequent malignancies within the irradiated tissue. Therefore, the guidelines recommend a maximum mean breast dose of 4 Gy and a V4 of less than 10%.

Treatment Guidelines

Diagnosis and Workup

For evaluation and initial workup of HL the panel recommends that an excisional lymph node biopsy generally be performed, although a core needle biopsy may be adequate if diagnostic. A diagnostic assessment based solely on fine-needle aspiration (FNA) biopsy is generally insufficient except in unusual circumstances when, in combination with immunohistochemistry (IHC), it is judged to be diagnostic of HL by an expert hematopathologist or cytopathologist. Immunostaining for CD3, CD15, CD20, CD30, CD45, CD79a, PAX5, and EBER-ISH is recommended for CHL. The Reed-Sternberg cells of CHL express CD30 in all patients, express CD15 in the majority of patients, and are usually negative for CD3 and CD45. CD20 may be detectable in less than 40% of patients. An extended panel of markers (ie, MUM-1, BOB-1, OCT-2) may be required, especially if there is an equivocal diagnosis. For NLPHL, the immunoarchitectural pattern should be specified as typical (subtypes A or B) or variant (subtypes C, D, E, or F).

Workup should include a thorough history and physical examination, including determination of B symptoms (unexplained fevers $>38^{\circ}\text{C}$, drenching night sweats, or unexplained weight loss of $>10\%$ of body weight within 6 months of diagnosis; other associated symptoms are alcohol intolerance, pruritus, fatigue, and poor performance status). Physical examination should include all lymphoid regions, spleen, and liver; standard laboratory tests (complete blood count [CBC], differential, ESR, serum lactate dehydrogenase [LDH], albumin, and liver and renal function tests); and FDG-PET/CT scan (skull base to mid-thigh or vertex to feet in selected cases).

The panel recommends imaging be obtained in accordance with the American College of Radiology (ACR) guidelines. A diagnostic CT enhanced with oral and/or intravenous (IV) contrast may be useful in selected cases (neck, chest, abdomen, and pelvis). At minimum, diagnostic CT scans should include involved areas identified as abnormal on FDG-PET scan. Posteroanterior and lateral chest x-rays are encouraged in selected cases for patients with large mediastinal mass.

The NCCN PET Task Force and the NCCN Guidelines consider FDG-PET scans essential for initial staging and for evaluating residual masses at the end of treatment.⁷⁴ An integrated FDG-PET scan plus a diagnostic CT is recommended for initial staging and should be obtained no longer than 1 month prior to the initiation of therapy. A separate contrast-enhanced diagnostic CT is not needed if it was part of the integrated FDG-PET scan. The panel supports the ACR⁷⁵ and Society of Nuclear Medicine and Molecular Imaging (SNMMI)⁷⁶ recommendations for FDG-PET/CT interpretation (see *Principles of FDG-PET/CT* in the algorithm).⁷⁷⁻⁸⁰ However, it should be noted that FDG-PET scans may be positive in sites of infection or inflammation, even in the absence of HL. In patients with FDG-PET–positive sites outside of the disease already identified, or if the FDG-PET–positive sites are inconsistent with the usual presentation of



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

HL, additional clinical or pathologic evaluation is recommended. In patients with newly diagnosed HL undergoing pretreatment staging with FDG-PET/CT, routine bone marrow biopsy is not required if the FDG-PET scan is negative or displays a homogenous pattern of bone marrow uptake, which may be secondary to cytokine release.^{81,82} The bone marrow may be assumed to be involved if the FDG-PET scan displays multifocal (three or more) skeletal lesions.^{81,83} However, a bone marrow biopsy may be performed if the FDG-PET scan is negative, but unexplained cytopenias other than anemia are present (eg, thrombocytopenia, neutropenia). In select cases, MRI with contrast to select sites may be considered, unless contraindicated. FDG-PET/MRI without contrast (skull base to mid-thigh) may also be considered for anatomical imaging.

Evaluation of ejection fraction is recommended if anthracycline-based therapy is indicated. HIV and hepatitis B or C testing should be encouraged for patients with risk factors for HIV or unusual disease presentations. Pulmonary function tests, including diffusing capacity of the lungs for carbon monoxide (DLCO), are recommended for patients receiving bleomycin-based chemotherapy. In general, a DLCO threshold of at least 60% is acceptable for bleomycin use.^{84,85} A seasonal influenza vaccine is recommended. Pneumococcal, Haemophilus influenzae (H-flu), and meningococcal vaccines are recommended if splenic RT is contemplated.

A pregnancy test should be performed before patients of childbearing age undergo treatment. Alkylating agent-based chemotherapy is associated with a higher risk of premature ovarian failure than chemotherapy with non-alkylating agent-based chemotherapy.⁸⁶ In select cases and if the patient is interested, the Guidelines recommend consideration of fertility preservation (ie, semen cryopreservation, ovarian tissue or oocyte

cryopreservation) prior to the initiation of chemotherapy with alkylating agents or pelvic RT.^{87,88}

Classic Hodgkin Lymphoma

Patients are divided into the following groups after initial diagnosis and workup:

- Stage I–II
- Stage III–IV

Patients with stage I–II are further classified into the following subgroups depending on the presence or absence of NCCN unfavorable factors:

- Stage IA–IIA (favorable with non-bulky disease)
- Stage IA–IIA (unfavorable with bulky mediastinal disease or >10 cm adenopathy)
- Stage IB–IIB (unfavorable disease)

RT alone was a standard treatment option for patients with early-stage HL for many decades.⁸⁹ However, the potential long-term toxicity of high-dose, large-field irradiation includes an increased risk for heart disease, pulmonary dysfunction, and secondary cancers.⁹⁰ With the incorporation of chemotherapy regimens routinely used in advanced disease (ABVD is the most commonly used systemic therapy based on a balance of efficacy and toxicity) into the management of early-stage disease, CMT has replaced RT alone as the treatment of choice for patients with early-stage, favorable disease. Bonadonna and colleagues initially established the safety and efficacy of ABVD (4 cycles) followed by 36 Gy IFRT as the standard treatment for patients with early-stage disease.⁵² The NCIC Clinical Trials Group (NCIC-CTG) HD.6 trial established ABVD alone as a potential treatment for patients with stage I–II disease.⁹¹ Selection of CMT or chemotherapy alone should be based on patient age, sex, family history of cancer or cardiac disease, comorbid



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

conditions, and sites of involvement. Generally, CMT provides for a better progression-free survival (PFS)/freedom from progression (FFP); however, there is no difference in overall survival (OS) in prospective randomized trials. Most patients will benefit from multidisciplinary input prior to final treatment decisions.

Stage I–II

The HD10 trial from the GHSG investigated the reduction of the number of cycles of ABVD as well as the IFRT dose in patients with stage I–II disease with no risk factors.⁵⁴ The definition of favorable disease implies the absence of unfavorable risk factors outlined in *Principles of Unfavorable Risk Factors* in the algorithm. It is worth noting that for purposes of stratification, the GHSG and EORTC do not define the lymph node regions strictly according to the Ann Arbor criteria. In this trial, patients were not eligible if they had three or more involved lymph node regions, any E-lesions, bulky mediastinal adenopathy, ESR greater than 50, or ESR greater than 30 in conjunction with B symptoms. In this trial, 1370 patients were randomized to one of the four treatment groups: 4 cycles of ABVD followed by 30 Gy or 20 Gy of IFRT or 2 cycles of ABVD followed by 30 Gy or 20 Gy of IFRT.⁵⁴ The final analysis of this trial showed that (with a median follow-up of 79–91 months) there were no significant differences between 4 and 2 cycles of ABVD in terms of 5-year OS (97.1% and 96.6%), freedom from treatment failure (FFTF) (93.0% vs. 91.1%), and PFS (93.5% vs. 91.2%). With respect to the dose of IFRT, the OS (97.7% vs. 97.5%), FFTF (93.4% vs. 92.9%), and PFS (93.7% vs. 93.2%) were also not significantly different between 30 Gy and 20 Gy IFRT.⁵⁴ More importantly, there were also no significant differences in OS, PFS, and FFTF among the four treatment arms. The results of the HD10 study confirm that 2 cycles of ABVD with 20 Gy of IFRT is an effective primary treatment for patients with a very favorable presentation of early-stage disease with no risk factors, thereby minimizing the risk of late effects.

Subsequent studies have assessed the value of interim FDG-PET scans in defining the need for RT in patients with stage I–II disease. The UK RAPID trial showed that patients with stages IA–IIA disease with a negative FDG-PET scan after 3 cycles of ABVD have an excellent outcome with or without IFRT.²⁷ In this study (n = 602; 426 patients had a negative FDG-PET scan after 3 cycles of ABVD), patients with stage IA–IIA favorable disease (no B symptoms or mediastinal bulky disease) and a Deauville score of 1 to 2 on interim FDG-PET scan after 3 cycles of ABVD were randomized to either IFRT (n = 209) or observation (n = 211). After a median follow-up of 60 months, in an intent-to-treat analysis, the estimated 3-year PFS rate was 94.6% for those treated with IFRT compared to 90.8% for those who received no further treatment ($P = .16$). The corresponding 3-year OS rates were 97.1% and 99.0%, respectively.²⁷ In the “per protocol” (as treated) analysis, the 3-year PFS rates were 97.1% and 90.8%, respectively, favoring the use of CMT ($P = .02$).

In the EORTC H10 trial, which included 754 patients in the favorable group (H10F), PET response after 2 cycles of ABVD facilitated early treatment adaptation.³⁰ In this study, mediastinal blood pool activity was used as the reference background activity for PET positivity of residual masses greater than or equal to 2 cm in greatest transverse diameter, regardless of location. A smaller residual mass or a normal-sized lymph node was considered positive if its activity was above that of the surrounding background. Patients who were PET negative after receiving 2 cycles of ABVD received 1 additional cycle of ABVD (total of 3 cycles) followed by INRT in the standard arm, or 2 additional cycles of ABVD (total of 4 cycles) only in the experimental arm.³⁰ After a median follow-up of 5 years, the intent-to-treat PFS rates were 99.0% and 87.1% in the ABVD + RT and ABVD only arms, respectively ($P = .002$).³⁰ If the interim PET was positive, patients in both the H10F and H10U (unfavorable group) were continued on ABVD for a total of 4 cycles on the standard arm or



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

treatment was intensified to 2 cycles of escalated BEACOPP + INRT in the experimental arm.³⁰

In the H10U group (n = 1196), patients were randomized into two treatment arms.³⁰ In the standard arm, patients were treated with 2 cycles of ABVD, underwent interim PET, and were treated with 2 additional cycles of ABVD + INRT (30–36 Gy). In the experimental arm, patients were treated with 2 cycles of ABVD, underwent interim PET scans, and if found to be PET negative, were treated with an additional 4 cycles of ABVD. For the interim PET-negative patients, the 5-year PFS was 92.1% following 4 cycles of ABVD + INRT versus 89.6% following 6 cycles of ABVD.³⁰ If patients were found to be PET positive after the initial 2 cycles of ABVD, chemotherapy was intensified with 2 cycles of escalated BEACOPP + INRT (30–36 Gy) as in the H10F group. The final results of this trial demonstrated that in patients with stage I–II (favorable or unfavorable disease), a PET-positive response after 2 cycles of ABVD facilitates early treatment adaptation to 2 cycles of escalated BEACOPP + INRT, with improved 5-year PFS when compared to 2 additional cycles of ABVD and INRT (90.6% vs. 77.4%, respectively).³⁰

The GHSG HD16 trial (n = 1150) included patients with stage I–II favorable disease according to GHSG criteria.⁹² Patients randomized to the standard arm received 2 cycles of ABVD followed by an interim PET and IFRT (20 Gy), regardless of the PET result. On the experimental arm, following 2 cycles of ABVD, patients with a negative PET (Deauville score <3) received no further therapy, while those with a positive PET received IFRT (20 Gy). Among the 628 patients in the combined arms who had a negative interim PET, the 5-year PFS was 93.4% following CMT and 86.1% following ABVD alone ($P = .04$).⁹² Relapse analysis from this trial revealed a higher 5-year local recurrence rate in PET-negative patients with omission of IFRT, at 10.5% with chemotherapy alone compared to 2.4% with CMT ($P = .54$).⁹³

The CALGB 50604 trial examined the use of interim PET to guide treatment of patients with stage I–II HL (excluding only patients with bulky disease).⁹⁴ Patients received 2 cycles of ABVD followed by PET. Patients with a PET-negative response (Deauville score of 1–3, which is different from the H10 and RAPID trials that used a score of 1–2) were given 2 more cycles of ABVD, whereas patients with a PET-positive response were treated with escalated BEACOPP + IFRT.⁹⁴ With a median follow-up time of 3.8 years, the estimated 3-year PFS for the PET-negative and PET-positive groups were 91% and 66%, respectively.⁹⁴ The 3-year PFS was 94% for patients with Deauville 1–2 response on interim PET compared to only 77% for patients with Deauville 3 response.

The HD14 trial of the GHSG evaluated patients with stage I–II unfavorable disease.⁹⁵ In this trial, 1528 patients were randomized to 4 cycles of ABVD (n = 765) or 2 cycles of escalated-dose BEACOPP followed by 2 cycles of ABVD (n = 763). Chemotherapy was followed by 30 Gy of IFRT in both arms. At a median follow-up of 43 months, the 5-year FFTF rate was 94.8% compared to 87.7% for ABVD ($P < .001$). The 5-year PFS rate was 95.4% and 89.1%, respectively ($P < .001$).⁹⁵ The 5-year OS rate was not significantly different between the two arms (97.2% and 96.8%, respectively; $P = .731$). The rate of progression or relapse was also lower in patients treated with BEACOPP followed by ABVD (2.5% vs. 8.4%; $P < .001$). However, the acute toxicity was greater in the BEACOPP/ABVD arm compared to the ABVD arm.⁹⁵ The risk for WHO grade 3–4 events was 87.1% and 50.7%, respectively. Grade 4 toxicity was reported in 56.6% and 5.9%, respectively. In a long-term follow-up analysis, there was no difference in 10-year OS between the two groups; however, the 10-year PFS was 91.2% in patients treated with BEACOPP followed by ABVD compared to 85.6% for the ABVD group ($P = .0001$).⁹⁶ This analysis also found no difference in second primary malignancies between the two groups. The Response-Adapted Therapy in Advanced Hodgkin Lymphoma (RATHL) trial examined the use of interim PET to guide



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

treatment for patients with advanced disease, which included 500 patients (41.6%) who had stage II disease with various risk factors (B symptoms, bulky disease, or at least 3 involved sites).^{23,31} In the randomized trial, 1119 patients with stage II–IV disease received 2 cycles of ABVD and underwent interim PET scans. Patients with a Deauville score of 1 to 3 were assigned in a 1:1 ratio to continue treatment with 4 cycles of either ABVD or AVD. At a median of 41 months, the 3-year PFS and OS rates between the ABVD and AVD groups did not differ significantly (85.7% vs. 84.4% and 97.2% vs. 97.6%, respectively). However, the omission of bleomycin from the ABVD regimen after negative PET results (ie, Deauville score of 1–3) led to a decrease in the incidence of pulmonary toxic effects when compared to continued ABVD.³¹ The potential value of added RT was not tested in this trial.

NCCN Recommendations for Stage IA–IIA Favorable, Non-Bulky Disease

The recommended primary treatment for stage I–IIA with favorable non-bulky disease is 2 cycles of ABVD (category 1), followed by restaging with FDG-PET/CT. If there is a preference to treat patients with CMT, treatment options for patients with a Deauville score of 1 to 3 include ISRT (20 Gy) if ESR is less than 50, no E-lesions are present, and there are fewer than 3 nodal sites^{54,92} or 1 cycle of ABVD (total 3) plus ISRT (30 Gy) for Deauville 1–2 versus 2 cycles of ABVD (total 4) plus ISRT (30 Gy) for Deauville 3.^{27,30}

If there is a preference to treat with chemotherapy alone, patients with a Deauville score of 1 to 2 are recommended to be treated with 1²⁷ or 2^{30,94} cycles of ABVD according to the RAPID, H10F, or CALGB trials, with a preference for 2 cycles. Per the RATHL trial, a Deauville score of 3 should be treated with 4 cycles of AVD.³¹

For patients with a Deauville score of 4, if only focally positive on interim FDG-PET, patients may continue with 2 additional cycles of ABVD before repeat scan. Following restaging, a biopsy is recommended for all patients

with a Deauville score of 4 to 5. The panel recommends escalating therapy for patients whose scan remains positive throughout the area(s) of initial disease. ISRT (30 Gy) is recommended for patients with a Deauville score of 1 to 3, or 4 to 5 with a negative biopsy.^{27,30} A Deauville score of 5 after interim restaging should be managed as described for refractory disease. Biopsy is recommended for all patients with a score of Deauville 5. If the biopsy is negative, treatment is as described for patients with a Deauville score of 4. If the biopsy is positive, or if a biopsy is not feasible, treatment is as described for refractory disease.

NCCN Recommendations for Stage I–II Unfavorable, B Symptoms, Bulky Mediastinal Disease, or Adenopathy >10 cm

For stage I–II unfavorable CHL with B symptoms, bulky mediastinal disease, or greater than 10 cm adenopathy, the preferred regimen, ABVD, is initially administered for 2 cycles followed by restaging with FDG-PET. If there is a preference to treat patients with CMT, patients with a Deauville score of 1 to 3 can be treated with 2 additional cycles of ABVD (total of 4) and ISRT (30 Gy).³⁰ If there is a preference to treat with chemotherapy alone, patients with a Deauville score of 1 to 3 are recommended to receive 4 cycles of AVD.³¹

Patients with a Deauville score of 4 to 5 are treated with 2 cycles of escalated BEACOPP followed by interim FDG-PET restaging. A Deauville score of 5 should prompt re-biopsy to inform subsequent therapy. If a biopsy is not performed, treatment should be escalated. Patients with a Deauville score of 1 to 3 who prefer CMT are followed up with ISRT (30 Gy).^{30,95,97} Two cycles of escalated BEACOPP is recommended for those who prefer chemotherapy alone. Biopsy is recommended for patients with a Deauville score of 4 to 5 after restaging. If the biopsy is negative, treatment is as described for patients with a Deauville score of 1 to 3. For patients with a positive biopsy, or those in whom biopsy is not feasible, treatment is as described for refractory disease.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

Stage III–IV

While chemotherapy is always used for patients with advanced-stage disease, CMT is an appropriate management approach in some instances, especially for patients with bulky disease, and is used for poor responders to chemotherapy in other treatment regimens.^{98,99}

ABVD has been the preferred treatment option based on several randomized clinical trials that failed to show a survival benefit for more intensive regimens.⁹⁹⁻¹⁰² The potential role for RT in stage III–IV disease has not been demonstrated in contemporary randomized clinical trials; however, it may be useful in selected clinical situations, such as described in the HD15 trial, below.

The results of the important RATHL trial demonstrated that the omission of bleomycin from the ABVD regimen in patients with negative interim PET scan (Deauville score 1–3) after 2 cycles of ABVD resulted in a lower incidence of pulmonary toxicity than with continued ABVD, without impacting efficacy (3-year PFS 81.6% and OS 97%).³¹ In this trial, patients who had a positive interim PET (Deauville 4–5) had treatment intensified to escalated BEACOPP. With a median follow-up of 5 years, the 3-year PFS and OS were 71% and 85%, respectively. Similar PET-adapted escalation has been evaluated in the U.S. Intergroup trial S0186^{103,104} and the Italian GITIL/FIL HD 0607 trial.¹⁰⁵ For the U.S. Intergroup trial, the 5-year PFS and OS for patients who had a positive interim PET were 65% and 97%, respectively.^{103,104} Similar results were also seen in the 0607 trial for patients who had a positive interim PET, with a 3-year PFS and OS of 60% and 89%, respectively.¹⁰⁵

BV-AVD has recently emerged as another preferred treatment option based on the results of the phase III ECHELON-1 trial.¹⁰⁶⁻¹⁰⁸ Initial results of the ECHELON-1 trial showed that BV-AVD had superior PFS compared to ABVD in first-line treatment of patients with stage III–IV

disease.^{106,107} In this trial patients with previously untreated stage III or IV CHL were randomized to receive ABVD (n = 670) or BV-AVD (n = 664).¹⁰⁶ Patients received 6 cycles of chemotherapy without treatment adaptation based on interim restaging. The 5-year follow-up data confirmed that PFS benefit for BV-AVD compared to ABVD was consistent in all patient subgroups independent of disease stage, age and IPS.¹⁰⁷

While the incidence of pulmonary toxicity was lower in the BV-AVD arm due to the elimination of bleomycin, there was a higher rate of peripheral neuropathy (19% compared to 9% for patients in the ABVD group) and febrile neutropenia (19% compared to 11% for patients in the ABVD group) mandating the use of growth factor support with this regimen.^{106,107} Furthermore, the rate of pulmonary toxicity in the control group does not reflect that of modern management, as bleomycin may be omitted in the vast majority of patients after the first 2 cycles (see RATHL trial discussion above).

A more recent interim analysis revealed a significant OS benefit with BV-AVD compared to ABVD (HR, 0.59; *P* = .009).¹⁰⁸ Estimated 6-year OS was 93.9% in the BV-AVD group versus 89.4% in the ABVD group. Consistent improvement in estimated 6-year OS was seen in both patients with positive PET scans following 2 cycles of treatment (95% vs. 77%; HR, 0.16) and in patients with negative PET scans following 2 cycles of treatment (94.9% vs. 90.6%; HR, 0.54). In the prespecified subgroups, more favorable estimates of treatment effect with BV-AVD over ABVD were observed in patients with stage IV disease, patients <60 years (vs. patients ≥60 years) and in patients with an IPS ≥4 (vs. IPS of 0–1). In accordance with previous reports, PFS estimates at 6 years favored BV-AVD compared to ABVD, with estimates of 82.3% and 74.5%, respectively (HR, 0.68). Consistent 6-year PFS benefit was seen with BV-AVD over ABVD across multiple subgroups, including those with stage III or IV



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

disease and those with negative or positive PET scans following two cycles of treatment.

More patients had ongoing peripheral neuropathy in the BV-AVD (18.9% compared to 9.0% in the ABVD group), though patients in both groups saw improvements (85.6% in the BV-AVD group had complete resolution or amelioration compared to 87.1% in the ABVD group).¹⁰⁸ Subsequent therapy was used less frequently in the BV-AVD group compared to the ABVD group, including autologous and allogeneic HCT and immunotherapies, though the use of subsequent RT was similar between the two groups. There was a higher proportion of deaths due to a second cancer in the ABVD group compared to the BV-AVD group (4.9% vs. 3.5%).

The efficacy of escalated BEACOPP in patients with advanced-stage disease has been demonstrated in several sequential studies by the GHSG.¹⁰⁹⁻¹¹¹ The final analysis of the HD15 trial that included patients with stage III–IV and IIB with large mediastinal adenopathy or extranodal disease established 6 cycles of escalated BEACOPP followed by PET-guided RT (to sites >2.5 cm that were PET positive) as the standard of care within the GHSG. The 5-year FFTF and OS rates were 89.3% and 95.3%, respectively.⁹⁸ One hundred ninety-one patients were FDG-PET positive, received consolidative RT, and achieved a 4-year PFS of 86.2% with outcomes similar to those who achieved a complete response (CR).¹¹¹

The subsequent HD18 trial investigated an interim PET-adapted design.¹¹² After 2 cycles of escalated BEACOPP, PET-negative (Deauville 1–2) patients were randomized to receive an additional 2 or 6 cycles of escalated BEACOPP, and PET-positive patients were randomized to receive an additional 6 cycles of escalated BEACOPP alone or with rituximab. The final results showed non-inferiority of 4 cycles of escalated BEACOPP (n = 501) compared to 6 or 8 cycles, with a 5-year PFS of

92.2% versus 90.8%, respectively.¹¹² These results suggest that 4 cycles of escalated BEACOPP is adequate therapy in patients with a negative interim PET.

The AHL2011 trial investigated whether PET monitoring during treatment could allow dose de-escalation by switching regimens from escalated BEACOPP to ABVD in early responders with newly diagnosed advanced-stage HL (stage IIB with large mediastinal mass or stage III–IV).¹¹³ In this study, all patients (n = 823) were randomized to receive standard treatment (6 cycles of escalated BEACOPP; n = 413) or PET-adapted treatment (n = 410). In the PET-adapted group, after 2 cycles of escalated BEACOPP, patients with positive PET2 scans (Deauville score 4 or 5) received 2 additional cycles of escalated BEACOPP, whereas patients with negative PET2 scans (Deauville score 1–3) were switched to 2 cycles of ABVD for the remaining induction therapy.¹¹³ With a median follow-up of 50.4 months (interquartile range [IQR], 42.9–59.3), the 5-year PFS by intention to treat in the standard treatment and PET-adapted treatment groups were 86.2% and 85.7% ($P = .65$), respectively.¹¹³ The PET-adapted treatment arm was also associated with significantly less treatment-related toxicities.¹¹³

Studies that have compared escalated-dose BEACOPP with standard-dose BEACOPP or ABVD failed to show an OS advantage for escalated-dose BEACOPP, although in some studies it resulted in better tumor control.^{102,114-116} However, some of these studies were not sufficiently powered to determine differences in OS due to small patient numbers. The EORTC 20012 trial evaluated BEACOPP (4 cycles of escalated-dose and 4 cycles of standard-dose) and ABVD (8 cycles) in high-risk patients with stage III–IV disease and IPS greater than or equal to 3 (274 patients in the BEACOPP arm and 275 patients in the ABVD arm).¹¹⁴ The results showed that there was no improvement in OS (86.7% and 90.3, respectively, at 4 years; $P = .208$) or event-free survival (EFS)



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

(63.7% and 69.3%, respectively, at 4 years; $P = .312$), although the PFS was significantly better with BEACOPP (83.4% vs. 72.8% for ABVD; $P = .005$). Early discontinuations were also more frequent with BEACOPP. The median follow-up was 3.6 years.¹¹⁴ Interestingly, long-term follow-up analysis of the HD2000 trial failed to show a PFS advantage of escalated BEACOPP over ABVD, largely due to the risk of secondary malignancy at 10 years, which was significantly higher with escalated BEACOPP than with ABVD (6.6 vs. 0.9; $P = .027$).¹⁰¹

NCCN Recommendations for Stage III–IV Disease

Based on the updated safety and efficacy data from the ECHELON-1 trial (discussed above),¹⁰⁸ BV-AVD is now included as a preferred treatment option with a category 1 recommendation along with ABVD. However, it should be noted that use of BV is contraindicated in patients with neuropathy and it should be used in caution in those >60 years.

ABVD is initially administered for 2 cycles followed by restaging with FDG-PET. Patients with a Deauville score of 1 to 3 are treated with 4 cycles of AVD based on results from the RATHL trial.³¹ After 4 cycles of AVD, patients should be followed and monitored for late effects as described.

For patients with a Deauville score of 4 to 5, recommended treatment is 3 cycles of escalated BEACOPP per RATHL trial results,³¹ followed by reassessment of response with FDG-PET. For patients with a Deauville score of 1 to 3, the recommended options are to continue on therapy with 1 additional cycle of escalated BEACOPP alone or combined with ISRT to initially bulky or selected FDG-PET–positive sites. A biopsy is recommended for patients with a Deauville score of 4 or 5. If the biopsy is negative, treatment is as described for patients with a Deauville score of 1 to 3. For patients with a positive biopsy, treatment is as described for refractory disease.

BV-AVD is initially administered for 6 cycles followed by restaging with PET.¹⁰⁸ If performing an FDG-PET/CT before completion of 6 cycles, a biopsy is recommended in patients with a Deauville score of 5. Therapy should be re-evaluated for positive biopsies. At the completion of therapy, patients with a Deauville score of 1 to 3 should be monitored for relapse/late effects (See the section on Follow up After Completion of Treatment in this discussion). ISRT to initially bulky or FDG-PET–positive sites may be considered for patients with a Deauville score of 4 to 5. Alternatively, a biopsy may be considered for patients with a Deauville score of 5 and, if positive, alternative therapy for refractory disease should be pursued.

It must be underscored that the ECHELON-1 trial design was not PET-adapted; consequently, patients treated with ABVD who could have benefited from dose escalation according to current practices or for whom bleomycin could have been omitted, were continued on ABVD. Consequently, the superiority of BV-AVD over PET-adapted ABVD according to RATHL study has not been established.

Escalated BEACOPP x 2 cycles followed by restaging with PET (and additional cycles of escalated BEACOPP [total of 4 or 6 cycles] or A(B)VD x 4 cycles depending on the Deauville score at interim restaging) is included as an option for select patients with advanced-stage disease who are <60 years with IPS greater than or equal to 4.^{112,113}

Escalated BEACOPP is initially administered for 2 cycles followed by restaging with FDG-PET. Treatment options for patients with a Deauville score of 1 to 3 include an additional 2 cycles of escalated BEACOPP (total of 4 cycles) or 4 cycles of ABVD. If reduced exposure to bleomycin is desired, the panel recommends omitting bleomycin from ABVD per the RATHL trial.³¹ Following an end-of-treatment FDG-PET, ISRT may be considered to initially bulky or FDG-PET–positive sites. For patients with a Deauville score of 4 to 5, a biopsy is recommended. For patients with a



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

positive biopsy, treatment is as described for refractory disease. Two cycles of escalated BEACOPP (total of 4 cycles)¹¹³ is recommended for negative biopsies, followed by restaging with FDG-PET. For patients with a Deauville score of 4 to 5, an additional biopsy is recommended. If the resulting Deauville score is 1 to 3, or 4 to 5 with a negative biopsy, an additional 2 cycles of escalated BEACOPP (total of 6 cycles), with or without ISRT, is recommended. Patients with a Deauville score of 4 to 5 with a positive biopsy, treatment is as described for refractory disease.

Management of Classic Hodgkin Lymphoma in Adults Age >60 years

CHL in patients >60 years is associated with worse disease outcomes.¹¹⁷ B symptoms, poor performance status, mixed cellularity, histologic subtype, Epstein-Barr virus-positive (EBV+) disease, and medical comorbidities are more frequent in this population.¹¹⁸ Standard chemotherapy regimens are associated with dose reductions, treatment toxicity, and transplant-related mortality (TRM) in older patients.¹¹⁹⁻¹²² However, there are limited prospective data evaluating alternatives to standard therapies for older patients. Selection of standard versus alternate first-line regimens should be based on clinical judgment and patient's performance status, with the goal of minimizing toxicity while maximizing efficacy.

In the HD10 and HD13 trials led by the GHSG, the impact of bleomycin in the ABVD regimen in patients ≥60 years with stage I–II favorable HL was evaluated. Two hundred eighty-seven patients were randomized to receive: 2 cycles of ABVD or 2 cycles of AVD followed by 20 or 30 Gy IFRT (HD13 study) and 2 cycles of ABVD or 4 cycles of ABVD followed by 20 or 30 Gy IFRT (HD10 study).¹²³ Overall grade III–IV toxicity and grade III–IV leukopenia and infection rates were higher in patients receiving 4 cycles of ABVD. The results of the study suggested limited benefit in patients ≥60 years receiving more than 2 cycles of bleomycin.¹²³

Due to pulmonary toxicity, bleomycin should be used with caution, as it may not be tolerated in older patients. In a retrospective analysis, 147 patients with stage I–IV HL aged at least 60 years were treated with ABVD and evaluated for toxicity and survival.¹²⁴ All patients received at least 1 full course of ABVD and 50 patients received additional RT (30–40 Gy). Bleomycin was removed or reduced in 53 patients due to pulmonary toxicity. CR was observed in 117 patients (80%) with a 5-year OS rate estimated at 67% (95% CI, 58–74).¹²⁴ Other risk factors that may be associated with bleomycin-induced pulmonary toxicity (BPT) include a history of smoking and use of granulocyte-colony stimulating factor (G-CSF) during treatment.^{125,126}

In a phase II multicenter study, the impact of sequential BV given before and after AVD was examined in untreated patients ≥60 years with stage II–IV HL (n = 48).¹²⁷ After two lead-in doses of BV, 37 of 48 patients (77%) completed 6 cycles of AVD, and 35 patients (73%) received at least one BV consolidation.¹²⁷ Among 42 response-evaluable patients, the overall response and CR rates after 6 cycles of AVD were 95% and 90%, respectively.¹²⁷ By intent-to-treat, the 2-year EFS, PFS, and OS rates were 80%, 84%, and 93%, respectively.¹²⁷

The following regimens have also been used as front-line chemotherapy in older patients with HL:

- CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone)¹²⁸
- BV plus dacarbazine (DTIC)^{129,130}
- VEPEMB (vinblastine, cyclophosphamide, prednisolone, procarbazine, etoposide, mitoxantrone, and bleomycin)^{131,132}
- BACOPP (bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone)¹²²
- PVAG (prednisone, vinblastine, doxorubicin, and gemcitabine)¹³³



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

NCCN Recommendations

The regimens listed below should be considered in patients >60 years to lessen or minimize toxicity. These regimens have not been proven to overcome the poorer disease outcomes observed in older patients. Clinical trial is recommended when available.

Stage I–II Favorable Disease

ABVD and CHOP are included as primary treatment options for patients >60 years with stage I–II favorable disease.^{54,123,124,128,132} In this setting, 2 cycles of ABVD, with or without 2 cycles of AVD, followed by ISRT is the preferred option. The other treatment regimen includes 4 cycles of CHOP with ISRT.

Stage I–II Unfavorable or Stage III–IV Disease

ABVD, BV lead in followed by AVD and BV maintenance, BV plus DTIC, and CHOP with or without ISRT are included as primary treatment options for elderly patients with stage I–II unfavorable or stage III–IV disease.^{31,127-130,133} For the ABVD regimen, a FDG-PET scan follows treatment with 2 cycles of ABVD. Bleomycin should not be used beyond 2 cycles if included in the regimen. If the FDG-PET scan is negative (Deauville score 1–3), patients can be treated with 4 cycles of AVD (total of 6 cycles), although 2 cycles of AVD (total of 4 cycles) followed by ISRT may be considered for stage I–II unfavorable disease. If the FDG-PET scan is positive (Deauville score 4–5) after 2 cycles of ABVD, an individualized treatment plan should be developed.

Nodular Lymphocyte-Predominant Hodgkin Lymphoma

NLPHL is characterized by an indolent course and occasional late relapse. It has a different natural history and response to therapy compared with CHL.¹³⁴ The majority of patients present with early-stage disease and rarely with B symptoms, mediastinal or extranodal involvement, or bulky disease.¹³⁵⁻¹³⁷ Patients who present with bulky disease, subdiaphragmatic

disease, or splenic involvement have a high risk for initial or later transformation to large cell lymphoma.^{2,138} Data suggest outcomes differ for typical immunoarchitectural patterns (A/B) versus variant patterns (C/D/E/F), with the variant patterns being associated with advanced-stage disease and a higher risk of relapse.^{2,139-141} In the retrospective analysis from the GHSG that included 394 patients with NLPHL, 63% had early-stage favorable, 16% had early-stage unfavorable, and 21% had advanced-stage disease. At a median follow-up of 50 months, FFTF (88% vs. 82%) and OS (96% vs. 92%) were better for NLPHL compared with CHL.¹³⁶ Among patients with NLPHL, FFTF was better for early-stage favorable disease (93%) compared with early-stage unfavorable (87%) and advanced-stage disease (77%). The European Task Force on Lymphoma also reported favorable FFTF for early-stage disease (85% for stage I; 71% for stage II) compared with those with stage III (62%) or stage IV (24%) disease.¹³⁵ Advanced stage at presentation, age (≥45 years), low hemoglobin, and the presence of B symptoms are associated with worse OS.^{136,137}

Several retrospective studies have reported favorable clinical outcomes for patients with stage I to II disease treated with RT alone¹⁴²⁻¹⁴⁶ or in combination with chemotherapy.^{137,147,148} RT alone is an effective treatment option for patients with stage IA–IIA disease.^{142,144,149} In a retrospective analysis, the Australasian Radiation Oncology Lymphoma Group reported follow-up of 202 patients with stage I–II NLPHL treated with RT alone, including mantle and total lymphoid irradiation (TLI).¹⁴⁴ At 15 years, FFP was 84% for patients with stage I disease and 73% for those with stage II disease. An additional retrospective analysis from the GHSG clinical trials reported favorable PFS and OS rates (91.9% and 99.0%, respectively) at 8 years in patients with stage IA disease treated with IFRT.¹⁴⁹ Among the studies that have evaluated the outcomes of patients treated with RT alone or CMT, the subgroup analysis of 64 patients with NLPHL included in the GHSG HD7 trial showed a



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

non-significant trend toward better 7-year FFTF for the combined modality group (96%) compared with the extended-field radiation therapy (EFRT) group (83%; $P = .07$).¹⁴⁸ However, other retrospective studies have shown no difference in outcome between patients treated with RT alone or in combination with chemotherapy.^{143,145,146} The GHSG retrospectively compared 3 treatment options, including EFRT, IFRT, and CMT in patients with stage IA NLPHL.¹⁴⁵ Median follow-up was 78 months for EFRT, 40 months for combined modality, and 17 months for IFRT. CRs were observed in 98% after EFRT, 95% after combined modality, and 100% after IFRT, and no significant differences were seen in FFTF, suggesting that IFRT is equally as effective as EFRT and CMT.

A report from the French Adult Lymphoma Study Group that analyzed the long-term outcomes of 164 patients with NLPHL (82% of patients had stage IA–IIA disease) included 58 patients who were observed following diagnosis and lymph node biopsy.¹⁵⁰ The 10-year PFS rate for this group of patients was 41% compared to 66% for patients who received specific treatment. However, the 10-year OS rate was not different between the two groups (91% and 93%, respectively), and 50% of patients treated with a watch-and-wait approach had achieved a CR at a median follow-up of 3 years. Watchful waiting has also been shown to be an appropriate treatment option in pediatric patients with early-stage NLPHL who are in complete remission following lymph node excision.^{151,152}

Binkley et al reported an international retrospective review of 559 adult patients with stage I–II NLPHL treated with RT alone ($n = 257$), CMT ($n = 184$), chemotherapy alone ($n = 47$), observation ($n = 37$), rituximab plus RT ($n = 19$), or rituximab monotherapy ($n = 15$). The 5-year PFS and OS for the entire cohort were 87.1% and 98.3%, respectively.¹⁵³ The 5-year PFS rates were 91.1% after RT, 90.5% after CMT, 77.8% after chemotherapy alone, 73.5% after observation, 80.8% after rituximab plus RT, and 38.5% after rituximab monotherapy.¹⁵³ The variant

immunoarchitectural pattern was associated with a worse PFS. Three point eight percent of patients developed large cell transformation.

Patients with advanced-stage NLPHL have a worse prognosis than those with early-stage favorable disease, and can be treated with chemotherapy. In the European Task Force on Lymphoma study, the 8-year disease-specific survival and FFTF were 94% and 62%, respectively, for stage III disease and 41% and 24%, respectively, for stage IV disease.¹³⁵ Most of these patients (80%–95%) were treated with chemotherapy (MOPP- or ABVD-like regimens), with or without RT.

In the absence of randomized trials comparing different chemotherapy regimens, no preferred chemotherapy regimen exists for NLPHL, although ABVD is often used based on the data for patients with CHL. Savage et al have reported that ABVD chemotherapy with ($n = 89$) or without ($n = 11$) RT was associated with superior outcomes compared to a historical cohort of patients treated with RT alone for stage IA, IB, or IIA NLPHL.¹⁵⁴ With a median follow-up of 6.4 years, patients treated with ABVD-like chemotherapy with or without RT had a superior 10-year time to progression (TTP) (98% vs. 76%), PFS (91% vs. 65%), and OS (93% vs. 84%) compared to those treated with RT alone. However, an analysis of the combined data from the CALGB trials and Dana-Farber Cancer Institute trials that included patients with stage III–IV NLPHL treated with chemotherapy alone, showed that the failure rate was 75% for the 12 patients treated with ABVD or EVA (etoposide, vinblastine, and doxorubicin) and 32% for the 25 patients treated with alkylating agent-containing regimens (MOPP or MOPP/ABVD).¹⁵⁵ Some investigators have also reported good response rates with CHOP plus rituximab^{156–158} or CVbP (cyclophosphamide, vinblastine, and prednisolone) in patients with early-stage or advanced disease.¹⁵⁹



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

Because NLPHL cells consistently express CD20 antigen, several clinical studies have explored the efficacy of rituximab, an anti-CD20 antibody, for patients with newly diagnosed and relapsed or refractory NLPHL.¹⁶⁰⁻¹⁶⁴

In a prospective phase II trial conducted by the Stanford group, previously treated (n = 10) and untreated (n = 12) patients with stage I–IV NLPHL received 4 weekly doses of rituximab at 375 mg/m². The overall response rate (ORR) was 100% (41% CR, 54% partial response [PR], and 5% CR unconfirmed [CRu]). At a median follow-up of 13 months, 9 patients had relapsed and the estimated median FFP was 10.2 months.¹⁶⁰ The estimated probability of disease progression at 10.2 months was 52%. Rituximab was well tolerated, with few adverse side effects.

In a GHSG phase II study that investigated rituximab in patients with newly diagnosed stage IA NLPHL (n = 28), the ORR was 100% (CR and PR were achieved in 86% and 14% of patients, respectively). At a median follow-up of 43 months, the OS rate was 100%; the PFS rate at 12, 24, and 36 months was 96%, 85%, and 81%, respectively.¹⁶² However, the relapse rate was 25%. In the GHSG phase II study that evaluated rituximab in patients with relapsed or refractory CD20-positive NLPHL (n = 15), the ORR was 94% (8 patients with CR and 6 patients with PR). At a median follow-up of 63 months, median TTP was 33 months and the median OS was not reached.¹⁶¹

Rituximab followed by rituximab maintenance has also been evaluated in patients with newly diagnosed and relapsed or refractory NLPHL. In a study conducted by the Stanford group, newly diagnosed or previously treated patients with NLPHL (n = 39) were treated with rituximab (4 weekly doses of rituximab at 375 mg/m²) or rituximab followed by rituximab maintenance (once every 6 months for 2 years).¹⁶⁴ The ORR was 100% (67% CR and 33% PR) at the end of initial therapy with rituximab alone. The median follow-up was 9.8 years for rituximab and 5 years for rituximab plus maintenance rituximab. The estimated 5-year PFS rate was

39.1% and 58.9%, respectively, for patients treated with rituximab and rituximab followed by maintenance rituximab. The corresponding 5-year OS rates were 95.7% and 85.7%, respectively. Rituximab as initial treatment was also associated with a pattern of relapse with evidence of transformation to aggressive B-cell lymphoma, primarily in patients with intra-abdominal disease. This underscores the importance of biopsy of intra-abdominal sites of disease at initial presentation or relapse. Rituximab maintenance for 2 years was associated with a non-significant increase in median PFS compared to rituximab alone (5.6 years and 3 years, respectively; *P* = .26).

Collectively, the above data suggest that rituximab alone or in combination with chemotherapy has activity in the management of newly diagnosed and relapsed NLPHL.^{160,162,164}

NCCN Recommendations for NLPHL

Available evidence from retrospective studies supports the use of ISRT alone as a treatment option for patients with early-stage disease.¹⁴²⁻¹⁴⁶

The panel recommends that ISRT (30–36 Gy) be the preferred treatment for all patients with stage IA or contiguous stage IIA non-bulky disease. Observation may be an option for highly selected patients with stage IA disease with a completely excised solitary node. A brief course of chemotherapy plus ISRT with rituximab is recommended for patients with stage IB or IIB disease and for very rare patients presenting with stage IA or IIA bulky or non-contiguous disease. For select patients with stage IB or stage IIA non-contiguous disease, ISRT alone may be considered.

Chemotherapy and rituximab with or without ISRT is recommended for all patients with stage III–IV disease. Alternatively, patients can be observed if asymptomatic, or treated with rituximab or with local RT for palliation of locally symptomatic disease. Abdominal involvement, especially involvement of the spleen, has been associated with the risk of



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

transformation to an aggressive B-cell lymphoma.¹⁶⁴ Biopsy of persistent or new subdiaphragmatic sites should be considered to rule out transformation for patients with stage III or IV disease.

Restaging with FDG-PET should be done for all patients after completion of initial therapy. Observation is recommended for all patients who are asymptomatic with a clinical response. ISRT is recommended if not received previously. Biopsy is recommended for patients with stable or progressive disease, especially of subdiaphragmatic sites. Asymptomatic patients with a negative biopsy can be observed. For those with a positive biopsy, treatment is as described for relapsed or refractory disease.

Rituximab may be used in combination with chemotherapy regimens that are most commonly used at NCCN Member Institutions (ABVD, CHOP, or CVbP).^{154,155,157,159} Ongoing clinical trials may clarify the role of observation, rituximab, or combination chemotherapy options for patients with NLPHL. The results of two large randomized trials have demonstrated the non-inferiority of subcutaneous rituximab (rituximab and hyaluronidase human injection for subcutaneous use) compared to IV rituximab when used in combination with chemotherapy in patients with certain subtypes of non-Hodgkin lymphoma (NHL).^{165,166} Rituximab and hyaluronidase human injection for subcutaneous use may be substituted for rituximab after patients have received the first full dose of rituximab by IV infusion. An FDA-approved biosimilar is an acceptable substitute for rituximab after patients have received the first full dose of rituximab by IV infusion.

Follow-up After Completion of Treatment

Recommendations included in the Guidelines are based largely on the clinical practices at NCCN Member Institutions and are not supported by high-level evidence, since there are very few data available on the follow-up and monitoring of late effects in patients with HL, after completion of treatment.¹⁶⁷

The panel overwhelmingly agrees that, given the long-term risks of the therapies for HL, patients should follow up with an oncologist who is aware of these risks and complications, and care should be coordinated with the primary care provider, especially during the first 5 years after treatment to detect recurrence and then annually due to the risk for late complications, including secondary cancers and cardiovascular disease.¹⁶⁷ The follow-up schedule should be individualized, depending on clinical circumstances such as patient's age, stage of disease, and initial treatment modality. Patients should be encouraged to undergo counseling on issues regarding survivorship, long-term treatment effects (secondary cancers, cardiac disease, and reproduction), health habits, and psychosocial issues. It is recommended that the patient be provided with a treatment summary at the completion of therapy, including details of RT, the dose to the OAR, and cumulative anthracycline dosage given.

Interim physical examinations and blood tests (CBC, platelets, chemistry profile, and ESR if elevated at initial diagnosis) should be performed every 3 to 6 months for 1 to 2 years, then every 6 to 12 months for the next 3 years, and then annually.¹⁶⁸ Patients who have had neck or superior mediastinal irradiation should have their thyroid function tested at least annually. Annual fasting glucose levels may also be monitored. An annual influenza vaccination and other vaccines as clinically indicated are recommended for all patients (see the [NCCN Guidelines for Survivorship](#)). In addition, patients treated with splenic RT or splenectomy should receive pneumococcal, meningococcal, and H-flu type b revaccination after 5 to 7 years (according to the current Centers for Disease Control and Prevention [CDC] recommendations).

Repeat imaging studies of initially involved sites are important, as are surveillance studies of the chest and abdomen.¹⁶⁹ In a randomized trial that compared the use of FDG-PET/CT with the combination of US and chest radiography for systematic follow-up of 300 patients with



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

advanced-stage disease, the sensitivity for the detection of relapse was similar for both procedures.¹⁷⁰ The specificity (96% vs. 86%, respectively; $P = .02$) and positive predictive value (91% vs. 73%, respectively; $P = .01$) were significantly higher for the combination of US and chest radiography. A neck/chest/abdomen/pelvis CT scan with contrast should not be obtained more often than every 6 months for the first 2 years following completion of therapy, or as clinically indicated after 2 years, especially in NLPHL, where late relapse can occur. However, PET scans are not recommended for routine surveillance due to the risk of false positives.^{77,78,80}

Monitoring for Late Effects

Secondary cancers, cardiovascular disease, hypothyroidism, and fertility issues are the most significant late effects in long-term survivors of HL. The incidence of these late effects increases with longer follow-up time. The risk may be less with current treatment programs compared to those used more than 10 years ago.

Secondary Cancers

Solid tumors are the most common secondary cancers and most develop more than 10 years after the completion of treatment. The risk of developing secondary cancers is highest when RT is used as a component of first-line treatment. Meta-analysis by Franklin and colleagues showed that the risk of developing secondary cancers was lower with CMT than with RT alone as the initial treatment.¹⁷¹ The risk was marginally higher with CMT when compared with chemotherapy alone as initial treatment. No significant differences in the risk of developing secondary cancers were seen with IFRT versus EFRT, although the risk of developing breast cancer was substantially higher for EFRT and was likely related to the extent of mediastinal and axillary irradiation. Risks for secondary lung cancer, NHL, and leukemia were increased after treatment with chemotherapy alone, whereas CMT was associated with an

increased risk for these and several other cancers.¹⁷² Lung cancer and breast cancer are the most common secondary cancers in patients treated for HL.

RT, and possibly some chemotherapy drugs such as alkylating agents, increase the risk of developing lung cancer, and the risk increases linearly with dose to the lung.^{173,174} The increased risk is most apparent in people who smoke, particularly those who continue to use tobacco after diagnosis.¹⁷⁵

In fact, continuing to smoke after thoracic RT multiplies the risk of developing lung cancer. Therefore, a concerted effort should be made to help patients who currently smoke and require thoracic RT to stop smoking. Lung cancer screening with low-dose CT may also be appropriate depending upon clinical circumstances including age, pack-year tobacco exposure history, and interval since quitting. See [NCCN Guidelines for Lung Cancer Screening](#).

Breast cancer is the most common malignancy in females and the risk is increased with doses as low as 4 Gy. Annual breast screening (mammography and MRI) beginning 8 years after completion of therapy or at age 40 years (whichever occurs earlier) is recommended for patients who have received chest or axillary irradiation.¹⁶⁹ They should also be encouraged to perform monthly breast self-examination and undergo yearly breast examination by a health care professional. In a prospective study that evaluated the sensitivity and specificity of breast MRI with that of mammography in females who received chest irradiation for HL, the sensitivity of the combined MRI and mammography as a combined screening modality was higher than that of MRI or mammography alone (94% for combined MRI and mammography; 67% and 68%, respectively, for MRI and mammography).¹⁷⁶ NCCN Guidelines recommend breast MRI in addition to mammography, often alternated every 6 months, for patients who received irradiation to the chest between ages 10 and 30 years,



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

which is consistent with the recommendation of the American Cancer Society Guidelines¹⁷⁷ and the NCCN Guidelines for Detection, Prevention, and Risk Reduction. While MRI can begin earlier, mammography should not be pursued until a patient is at least 30 years of age. See [NCCN Guidelines for Breast Cancer Screening and Diagnosis \(BSCR-2\)](#).

Chemoprevention with selective estrogen receptor modulators and aromatase inhibitors have been demonstrated to reduce the risk of breast cancer by 50% to 60% in high-risk populations. These trials, however, did not include individuals with prior breast RT for non-epithelial breast cancers. Patients should consider discussion of chemoprevention with their oncologist or breast specialist. See [NCCN Guidelines for Breast Cancer Risk Reduction](#).

NCCN Guidelines recommend that routine surveillance tests for cervical, colorectal, endometrial, lung, and prostate cancer be performed as per the American Cancer Society Guidelines.

Cardiovascular Disease

Mediastinal irradiation and anthracycline-based chemotherapy are the highest risk factors for developing cardiac disease, which may be asymptomatic.¹⁷⁸⁻¹⁸⁰ RT-induced cardiotoxicity is usually observed more than 5 to 10 years after completion of treatment. However, cardiovascular symptoms may emerge at any age. Coronary CT angiography abnormalities have been detected in nearly 15% of the patients within the first 5 years after treatment, and their incidence significantly increases 10 years after treatment.¹⁸¹ In a multivariate analysis, patient's age at treatment, hypercholesterolemia, hypertension, and RT dose to the coronary artery origins were identified as independent prognostic factors.

Based on data regarding increased long-term risk of cardiac disease, annual blood pressure monitoring (even in asymptomatic individuals) and aggressive management of cardiovascular risk factors is recommended.¹⁶⁹

A baseline stress test, echocardiogram, or coronary artery calcium (CAC) score and carotid US (for patients treated with neck RT) should be considered at 10-year intervals after completion of treatment.^{169,182}

Hypothyroidism

Abnormal thyroid function, mostly hypothyroidism, is reported in approximately 50% of long-term survivors who received neck or upper mediastinal irradiation.¹⁶⁷ A careful thyroid examination should be a part of the physical examination. Thyroid function tests should be done at least annually to rule out hypothyroidism, especially in patients treated with RT to the neck.

Myelosuppression

Myelosuppression is the most common side effect of chemotherapy and is associated with increased risk of infections. It is uncommon for myelosuppression to continue for very long beyond completion of the primary treatment program. However, patients who undergo high-dose therapy (HDT)/autologous stem cell rescue (ASCR) or allogeneic hematopoietic cell transplant (HCT) may be at continued risk for infection. Pneumococcal, meningococcal, and H-flu revaccinations are recommended every 5 years for patients treated with splenic RT or splenectomy.

Infertility

Certain chemotherapy combinations (eg, escalated BEACOPP) may cause immediate and permanent infertility.^{183,184} Other combinations (eg, ABVD) are only rarely associated with infertility.^{88,185} Since patients assigned female at birth who have received chemotherapy with alkylating agents and who maintain short-term fertility may experience premature menopause,⁸⁶ this should be taken into consideration with respect to family planning.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

Pulmonary Toxicity

Bleomycin pulmonary toxicity (BPT) is well documented in patients with HL treated with bleomycin-containing chemotherapy regimens. Risk factors include older age, cumulative bleomycin dose, pulmonary irradiation, and prior history of lung disease. Some reports have suggested that the use of growth factors increases the incidence of pulmonary toxicity. Martin and colleagues reported that BPT significantly decreases the 5-year OS rate, especially in patients ≥ 40 years.¹⁸⁶ They also showed that the use of growth factors with chemotherapy significantly increases the incidence of BPT (26% vs. 9%). Two separate studies confirmed that ABVD chemotherapy can be safely administered at the full-dose intensity without any growth factor support.^{187,188} Five-year EFS (87.4% vs. 80%, respectively) and OS (94.1% vs. 91.3%, respectively) rates in patients who received ABVD with no growth factors were comparable to those in patients who received prophylactic growth factor support with the ABVD regimen.¹⁸⁸

Leukopenia is not a risk factor for reduction of dose intensity. The NCCN Guidelines do not recommend the routine use of growth factors with ABVD regimens.

Relapsed or Refractory Disease

Classic Hodgkin Lymphoma

Two randomized phase III studies performed by the British National Lymphoma Investigation¹⁸⁹ and the GHSG/European Group for Blood and Marrow Transplantation¹⁹⁰ have compared HDT/ASCR with conventional chemotherapy in patients with relapsed or refractory HL. Both studies showed significant improvements in EFS, PFS, and FFTR (with no difference in OS) for patients with relapsed or refractory HL who underwent HDT/ASCR compared with conventional chemotherapy alone.

Studies have suggested that patients with a CR or with chemosensitive disease to second-line therapy have improved outcomes following HDT/ASCR compared to those with resistant disease.^{191,192} Moskowitz et al reported that the EFS, PFS, and OS were significantly better for patients with disease responding to second-line chemotherapy (60%, 62%, and 66%, respectively) compared to those who had a poor response (19%, 23%, and 17%, respectively) ($P < .001$).¹⁹¹ Sirohi et al also reported similar findings; the 5-year OS rate was 79%, 59%, and 17%, respectively, for patients who were in CR, PR, or those with resistant disease at the time of HDT/ASCR ($P < .0001$), and the 5-year PFS rates were 69%, 44%, and 14%, respectively ($P < .001$).¹⁹²

Several investigators have developed prognostic models to predict the outcome in patients with relapsed or refractory disease undergoing HDT/ASCR. Brice and colleagues used end-of-treatment to relapse interval (≤ 12 months) and extranodal disease at relapse as adverse prognostic factors to predict outcome of 280 patients undergoing HDT/ASCR.¹⁹³ The PFS rates were 93%, 59%, and 43%, respectively, for patients with 0, 1, or 2 of these risk factors. In a prospective study, Moskowitz and colleagues identified extranodal sites, CR duration of less than 1 year, primary refractory disease, and B symptoms as adverse prognostic factors associated with poor survival after HDT/ASCR.¹⁹⁴ In patients with 0 to 1 risk factors, 5-year EFS and OS were 83% and 90%, respectively, which decreased to 10% and 25% if all factors were present. This prognostic model has been used for the risk-adapted augmentation of treatment for relapsed or refractory disease to improve EFS in poorer-risk patients.¹⁹⁵ In a retrospective analysis of 422 patients with relapsed disease, Josting and colleagues from the GHSG identified time to relapse, clinical stage at relapse, and anemia at relapse as independent risk factors to develop a prognostic score that classified patients into four subgroups with significantly different freedom from second failure and OS.¹⁹⁶ Investigators of the GEL/TAMO group identified bulky disease at



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

diagnosis, a short duration of first CR (<1 year), detectable disease at transplant, and the presence of >1 extranodal site as adverse factors for OS.¹⁹⁷ Other groups have identified extent of prior chemotherapy,¹⁹⁸ short time from diagnosis to transplant,¹⁹⁹ and disease status at transplantation²⁰⁰ as significant prognostic factors for OS and PFS. Pretransplant functional imaging status has also been identified as an independent predictor of outcome and it may be the most important factor in patients with recurrent/refractory HL.²⁰¹⁻²⁰⁴ The main potential of these prognostic factor studies is to facilitate comparison of outcomes at different centers, where the preparatory regimens may vary.

Several studies have shown the importance of cytoreduction with second-line chemotherapy before HDT/ASCR.^{194,205-213} ICE (ifosfamide, carboplatin, and etoposide) and DHAP (dexamethasone, cisplatin, and high-dose cytarabine) are the most commonly used regimens. Gemcitabine-based combination regimens, such as GVD (gemcitabine, vinorelbine, and pegylated liposomal doxorubicin),²¹⁴ IGEV (ifosfamide, gemcitabine, and vinorelbine),²¹⁵ GCD (gemcitabine, cisplatin, and dexamethasone),^{216,217} and GEMOX (gemcitabine and oxaliplatin)²¹⁸ have also been effective for relapsed or refractory HL. However, none of these regimens has been studied in randomized trials.

Bendamustine, lenalidomide, and everolimus as single agents have also shown activity in patients with relapsed or refractory HL.²¹⁹⁻²²¹ In a phase II trial, bendamustine was well tolerated and highly active in heavily pretreated patients with relapsed or refractory disease (including those with HL that failed to respond to HDT/ASCR treatment), resulting in an ORR of 56% among evaluable patients (34 out of 36 patients enrolled).²¹⁹ The ORR by intent-to-treat analysis was 53% (33% CR and 19% PR). The median response duration was 5 months. Lenalidomide and everolimus have also shown single-agent activity in a small cohort of patients with relapsed or refractory HL, resulting in ORRs of 19% and 47%,

respectively.^{220,221} In a phase II study, bendamustine in combination with gemcitabine and vinorelbine (BeGEV) was used as induction therapy before HDT/ASCR in patients with relapsed or refractory HL, resulting in an ORR of 83% (73% CR and 10% PR).²²² In a phase I/II study, bendamustine with carboplatin and etoposide also demonstrated 85% response rates (70% CR) in patients with relapsed or refractory HL.²²³

BV, a CD30-directed antibody-drug conjugate, has demonstrated activity in patients with relapsed or refractory CD30-positive lymphomas.^{224,225} In a pivotal phase II multicenter study of 102 patients with relapsed or refractory HL after HDT/ASCR, BV induced objective responses and CRs in 75% and 34% of patients, respectively, with a median follow-up of more than 1.5 years. The median PFS for all patients and the median duration of response for those in CR were 5.6 months and 20.5 months, respectively.²²⁴ Based on the results of this study, the FDA approved BV for the treatment of patients with HL after failure of HDT/ASCR or at least two prior chemotherapy regimens in patients who are not candidates for HDT/ASCR. The 3-year follow-up data confirmed durable remissions in patients with disease responding to BV.²²⁵ After a median follow-up of approximately 3 years, the estimated median OS and PFS were 40.5 months and 9.3 months, respectively. In patients who achieved a CR on BV, the estimated 3-year OS and PFS rates were 73% and 58%, respectively.²²⁵ A systematic review and meta-analysis of effectiveness outcomes for BV revealed similar results to the pivotal phase II trial, with pooled ORR estimates of 62.6% after 4 cycles, 66.7 after 4 to 6 cycles, and 72% after >6 cycles. Pooled CR rates were similar between all cycle subgroups, at 33.4% after >6 cycles.²²⁶

Several studies are investigating the utility of BV in combination with other regimens, as second-line therapy for relapsed or refractory disease prior to HDT/ASCR. Preliminary data from studies have evaluated BV in combination with ICE or bendamustine have reported PET-negative



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

responses ranging from approximately 75% to 90%.²²⁷⁻²²⁹ A trial from Memorial Sloan Kettering Cancer Center (MSKCC) used a PET-adapted design in which 45 patients received 2 cycles of BV followed by a PET scan.²²⁷ Patients who achieved a CR after BV (27%) proceeded directly to HDT/ASCR, while patients with residual disease received 2 cycles of augmented ICE. Overall, 76% of patients achieved a CR prior to HDT/ASCR using this PET-adapted approach.²²⁷ A similar approach was used by investigators at City of Hope National Medical Center in which 37 patients received 4 cycles of BV followed by a PET scan.²³⁰ Patients who achieved a CR after BV (35%) proceeded directly to HDT/ASCR, while those with residual disease received platinum-based salvage chemotherapy. Overall, 65% of patients achieved a CR prior to HDT/ASCR using this approach.²³⁰

The use of BV as consolidation therapy following HDT/ASCR was evaluated in the AETHERA trial.²³¹ For high-risk patients defined as having primary refractory disease, duration of first CR less than 1 year, or relapse with extranodal or advanced-stage disease, the phase 3 AETHERA trial randomized patients to receive up to 16 cycles of BV consolidation or placebo post-HDT/ASCR. Patients were required to have obtained a CR, PR, or stable disease to second-line therapy prior to HDT/ASCR. At 5-year follow-up, there was a sustained PFS benefit with BV consolidation compared to placebo (5-year PFS, 59% vs. 41%; HR, 0.52; 95% CI, 0.38–0.72) but no difference in OS. Peripheral sensory neuropathy was a common side effect of BV consolidation, but improved or resolved in the majority of patients after discontinuing therapy.²³²

Attempts to increase the CR rate prior to HDT/ASCR have led to numerous trials incorporating the novel agents into initial second-line therapy. Checkpoint inhibitors (CPIs) including programmed death 1 (PD-1)-blocking monoclonal antibodies (eg, nivolumab or pembrolizumab) have also demonstrated activity in patients with relapsed or refractory

PD-1–positive lymphomas (either as monotherapy or in combination regimens).²³³⁻²⁴²

In a phase II study (CheckMate 205 trial) of 80 patients with relapsed or refractory HL pretreated with both HDT/ASCR and BV, at a median follow-up of 8.9 months, nivolumab monotherapy induced an ORR of 66.3% (95% CI, 54.8–76.4) as determined by an independent radiologic review committee.²³⁴ Extended follow-up of the CheckMate 205 trial analyzed the safety and efficacy of nivolumab in patients with relapsed or refractory HL according to treatment history: BV-naïve, BV after HDT/ASCR, or BV received before and/or after HDT/ASCR.²³⁵ The ORR was 69% (95% CI, 63%–75%) overall and 65% to 73% in each cohort, with a median duration of response of 16.6 months (95% CI, 13.2–20 months).²³⁵

In a phase III trial (KEYNOTE-204), pembrolizumab monotherapy versus BV was evaluated on the parameters of safety and efficacy in adults with relapsed or refractory CHL (patients who were ineligible for transplant or those with relapse after autologous HCT); 151 patients were randomly assigned to pembrolizumab and 153 patients to BV.²⁴⁰ At second interim analysis, primary endpoint PFS (OS not analyzed in interim analysis) was 13.2 months for pembrolizumab, and 8.3 months for BV ($P = .0027$).²⁴⁰ Treatment-emergent adverse events (TEAEs) were observed in 74% of patients receiving pembrolizumab and 77% of patients receiving BV. The most common grade 3–5 TEAEs were pneumonitis (4% in the pembrolizumab group vs. 1% in the BV group), neutropenia (2% vs. 7%, respectively), decreased neutrophil count (1% vs. 5%, respectively), and peripheral neuropathy (1% vs. 3%, respectively).²⁴⁰ Serious TEAEs were observed in 16% of patients receiving pembrolizumab and 11% of patients receiving BV.²⁴⁰

Nivolumab in combination with BV was evaluated as an option for relapsed or refractory HL prior to transplant.²³⁷ In a phase I/II study of 91



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

patients with relapsed or refractory CHL, the combination of nivolumab with BV resulted in an ORR of 85% (67% CR). At a median follow-up of 34 months, the estimated 3-year PFS and OS rates were 77% (91% for patients who underwent HDT/ASCR directly after study treatment with BV + nivolumab) and 93%, respectively.²³⁷ Nivolumab alone or in combination with ICE as second-line therapy and bridge to autologous HCT was studied in a phase II trial in patients with relapsed or refractory CHL.²⁴² In this study, patients received up to 6 cycles of nivolumab. Those in CR after cycle 6 went on to autologous HCT while those with progressive disease at any point or those not in CR after cycle 6 received 2 cycles of nivolumab plus ICE. Following nivolumab alone, ORR and CR rates were 81% and 71%, respectively. Following nivolumab/nivolumab plus ICE, ORR and CR rates were 93% and 91%, respectively. Two-year PFS and OS were 72% and 95%, respectively, in all patients, with 2-year PFS of 94% in those who bridged directly to autologous HCT.²⁴²

Pembrolizumab used in combination with GVD has also demonstrated activity as second-line treatment in transplant-eligible patients with relapsed or refractory CHL resulting in a CR rate of 95%.²⁴¹ At a median follow-up of 13.5 months, all patients who had undergone transplant had achieved remission.

The role of RT in the second-line therapy setting includes its use to cytoreduce prior to HDT/ASCR, its selective use to sites of relapse following HDT/ASCR, and occasionally its use as a primary component of second-line therapy. Moskowitz and colleagues have demonstrated the efficacy and feasibility of second-line RT with chemotherapy in patients with relapsed or refractory disease.¹⁹⁴ At a median follow-up of 43 months, the response rate to ICE and IFRT was 88% and the EFS rate for patients who underwent HDT/ASCR was 68%. Thus, RT may improve the chance of transitioning to HDT/ASCR in relapsed or refractory disease. Alternately, second-line RT may be effective in patients who are in good

performance status with limited-stage late relapses and without B symptoms. It may be a very effective treatment for patients with initial favorable stage I–II disease who are treated with chemotherapy alone and relapse in initially involved sites. Josting and colleagues from the GHSG reported that second-line RT may be effective in a select subset of patients with relapsed or refractory disease.²⁴³ The 5-year FFTF and OS rates were 28% and 51%, respectively. B symptoms and stage at the time of disease progression or relapse were identified as significant prognostic factors for OS. A comprehensive review and recommendations for incorporation of RT into salvage treatment programs is provided by the International Lymphoma Radiation Oncology Group consensus guidelines.²⁴⁴

NCCN Recommendations for Refractory CHL

Histologic confirmation with biopsy is recommended before initiating treatment for refractory disease. Although further cytoreduction and HDT/ASCR (with RT if not previously given) are often appropriate, occasional clinical circumstances may warrant the use of RT or systemic therapy with or without RT. Conventional-dose second-line systemic therapy may precede HDT/ASCR. RT should be strongly considered for selected sites of relapse that have not been previously irradiated. In radiation-naïve patients, TLI may be an appropriate component of HDT/ASCR.²⁴⁵

Second-line systemic therapy followed by response assessment with FDG-PET is recommended for all patients. Patients with a Deauville score of 1 to 3 should proceed to HDT/ASCR with or without RT (category 1). Observation with or without RT can be considered, if HDT/ASCR is contraindicated. Maintenance therapy with BV can be considered for patients with high risk of relapse as defined by the AETHERA trial (defined as those having primary refractory disease, duration of first CR <1 year, or relapse with extranodal or advanced-stage disease).²³¹ An alternative



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

regimen with or without RT or RT alone is recommended for patients with a Deauville score of 4 or 5 after second-line systemic therapy. Autologous or allogeneic HCT following additional therapy may be considered in these patients. Another approach for patients with a Deauville score of 4 is to proceed with HDT/ASCR with or without RT, followed by maintenance therapy with BV for patients with a high risk of relapse. It is worth noting that the role of maintenance BV has not been well defined in patients who received BV earlier in the management of their disease.

BV alone or in combination with bendamustine, nivolumab, or ICE^{229,237,246,247}; DHAP^{206,209}; GVD with or without pembrolizumab^{214,241}; ICE alone or in combination with nivolumab^{194,206,242}; IGEV²¹⁵; BeGEV²²²; and pembrolizumab^{239,240} regimens are included as options for second-line and subsequent therapy for patients with relapsed or refractory CHL. Bendamustine, everolimus, lenalidomide, and vinblastine are included as therapy options for patients with disease refractory to at least 3 prior lines of therapy.^{219-221,248} Nivolumab alone^{234,235} is also included as a therapy option for disease refractory to at least 3 prior lines of systemic therapy and also for patients with relapse or disease progression following HDT/ASCR.

Allogeneic HCT with myeloablative conditioning has been associated with lower relapse rate in patients with relapsed or refractory disease; however, TRM was greater than 50%. Allogeneic HCT with reduced-intensity conditioning has been reported to have decreased rates of TRM.^{249,250} However, this approach remains investigational. Nonmyeloablative allogeneic HCT and post-infusion cyclophosphamide has excellent outcomes even in haploidentical patients with estimated OS and PFS rates of 63% and 59%, respectively, at 3 years.²⁵¹ The panel has included allogeneic HCT with a category 3 recommendation for select patients with relapsed or refractory disease. Autologous or allogeneic HCT is an option for patients with FDG-PET–positive

refractory HL (Deauville 5) that is responsive to RT alone or to subsequent systemic therapy, with or without RT. If a CPI is used for relapsed or refractory disease prior to allogeneic HCT, the transplant regimen needs to be carefully considered by the transplant team due to potential increased risk of immune-related toxicities.

NCCN Recommendations for Relapsed CHL

Suspected relapse at any point should be confirmed with biopsy.

Observation (with short-interval follow-up with FDG-PET/CT) is appropriate if biopsy is negative. Restaging is recommended for patients with positive biopsy. Most patients require second-line systemic therapy followed by RT or HDT/ASCR with or without ISRT. For patients with initial stage I–IIA disease treated initially with abbreviated chemotherapy alone (3–4 cycles) and relapsed in initial sites of disease, RT alone may be appropriate.

Restaging after completion of treatment is recommended for all patients. Subsequent treatment options (based on the score on interim FDG-PET scan) are as described for patients with refractory disease.

NCCN Recommendations for the Management of Relapsed or Refractory CHL in Adults Age >60 years

Outcomes are uniformly poor for elderly patients with relapsed or refractory disease.²⁵² No uniform recommendation can be made, although clinical trials or possibly single-agent therapy with a palliative approach is recommended. Palliative therapy options include bendamustine,²¹⁹ BV,²⁵³ everolimus,²²¹ lenalidomide,²²⁰ nivolumab,^{234,235} and pembrolizumab.²⁴⁰ Nivolumab and pembrolizumab may be considered when patients have been previously treated with BV or after three or more lines of systemic therapy, including HDT/ASCR. ISRT alone is an option when systemic therapy is not considered feasible or safe.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Relapsed or refractory NLPHL can be managed with second-line therapy as described below. However, some patients have chronic indolent disease and may not require aggressive treatment. Individualized treatment is recommended since there are no data available to support a superior outcome with any of the treatment modalities. Rituximab should be considered with all second-line chemotherapy regimens for patients with relapsed or refractory NLPHL.

NCCN Recommendations for Refractory or Suspected Relapsed NLPHL

Late relapse or transformation to diffuse large B-cell lymphoma (DLBCL) has been reported in patients with NLPHL.²⁵⁴⁻²⁵⁶ In a study of 95 patients diagnosed with NLPHL, with a median follow-up of 6.5 years, transformation to aggressive lymphoma was seen in 13 (14%) patients and the actuarial risk at 10 and 20 years was 7% and 30%, respectively.²⁵⁶

Re-biopsy should be considered to rule out transformation to aggressive lymphoma prior to initiation of treatment for refractory disease or suspected disease relapse. Patients with a negative biopsy can be observed with short-interval follow-up. All patients with biopsy-proven relapsed NLPHL should be observed or treated with second-line therapy (rituximab and/or chemotherapy and/or ISRT) followed by restaging with FDG-PET/CT. No further treatment is necessary for patients with clinical response. Biopsy is recommended for patients with progressive disease to rule out transformation. At this stage, treatment is as described for refractory disease or treatment with any second-line therapy that was not previously used (rituximab and/or chemotherapy and/or ISRT) can be pursued, followed by re-evaluation with FDG-PET. Maintenance rituximab for 2 years may be considered for patients treated with rituximab alone.¹⁶⁴ Disease transformation to DLBCL should be managed as discussed in the [NCCN Guidelines for B-Cell Lymphomas](#).

Summary

HL is an uncommon malignancy of B-cell origin. CHL and NLPHL are the two main types of HL. CHL is characterized by the presence of Reed-Sternberg cells in an inflammatory background, whereas NLPHL is characterized by the presence of lymphocytic and histiocytic (LP or “popcorn”) cells.

Current management of CHL involves initial treatment with chemotherapy or CMT, followed by restaging with FDG-PET/CT to assess treatment response using the Deauville criteria (5-PS). CMT or chemotherapy alone are included as treatment options for patients with stage I or II CHL. Systemic therapy (ABVD and BV-AVD are included as preferred treatment options) followed by restaging with FDG-PET/CT to assess treatment response is recommended for patients with stage III–IV CHL.

Second-line systemic therapy followed by HDT/ASCR with or without RT is recommended for patients with relapsed or refractory CHL. Maintenance therapy with BV following HDT/ASCR can be considered for patients with high risk of relapse. Nivolumab or pembrolizumab (as monotherapy or in combination regimens) are also included as options for relapsed or refractory disease in appropriate patients.

ISRT is the preferred treatment for patients with stage IA or IIA non-bulky NLPHL. Observation may be an option for highly selected patients with stage IA disease with a completely excised solitary node. A brief course of chemotherapy plus ISRT with rituximab is recommended for patients with stage IB or IIB disease and for very rare patients presenting with stage IA or IIA bulky or non-contiguous disease. Chemotherapy with rituximab and with or without ISRT is recommended for all patients with stage III–IV disease. Alternatively, selected patients with stage III–IV disease can either be observed (if asymptomatic) or treated with local palliative RT or rituximab.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

Late relapse or transformation to DLBCL has been reported in patients with NLPHL. In patients with suspected relapse, re-biopsy should be considered to rule out transformation to DLBCL. Relapsed or refractory NLPHL can be treated with second-line therapy. However, some patients have chronic indolent disease and may not require aggressive treatment, unless they are symptomatic.

Long-term follow-up with careful monitoring for late treatment-related side effects and counseling about issues of survivorship should be an integral part of management of HL. Consistent with NCCN philosophy, participation in clinical trials is always encouraged.



References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin* 2022;72:7-33. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35020204>.
2. Swerdlow SH, Campo E, Harris NL, et al. *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*. Revised 4th ed. IARC Press: Lyon 2017.
3. PubMed Overview. Available at: <https://pubmed.ncbi.nlm.nih.gov/about/>. Accessed
4. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. *Cancer Res* 1971;31:1860-1861. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/5121694>.
5. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. *J Clin Oncol* 2014;32:3059-3068. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25113753>.
6. Mauch P, Goodman R, Hellman S. The significance of mediastinal involvement in early stage Hodgkin's disease. *Cancer* 1978;42:1039-1045. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/698907>.
7. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. *J Clin Oncol* 1989;7:1630-1636. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/2809679>.
8. Henry-Amar M, Friedman S, Hayat M, et al. Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC Lymphoma Cooperative Group. *Ann Intern Med* 1991;114:361-365. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/1992877>.
9. Tubiana M, Henry-Amar M, Hayat M, et al. Prognostic significance of the number of involved areas in the early stages of Hodgkin's disease. *Cancer* 1984;54:885-894. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/6378359>.
10. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. *N Engl J Med* 1998;339:1506-1514. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/9819449>.
11. Moccia AA, Donaldson J, Chhanabhai M, et al. International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era. *J Clin Oncol* 2012;30:3383-3388. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22869887>.
12. Cheson BD. Role of functional imaging in the management of lymphoma. *J Clin Oncol* 2011;29:1844-1854. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21482982>.
13. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. *J Clin Oncol* 2014;32:3048-3058. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25113771>.
14. Isasi CR, Lu P, Blafox MD. A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. *Cancer* 2005;104:1066-1074. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16047335>.
15. de Wit M, Bohuslavizki KH, Buchert R, et al. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. *Ann Oncol* 2001;12:29-37. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11249046>.
16. Guay C, Lepine M, Verreault J, Benard F. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. *J Nucl Med* 2003;44:1225-1231. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/12902411>.
17. Sher DJ, Mauch PM, Van Den Abbeele A, et al. Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy. *Ann Oncol* 2009;20:1848-1853. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19541793>.
18. Meignan M, Gallamini A, Haioun C, Polliack A. Report on the Second International Workshop on interim positron emission tomography in



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

lymphoma held in Menton, France, 8-9 April 2010. *Leuk Lymphoma* 2010;51:2171-2180. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21077737>.

19. Meignan M, Gallamini A, Itti E, et al. Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. *Leuk Lymphoma* 2012;53:1876-1881. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22432519>.

20. Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. *Eur J Nucl Med Mol Imaging* 2010;37:1824-1833. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20505930>.

21. Barrington SF, Kluge R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. *Eur J Nucl Med Mol Imaging* 2017;44:97-110. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28411336>.

22. Schaefer NG, Taverna C, Strobel K, et al. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed? *Radiology* 2007;244:257-262. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/17581905>.

23. Barrington SF, Kirkwood AA, Franceschetto A, et al. PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. *Blood* 2016;127:1531-1538. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26747247>.

24. Biggi A, Gallamini A, Chauvie S, et al. International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. *J Nucl Med* 2013;54:683-690. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23516309>.

25. Gallamini A, Barrington SF, Biggi A, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. *Haematologica* 2014;99:1107-1113. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24658820>.

26. Gallamini A, Kostakoglu L. Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials? *Blood* 2012;120:4913-4920. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22932799>.

27. Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. *N Engl J Med* 2015;372:1598-1607. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25901426>.

28. Aldin A, Umlauff L, Estcourt LJ, et al. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. *Cochrane Database Syst Rev* 2019;9:CD012643. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/31525824>.

29. Kobe C, Goergen H, Baues C, et al. Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma. *Blood* 2018;132:2273-2279. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/30166329>.

30. Andre MPE, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: Final results of the randomized EORTC/LYSA/FIL H10 trial. *J Clin Oncol* 2017;35:1786-1794. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/28291393>.

31. Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. *N Engl J Med* 2016;374:2419-2429. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/27332902>.

32. Gallamini A, Hutchings M, Avigdor A, Polliack A. Early interim PET scan in Hodgkin lymphoma: where do we stand? *Leuk Lymphoma* 2008;49:659-662. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18398732>.

33. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. *J Clin Oncol* 2009;27:1906-1914. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19273713>.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

34. Lynch RC, Advani RH. Risk-adapted treatment of advanced Hodgkin lymphoma with PET-CT. Am Soc Clin Oncol Educ Book 2016;35:e376-385. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27249744>.

35. Dabaja BS, Hoppe BS, Plataras JP, et al. Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. Blood 2018;132:1635-1646. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30108066>.

36. Li J, Dabaja B, Reed V, et al. Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma. Int J Radiat Oncol Biol Phys 2011;81:167-174. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20643518>.

37. Hoppe BS, Flampouri S, Su Z, et al. Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2012;84:449-455. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22386373>.

38. Girinsky T, Pichenot C, Beaudre A, et al. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? Int J Radiat Oncol Biol Phys 2006;64:218-226. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16169675>.

39. Nieder C, Schill S, Kneschaurek P, Molls M. Influence of different treatment techniques on radiation dose to the LAD coronary artery. Radiat Oncol 2007;2:20. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17547777>.

40. Paumier A, Ghalibafian M, Gilmore J, et al. Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2012;82:1522-1527. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21705151>.

41. Filippi AR, Ragona R, Fusella M, et al. Changes in breast cancer risk associated with different volumes, doses, and techniques in female Hodgkin lymphoma patients treated with supra-diaphragmatic radiation

therapy. Pract Radiat Oncol 2013;3:216-222. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24674367>.

42. Charpentier A-M, Conrad T, Sykes J, et al. Active breathing control for patients receiving mediastinal radiation therapy for lymphoma: Impact on normal tissue dose. Pract Radiat Oncol 2014;4:174-180. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24766684>.

43. Filippi AR, Ciammella P, Piva C, et al. Involved-site image-guided intensity modulated versus 3D conformal radiation therapy in early stage supradiaphragmatic Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2014;89:370-375. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24613810>.

44. Voong KR, McSpadden K, Pinnix CC, et al. Dosimetric advantages of a "butterfly" technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin's lymphoma. Radiat Oncol 2014;9:94. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24735767>.

45. Ntentas G, Dedekova K, Andrik M, et al. Proton therapy in supradiaphragmatic lymphoma: Predicting treatment-related mortality to help optimize patient selection. Int J Radiat Oncol Biol Phys 2022;112:913-925. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34762970>.

46. Rechner LA, Maraldo MV, Vogelius IR, et al. Life years lost attributable to late effects after radiotherapy for early stage Hodgkin lymphoma: The impact of proton therapy and/or deep inspiration breath hold. Radiother Oncol 2017;125:41-47. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28838605>.

47. Girinsky T, van der Maazen R, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006;79:270-277. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16797755>.

48. Paumier A, Ghalibafian M, Beaudre A, et al. Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2011;80:199-205. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21481723>.



49. Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). *Int J Radiat Oncol Biol Phys* 2014;89:854-862. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23790512>.

50. Hoskin PJ, Diez P, Williams M, et al. Recommendations for the use of radiotherapy in nodal lymphoma. *Clin Oncol (R Coll Radiol)* 2013;25:49-58. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22889569>.

51. Gregoire V, Mackie TR. State of the art on dose prescription, reporting and recording in Intensity-Modulated Radiation Therapy (ICRU report No. 83). *Cancer Radiother* 2011;15:555-559. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21802333>.

52. Bonadonna G, Bonfante V, Viviani S, et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. *J Clin Oncol* 2004;22:2835-2841. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15199092>.

53. Advani RH, Hoppe RT, Baer D, et al. Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial. *Ann Oncol* 2013;24:1044-1048. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23136225>.

54. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. *N Engl J Med* 2010;363:640-652. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20818855>.

55. Berrington de Gonzalez A, Gilbert E, Curtis R, et al. Second solid cancers after radiation therapy: a systematic review of the epidemiologic studies of the radiation dose-response relationship. *Int J Radiat Oncol Biol Phys* 2013;86:224-233. Available at: <https://pubmed.ncbi.nlm.nih.gov/23102695/>.

56. Dracham CB, Shankar A, Madan R. Radiation induced secondary malignancies: a review article. *Radiat Oncol J* 2018;36:85-94. Available at: <https://pubmed.ncbi.nlm.nih.gov/29983028/>.

57. van Nimwegen FA, Ntentsas G, Darby SC, et al. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation

and anthracyclines. *Blood* 2017;129:2257-2265. Available at: <https://pubmed.ncbi.nlm.nih.gov/28143884/>.

58. Wright JL, Yom SS, Awan MJ, et al. Standardizing normal tissue contouring for radiation therapy treatment planning: An ASTRO consensus paper. *Pract Radiat Oncol* 2019;9:65-72. Available at: <https://pubmed.ncbi.nlm.nih.gov/30576843/>.

59. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). *Eur Heart J* 2016;37:2768-2801. Available at: <https://pubmed.ncbi.nlm.nih.gov/27567406/>.

60. Hoppe BS, Bates JE, Mendenhall NP, et al. The meaningless meaning of mean heart dose in mediastinal lymphoma in the modern radiation therapy era. *Pract Radiat Oncol* 2020;10:e147-e154. Available at: <https://pubmed.ncbi.nlm.nih.gov/31586483/>.

61. Totzeck M, Schuler M, Stuschke M, et al. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. *Int J Cardiol* 2019;280:163-175. Available at: <https://pubmed.ncbi.nlm.nih.gov/30661849/>.

62. Maraldo MV, Giusti F, Vogelius IR, et al. Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials. *Lancet Haematol* 2015;2:e492-502. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26686259>.

63. van Nimwegen FA, Schaapveld M, Cutter DJ, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. *J Clin Oncol* 2016;34:235-243. Available at: <https://pubmed.ncbi.nlm.nih.gov/26573075/>.

64. Schellong G, Riepenhausen M, Bruch C, et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. *Pediatr Blood Cancer* 2010;55:1145-1152. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20734400>.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

65. Cutter DJ, Schaapveld M, Darby SC, et al. Risk of valvular heart disease after treatment for Hodgkin lymphoma. *J Natl Cancer Inst* 2015;107:djv008. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25713164>.

66. Moignier A, Broggio D, Derreumaux S, et al. Coronary stenosis risk analysis following Hodgkin lymphoma radiotherapy: A study based on patient specific artery segments dose calculation. *Radiother Oncol* 2015;117:467-472. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26277431>.

67. Hahn E, Jiang H, Ng A, et al. Late Cardiac Toxicity After Mediastinal Radiation Therapy for Hodgkin Lymphoma: Contributions of Coronary Artery and Whole Heart Dose-Volume Variables to Risk Prediction. *Int J Radiat Oncol Biol Phys* 2017;98:1116-1123. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28721895>.

68. Milgrom SA, Varghese B, Gladish GW, et al. Coronary artery dose-volume parameters predict risk of calcification after radiation therapy. *J Cardiovasc Imaging* 2019;27:268-279. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31614398>.

69. Atkins KM, Chaunzwa TL, Lamba N, et al. Association of left anterior descending coronary artery radiation dose with major adverse cardiac events and mortality in patients with non-small cell lung cancer. *JAMA Oncol* 2021;7:206-219. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33331883>.

70. Gagliardi G, Constone LS, Moiseenko V, et al. Radiation dose-volume effects in the heart. *Int J Radiat Oncol Biol Phys* 2010;76:S77-85. Available at: <https://pubmed.ncbi.nlm.nih.gov/20171522/>.

71. Cooper BT, Li X, Shin SM, et al. Preplanning prediction of the left anterior descending artery maximum dose based on patient, dosimetric, and treatment planning parameters. *Adv Radiat Oncol* 2016;1:373-381. Available at: <https://pubmed.ncbi.nlm.nih.gov/28740908/>.

72. Marks LB, Bentzen SM, Deasy JO, et al. Radiation dose-volume effects in the lung. *Int J Radiat Oncol Biol Phys* 2010;76:S70-76. Available at: <https://pubmed.ncbi.nlm.nih.gov/20171521/>.

73. Pinnix CC, Smith GL, Milgrom S, et al. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. *Int J Radiat Oncol Biol Phys* 2015;92:175-182. Available at: <https://pubmed.ncbi.nlm.nih.gov/25863764/>.

74. Podoloff DA, Advani RH, Allred C, et al. NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. *J Natl Compr Canc Netw* 2007;5 Suppl 1:S1-S22; quiz S23-22. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17509259>.

75. American College of Radiology. ACR-SPR Practice Parameters for Performing FDG-PET/CT in Oncology. 2016. Available at: <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/FDG-PET-CT.pdf?la=en>. Accessed January 24, 2020.

76. Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. *Eur J Nucl Med Mol Imaging* 2015;42:328-354. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25452219>.

77. El-Galaly T, Mylam KJ, Brown P, et al. PET/CT surveillance in patients with Hodgkin lymphoma in first remission is associated with low positive predictive value and high costs. *Haematologica* 2012 97:931-936. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22207683>.

78. El-Galaly TC, Mylam KJ, Bogsted M, et al. Role of routine imaging in detecting recurrent lymphoma: A review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma. *Am J Hematol* 2014;89:575-580. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24493389>.

79. Gandikota N, Hartridge-Lambert S, Migliacci JC, et al. Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy. *Cancer* 2015;121:1985-1992. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25739719>.

80. Mocikova H, Obrtlíkova P, Vackova B, Trnecny M. Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study. *Ann Oncol* 2010;21:1222-1227. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19901011>.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

81. El-Galaly TC, d'Amore F, Mylam KJ, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naïve patients with Hodgkin lymphoma. *J Clin Oncol* 2012;30:4508-4514. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23150698>.
82. Salaun PY, Gastinne T, Bodet-Milin C, et al. Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation? *Eur J Nucl Med Mol Imaging* 2009;36:1813-1821. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19499219>.
83. Moulin-Romsee G, Hindie E, Cuenca X, et al. (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. *Eur J Nucl Med Mol Imaging* 2010;37:1095-1105. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20204358>.
84. Kumar A, Casulo C, Yahalom J, et al. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. *Blood* 2016;128:1458-1464. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27458003>.
85. Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. *Blood* 2004;104:3483-3489. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15315964>.
86. van der Kaaij MA, Heutte N, Meijnders P, et al. Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study. *J Clin Oncol* 2012;30:291-299. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22184372>.
87. Sieniawski M, Reineke T, Nogova L, et al. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). *Blood* 2008;111:71-76. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17890456>.
88. van der Kaaij MA, van Echten-Arends J, Simons AH, Kluin-Nelemans HC. Fertility preservation after chemotherapy for Hodgkin lymphoma. *Hematol Oncol* 2010;28:168-179. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20232475>.
89. Duhmke E, Franklin J, Pfreundschuh M, et al. Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. *J Clin Oncol* 2001;19:2905-2914. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11387364>.
90. Gustavsson A, Osterman B, Cavallin-Stahl E. A systematic overview of radiation therapy effects in Hodgkin's lymphoma. *Acta Oncol* 2003;42:589-604. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14596517>.
91. Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. *N Engl J Med* 2012;366:399-408. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22149921>.
92. Fuchs M, Goergen H, Kobe C, et al. Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: Final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group. *J Clin Oncol* 2019;37:2835-2845. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31498753>.
93. Baues C, Goergen H, Fuchs M, et al. Involved-field radiation therapy prevents recurrences in the early stages of Hodgkin lymphoma in PET-negative patients after ABVD chemotherapy: Relapse analysis of GHSG phase 3 HD16 trial. *Int J Radiat Oncol Biol Phys* 2021;111:900-906. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34389407>.
94. Straus DJ, Jung SH, Pitcher B, et al. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. *Blood* 2018;132:1013-1021. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30049811>.
95. von Tresckow B, Plutschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. *J Clin Oncol* 2012;30:907-913. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22271480>.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

96. Gillessen S, Plutschow A, Fuchs M, et al. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14). *Lancet Haematol* 2021;8:e278-e288. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33770483>.

97. Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. *J Clin Oncol* 2010;28:4199-4206. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20713848>.

98. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. *Lancet* 2012;379:1791-1799. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22480758>.

99. Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an Intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). *J Clin Oncol* 2013;31:684-691. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23182987>.

100. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. *N Engl J Med* 1992;327:1478-1484. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1383821>.

101. Merli F, Luminari S, Gobbi PG, et al. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. *J Clin Oncol* 2016;34:1175-1181. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26712220>.

102. Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. *N Engl J Med* 2011;365:203-212. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21774708>.

103. Press OW, Li H, Schoder H, et al. US Intergroup Trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816. *J Clin Oncol* 2016;34:2020-2027. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27069074>.

104. Stephens DM, Li H, Schoder H, et al. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. *Blood* 2019;134:1238-1246. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31331918>.

105. Gallamini A, Tarella C, Viviani S, et al. Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: Long-term results of the GITIL/FIL HD 0607 Trial. *J Clin Oncol* 2018;36:454-462. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29360414>.

106. Straus DJ, Długosz-Danecka M, Alekseev S, et al. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. *Blood* 2020;135:735-742. Available at: <https://pubmed.ncbi.nlm.nih.gov/31945149/>.

107. Straus DJ, Długosz-Danecka M, Connors JM, et al. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. *Lancet Haematol* 2021;8:e410-e421. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34048680>.

108. Ansell SM, Radford J, Connors JM, et al. Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma. *N Engl J Med* 2022;387:310-320. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35830649>.

109. Borchmann P, Haverkamp H, Diehl V, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. *J Clin Oncol* 2011;29:4234-4242. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21990399>.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

110. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. *J Clin Oncol* 2009;27:4548-4554. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19704068>.

111. Kriz J, Reinartz G, Dietlein M, et al. Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study Group. *Int J Radiat Oncol Biol Phys* 2015;92:46-53. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25863753>.

112. Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. *Lancet* 2018;390:2790-2802. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29061295>.

113. Casasnovas RO, Bouabdallah R, Brice P, et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. *Lancet Oncol* 2019;20:202-215. Available at: <https://pubmed.ncbi.nlm.nih.gov/30658935/>.

114. Carde P, Karrasch M, Fortpied C, et al. Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, International Prognostic Score ≥ 3 , high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 Intergroup trial. *J Clin Oncol* 2016;34:2028-2036. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/27114593>.

115. Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. *J Clin Oncol* 2009;27:805-811. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19124807>.

116. Mounier N, Brice P, Bologna S, et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial dagger. *Ann Oncol* 2014;25:1622-1628. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24827123>.

117. Jagadeesh D, Diefenbach C, Evens AM. XII. Hodgkin lymphoma in older patients: challenges and opportunities to improve outcomes. *Hematol Oncol* 2013;31 Suppl 1:69-75. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23775654>.

118. Evens AM, Sweetenham JW, Horning SJ. Hodgkin lymphoma in older patients: an uncommon disease in need of study. *Oncology (Williston Park)* 2008;22:1369-1379. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19086599>.

119. Ballova V, Ruffer JU, Haverkamp H, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). *Ann Oncol* 2005;16:124-131. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15598949>.

120. Boll B, Gorgen H, Fuchs M, et al. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. *J Clin Oncol* 2013;31:1522-1529. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23509310>.

121. Evens AM, Hong F, Gordon LI, et al. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. *Br J Haematol* 2013;161:76-86. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23356491>.

122. Halbsguth TV, Nogova L, Mueller H, et al. Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). *Blood* 2010;116:2026-2032. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20551376>.

123. Boll B, Goergen H, Behringer K, et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. *Blood* 2016;127:2189-2192. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26834240>.

124. Stamatoullas A, Brice P, Bouabdallah R, et al. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

use of bleomycin in the elderly. *Br J Haematol* 2015;170:179-184. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25891777>.

125. Andersen MD, Kamper P, d'Amore A, et al. The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor (daggar). *Leuk Lymphoma* 2019;60:927-933. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30277120>.

126. Sun H, Atenafu E, Tsang R, et al. Incidence and predictors of bleomycin pulmonary toxicity in Hodgkin lymphoma (HL) patients treated with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD). *Blood* 2011;118:3643. Available at: <https://doi.org/10.1182/blood.V118.21.3643.3643>.

127. Evens AM, Advani RH, Helenowski IB, et al. Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. *J Clin Oncol* 2018;36:3015-3022. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30179569>.

128. Kolstad A, Nome O, Delabie J, et al. Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma. *Leuk Lymphoma* 2007;48:570-576. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17454601>.

129. Friedberg JW, Forero-Torres A, Bordoni RE, et al. Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL. *Blood* 2017;130:2829-2837. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29038340>.

130. Friedberg JW, Forero-Torres A, Holkova B, et al. Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma. *J Clin Oncol* 2018;36:7542-7542. Available at: http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.7542.

131. Levis A, Anselmo AP, Ambrosetti A, et al. VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. *Ann Oncol* 2004;15:123-128. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14679131>.

132. Proctor SJ, Wilkinson J, Jones G, et al. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. *Blood* 2012;119:6005-6015. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22577177>.

133. Boll B, Bredenfeld H, Gorgen H, et al. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. *Blood* 2011;118:6292-6298. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21917759>.

134. Advani RH, Hoppe RT. How I treat nodular lymphocyte predominant Hodgkin lymphoma. *Blood* 2013;122:4182-4188. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24215035>.

135. Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. *J Clin Oncol* 1999;17:776-783. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10071266>.

136. Nogova L, Reineke T, Brillant C, et al. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. *J Clin Oncol* 2008;26:434-439. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18086799>.

137. Jackson C, Sirohi B, Cunningham D, et al. Lymphocyte-predominant Hodgkin lymphoma—clinical features and treatment outcomes from a 30-year experience. *Ann Oncol* 2010;21:2061-2068. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20332141>.

138. Kenderian SS, Habermann TM, Macon WR, et al. Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution. *Blood* 2016;127:1960-1966. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26837698>.

139. Fan Z, Natkunam Y, Bair E, et al. Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation. *Am J Surg Pathol* 2003;27:1346-1356. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/14508396>.



140. Hartmann S, Eichenauer DA, Plutschow A, et al. The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSg). *Blood* 2013;122:4246-4252; quiz 4292. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24100447>.

141. Spinner MA, Varma G, Advani RH. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma. *Br J Haematol* 2019;184:17-29. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30485408>.

142. Schlembach PJ, Wilder RB, Jones D, et al. Radiotherapy alone for lymphocyte-predominant Hodgkin's disease. *Cancer J* 2002;8:377-383. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12416895>.

143. Wilder RB, Schlembach PJ, Jones D, et al. European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. *Cancer* 2002;94:1731-1738. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11920535>.

144. Wirth A, Yuen K, Barton M, et al. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. *Cancer* 2005;104:1221-1229. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16094666>.

145. Nogova L, Reineke T, Eich HT, et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSg). *Ann Oncol* 2005;16:1683-1687. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16093276>.

146. Chen RC, Chin MS, Ng AK, et al. Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up. *J Clin Oncol* 2010;28:136-141. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19933914>.

147. Feugier P, Labouyrie E, Djeridane M, et al. Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at

clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation. *Blood* 2004;104:2675-2681. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15231567>.

148. Engert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSg HD7 trial. *J Clin Oncol* 2007;25:3495-3502. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17606976>.

149. Eichenauer DA, Plutschow A, Fuchs M, et al. Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. *J Clin Oncol* 2015;33:2857-2862. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26240235>.

150. Biasoli I, Stamatoullas A, Meignin V, et al. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. *Cancer* 2010;116:631-639. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20029973>.

151. Pellegrino B, Terrier-Lacombe MJ, Oberlin O, et al. Lymphocyte-predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection--a Study of the French Society of Pediatric Oncology. *J Clin Oncol* 2003;21:2948-2952. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12885814>.

152. Mauz-Korholz C, Gorde-Grosjean S, Hasenclever D, et al. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. *Cancer* 2007;110:179-185. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17526010>.

153. Binkley MS, Rauf MS, Milgrom SA, et al. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. *Blood* 2020;135:2365-2374. Available at: <https://pubmed.ncbi.nlm.nih.gov/32211877/>.

154. Savage KJ, Skinnider B, Al-Mansour M, et al. Treating limited stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

Hodgkin lymphoma with ABVD may improve outcome. Blood 2011;118:4585-4590. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21873543>.

155. Canellos GP, Mauch P. What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin's Lymphoma? . J Clin Oncol 2010;28:e8. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19933898>.

156. Unal A, Sari I, Deniz K, et al. Familial nodular lymphocyte predominant Hodgkin lymphoma: successful treatment with CHOP plus rituximab Leuk Lymphoma 2005;46:1613-1617. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16236615>.

157. Fanale MA, Cheah CY, Rich A, et al. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood 2017;130:472-477. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/28522441>.

158. Fanale MA, Lai C-M, McLaughlin P, et al. Outcomes of nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) patients treated with R-CHOP. Blood 2010;116:2812. Available at:

<https://doi.org/10.1182/blood.V116.21.2812.2812>.

159. Shankar A, Hall GW, Gorde-Grosjean S, et al. Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin's lymphoma - an Anglo-French collaborative report. Eur J Cancer 2012;48:1700-1706. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22093944>.

160. Ekstrand BC, Lucas JB, Horwitz SM, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 2003;101:4285-4289. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12586628>.

161. Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008;111:109-111. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/17938252>.

162. Eichenauer DA, Fuchs M, Pluetschow A, et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 2011;118:4363-4365. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21828141>.

163. Saini KS, Azim HA, Jr., Cocorocchio E, et al. Rituximab in Hodgkin lymphoma: is the target always a hit? Cancer Treat Rev 2011;37:385-390. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21183282>.

164. Advani RH, Horning SJ, Hoppe RT, et al. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol 2014;32:912-918. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24516013>.

165. Davies A, Merli F, Mihaljevic B, et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol 2017;4:e272-e282. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/28476440>.

166. Lugtenburg P, Avivi I, Berenschot H, et al. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica 2017;102:1913-1922. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/28935843>.

167. Mauch P, Ng A, Aleman B, et al. Report from the Rockefeller Foundation sponsored international workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease. Eur J Haematol Suppl 2005;68-76. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16007872>.

168. Lynch RC, Sundaram V, Desai M, et al. Utility of routine surveillance laboratory testing in detecting relapse in patients with classic Hodgkin lymphoma in first remission: Results from a large single-institution study. JCO Oncol Pract 2020;16:e902-e911. Available at:

<https://pubmed.ncbi.nlm.nih.gov/32369413/>.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

169. Ng A, Constine LS, Advani R, et al. ACR Appropriateness Criteria: follow-up of Hodgkin's lymphoma. *Curr Probl Cancer* 2010;34:211-227. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20541059>.

170. Picardi M, Pugliese N, Cirillo M, et al. Advanced-stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission--a randomized trial of routine surveillance imaging procedures. *Radiology* 2014;272:262-274. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24708193>.

171. Franklin J, Pluetschow A, Paus M, et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. *Ann Oncol* 2006;17:1749-1760. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16984979>.

172. Swerdlow AJ, Higgins CD, Smith P, et al. Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. *J Clin Oncol* 2011;29:4096-4104. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21969511>.

173. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. *J Natl Cancer Inst* 2002;94:182-192. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11830608>.

174. Schaapveld M, Aleman BM, van Eggermond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma. *N Engl J Med* 2015;373:2499-2511. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26699166>.

175. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. *J Natl Cancer Inst* 1995;87:1530-1537. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/7563187>.

176. Ng AK, Garber JE, Diller LR, et al. Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma. *J Clin Oncol* 2013;31:2282-2288. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23610104>.

177. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography.

CA Cancer J Clin 2007;57:75-89. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17392385>.

178. Heidenreich PA, Hancock SL, Lee BK, et al. Asymptomatic cardiac disease following mediastinal irradiation. *J Am Coll Cardiol* 2003;42:743-749. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12932613>.

179. Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. *J Clin Oncol* 2004;22:3139-3148. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15284266>.

180. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. *Blood* 2007;109:1878-1886. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17119114>.

181. Girinsky T, M'Kacher R, Lessard N, et al. Prospective coronary heart disease screening in asymptomatic Hodgkin lymphoma patients using coronary computed tomography angiography: results and risk factor analysis. *Int J Radiat Oncol Biol Phys* 2014;89:59-66. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24613809>.

182. Oliva S, Puzzovivo A, Gerardi C, et al. Late cardiological sequelae and long-term monitoring in classical Hodgkin lymphoma and diffuse large B-cell lymphoma survivors: A systematic review by the Fondazione Italiana Linfomi. *Cancers (Basel)* 2021;14. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35008222>.

183. Behringer K, Breuer K, Reineke T, et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. *J Clin Oncol* 2005;23:7555-7564. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16234521>.

184. van der Kaaij MA, Heutte N, Le Stang N, et al. Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte. *J Clin Oncol* 2007;25:2825-2832. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17515571>.



185. Hodgson DC, Pintilie M, Gitterman L, et al. Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. *Hematol Oncol* 2007;25:11-15. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17036376>.

186. Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. *J Clin Oncol* 2005;23:7614-7620. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16186594>.

187. Boleti E, Mead GM. ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. *Ann Oncol* 2007;18:376-380. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17071938>.

188. Evens AM, Cilley J, Ortiz T, et al. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. *Br J Haematol* 2007;137:545-552. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17459049>.

189. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. *Lancet* 1993;341:1051-1054. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8096958>.

190. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. *Lancet* 2002;359:2065-2071. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12086759>.

191. Moskowitz CH, Kewalramani T, Nimer SD, et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. *Br J Haematol* 2004;124:645-652. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14871252>.

192. Sirohi B, Cunningham D, Powles R, et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's

lymphoma. *Ann Oncol* 2008;19:1312-1319. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18356139>.

193. Brice P, Bouabdallah R, Moreau P, et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. *Societe Francaise de Greffe de Moelle. Bone Marrow Transplant* 1997;20:21-26. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9232251>.

194. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. *Blood* 2001;97:616-623. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11157476>.

195. Moskowitz CH, Yahalom J, Zelenetz AD, et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. *Br J Haematol* 2010;148:890-897. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20085577>.

196. Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. *J Clin Oncol* 2002;20:221-230. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11773173>.

197. Sureda A, Constans M, Iriando A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. *Ann Oncol* 2005;16:625-633. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15737986>.

198. Stiff PJ, Unger JM, Forman SJ, et al. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. *Biol Blood Marrow Transplant* 2003;9:529-539. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12931122>.

199. Wheeler C, Eickhoff C, Elias A, et al. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

disease: a prognostic model for treatment outcomes. *Biol Blood Marrow Transplant* 1997;3:98-9106. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/9267670>.

200. Horning SJ, Chao NJ, Negrin RS, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. *Blood* 1997;89:801-813. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/9028311>.

201. Jabbour E, Hosing C, Ayers G, et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. *Cancer* 2007;109:2481-2489. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17497648>.

202. Mocikova H, Pytlik R, Markova J, et al. Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma. *Leuk Lymphoma* 2011;52:1668-1674. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21699377>.

203. Smeltzer JP, Cashen AF, Zhang Q, et al. Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. *Biol Blood Marrow Transplant* 2011;17:1646-1652. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21601641>.

204. Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. *Blood* 2012;119:1665-1670. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22184409>.

205. ChIVPP therapy for Hodgkin's disease: experience of 960 patients. The International ChIVPP Treatment Group. *Ann Oncol* 1995;6:167-172. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/7786824>.

206. Abali H, Urun Y, Oksuzoglu B, et al. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. *Cancer Invest* 2008;26:401-406. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18443961>.

207. Aparicio J, Segura A, Garcera S, et al. ESHAP is an active regimen for relapsing Hodgkin's disease. *Ann Oncol* 1999;10:593-595. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/10416011>.

208. Colwill R, Crump M, Couture F, et al. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. *J Clin Oncol* 1995;13:396-402. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/7844600>.

209. Josting A, Rudolph C, Reiser M, et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. *Ann Oncol* 2002;13:1628-1635. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12377653>.

210. Labrador J, Cabrero-Calvo M, Perez-Lopez E, et al. ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma. *Ann Hematol* 2014;93:1745-1753. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24863692>.

211. Martin A, Fernandez-Jimenez MC, Caballero MD, et al. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. *Br J Haematol* 2001;113:161-171. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/11328296>.

212. Phillips JK, Spearing RL, Davies JM, et al. VIM-D salvage chemotherapy in Hodgkin's disease. *Cancer Chemother Pharmacol* 1990;27:161-163. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/2249334>.

213. Rodriguez MA, Cabanillas FC, Hagemester FB, et al. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. *Ann Oncol* 1995;6:609-611. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/8573542>.

214. Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. *Ann Oncol* 2007;18:1071-1079. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17426059>.



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

215. Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. *Haematologica* 2007;92:35-41. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17229633>.

216. Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. *J Clin Oncol* 2014;32:3490-3496. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25267740>.

217. Gopal AK, Press OW, Shustov AR, et al. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. *Leuk Lymphoma* 2010;51:1523-1529. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20578815>.

218. Gutierrez A, Rodriguez J, Martinez-Serra J, et al. Gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma. *Onco Targets Ther* 2014;7:2093-2100. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25419147>.

219. Moskowitz AJ, Hamlin PA, Perales M-A, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. *J Clin Oncol* 2013;31:456-460. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23248254>.

220. Fehniger TA, Larson S, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. *Blood* 2011;118:5119-5125. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21937701>.

221. Johnston PB, Inwards DJ, Colgan JP, et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. *Am J Hematol* 2010;85:320-324. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20229590>.

222. Santoro A, Mazza R, Pulsoni A, et al. Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or

refractory Hodgkin lymphoma: Final results of a multicenter phase II study. *J Clin Oncol* 2016;34:3293-3299. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27382096>.

223. Budde LE, Wu D, Martin DB, et al. Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. *Br J Haematol* 2018;183:601-607. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30596402>.

224. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. *J Clin Oncol* 2012;30:2183-2189. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22454421>.

225. Gopal AK, Chen R, Smith SE, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. *Blood* 2015;125:1236-1243. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25533035>.

226. Plattel WJ, Bergamasco A, Trinchese F, et al. Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis. *Leuk Lymphoma* 2021;62:3320-3332. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34323643>.

227. Moskowitz AJ, Schoder H, Yahalom J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosfamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. *Lancet Oncol* 2015;16:284-292. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25683846>.

228. LaCasce AS, Bociek RG, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. *Blood* 2018;132:40-48. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29703778>.

229. O'Connor OA, Lue JK, Sawas A, et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial. *Lancet Oncol*



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

2018;19:257-266. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/29276022>.

230. Chen R, Palmer JM, Martin P, et al. Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma. *Biol Blood Marrow Transplant* 2015;21:2136-2140. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/26211987>.

231. Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet* 2015;385:1853-1862. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25796459>.

232. Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. *Blood* 2018;132:2639-2642. Available at:

<https://doi.org/10.1182/blood-2018-07-861641>.

233. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. *N Engl J Med* 2015;372:311-319. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25482239>.

234. Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. *Lancet Oncol* 2016;17:1283-1294. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/27451390>.

235. Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: Extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. *J Clin Oncol* 2018;36:1428-1439. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29584546>.

236. Herrera AF, Manley T, Sacchi M, et al. Brentuximab vedotin and nivolumab for relapsed or refractory classic Hodgkin lymphoma: Long-term follow-up results from the single-arm phase 1/2 study. *Blood* 2019;134:238. Available at: <https://doi.org/10.1182/blood-2019-122576>.

237. Advani RH, Moskowitz AJ, Bartlett NL, et al. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. *Blood* 2021;138:427-438. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/33827139>.

238. Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. *J Clin Oncol* 2016;36:3733-3739. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/27354476>.

239. Chen R, Zinzani PL, Fanale MA, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. *J Clin Oncol* 2017;35:2125-2132. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/28441111>.

240. Kuruvilla J, Ramchandren R, Santoro A, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. *Lancet Oncol* 2021;22:512-524. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/33721562>.

241. Moskowitz AJ, Shah G, Schöder H, et al. Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. *J Clin Oncol* 2021;39:3109-3117. Available at:

<https://ascopubs.org/doi/abs/10.1200/JCO.21.01056>.

242. Mei MG, Lee HJ, Palmer JM, et al. Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. *Blood* 2022;139:3605-3616. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/35316328>.

243. Josting A, Nogova L, Franklin J, et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. *J Clin Oncol* 2005;23:1522-1529. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/15632410>.

244. Constine LS, Yahalom J, Ng AK, et al. The role of radiation therapy in patients with relapsed or refractory Hodgkin lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. *Int J Radiat Oncol*



NCCN Guidelines Version 2.2023

Hodgkin Lymphoma

Biol Phys 2018;100:1100-1118. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/29722655>.

245. Evens AM, Altman JK, Mittal BB, et al. Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma. Ann Oncol 2007;18:679-688. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/17307757>.

246. Herrera AF, Moskowitz AJ, Bartlett NL, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 2018;131:1183-1194. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29229594>.

247. Lynch RC, Cassaday RD, Smith SD, et al. Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. Lancet Haematol 2021;8:e562-e571. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34329577>.

248. Neoplastic disease: Treatment with vinblastine a cooperative study. Archives of Internal Medicine 1965;116:846-852. Available at: <https://doi.org/10.1001/archinte.1965.03870060044010>.

249. Alvarez I, Sureda A, Caballero MD, et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. Biol Blood Marrow Transplant 2006;12:172-183. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16443515>.

250. Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012;97:310-317. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21993674>.

251. Castagna L, Bramanti S, Devillier R, et al. Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin

lymphoma. Bone Marrow Transplant 2017;52:797. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28465624>.

252. Boll B, Goergen H, Arndt N, et al. Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group. J Clin Oncol 2013;31:4431-4437. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24190119>.

253. Chen RW, Palmer J, Martin P, et al. Results of a phase II trial of brentuximab vedotin as first line salvage therapy in relapsed/refractory HL prior to AHCT. Blood 2014;124:501. Available at: <https://doi.org/10.1182/blood.V124.21.501.501>.

254. Miettinen M, Franssila KO, Saxen E. Hodgkin's disease, lymphocytic predominance nodular. Increased risk for subsequent non-Hodgkin's lymphomas. Cancer 1983;51:2293-2300. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/6850508>.

255. Huang JZ, Weisenburger DD, Vose JM, et al. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma: a report of 21 cases from the Nebraska Lymphoma Study Group. Leuk Lymphoma 2004;45:1551-1557. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15370206>.

256. Al-Mansour M, Connors JM, Gascoyne RD, et al. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. J Clin Oncol 2010;28:793-799. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20048177>.